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Abstract
Applications of Ultra Performance Liquid Chromatography (UPLC) and Tandem Mass
Spectrometry for the Detection and Quantification of Cocaine, Amphetamine, and Opiate
Derivatives in Human Meconium
By Joshua A. Gunn
Development and validation of ultra performance liquid chromatography tandem mass
spectrometry (UPLC-MS/MS) methodologies for the purpose of detecting and quantifying
common drugs of abuse in human meconium specimens is described. Meconium is the first stool
passed by a newborn infant. Meconium formation occurs over several months of gestation and
subsequent toxicological analysis of the specimens can be useful for identifying drugs and other
xenobiotics indicative of prenatal drug exposure.
Ultra performance liquid chromatography (UPLC) is an emerging analytical technique
which draws upon the principles of chromatography to run separations at higher flow rates for
increased speed, while simultaneously achieving superior resolution and sensitivity. Tandem
mass spectrometry experiments were performed using a triple quadrupole mass spectrometer
equipped with an electrospray ionization (ESI) source operating in positive ion mode.
Methodologies were developed and validated to detect and quantify amphetamine,
methamphetamine, cocaine, benzoylecgonine, morphine, codeine, hydromorphone, and 6monoacetylmorphine (6-MAM) in authentic meconium specimens.
Analytes were extracted from the meconium matrix using either a mixed mode solid
phase extraction (SPE), or a supported-liquid extraction (SLE) employing columns containing a
modified form of diatomaceous earth. Data acquisition was performed using multiple reaction
monitoring (MRM) and quantitation of each analyte was performed using a working standard

calibration curve. The analytical methodologies were fully validated for the meconium matrix,
where linearity, matrix equivalence, selectivity, accuracy, precision, sensitivity, stability, and
recovery were evaluated.
Equivalence studies indicated that in all cases, certified drug free whole blood was a
suitable matrix for the preparation of working calibration curves. Blank meconium specimens
containing analytes at the LOQ, were spiked with various exogenous interferences and analyzed
to assess the selectivity of the analytical method. All methodologies were deemed highly
selective for the analyte of interest even in the presence of exogenous compounds commonly
encountered in forensic specimens. Accuracy, precision, stability, and recovery were assessed at
three different analyte concentrations corresponding to the LOQ, the ULOQ, and a concentration
point midway between the two. Mean accuracies ranged from 94.6% to 99.6% over the three
concentrations for the cocaine/benzoylecgonine methodology while the amphetamine and opiate
assays also exhibited high accuracies with mean ranges of 93.6% to 98.4% and 93% to 99.6%,
respectively. Inter and intra batch precision data indicated enhanced method precision and
reproducibility relative to existing techniques. Intra-batch CV values ranged from 1.6 to 11.8%
for the cocaine/benzoylecgonine methodology while inter-batch CV values ranged from 3.9% to
6.2%. Intra-batch CV values ranged from 0.7% to 8.5% for the amphetamine/methamphetamine
methodology while inter-batch CV values ranged from 1.9% to 6.2%. The opiate methodology
was also highly precise with intra-batch CV values ranging from 1.2% to 10.7% while interbatch CV values ranged from 0.5% to 6.1% across the four analytes. While mean analyte
recoveries ranged from 9.3% for benzoylecgonine to 76.3% for 6-monoacetylmorphine, the
consistency and reproducibility of the extraction was acceptable for all analytes. Stability studies
indicated that all analytes are stable in the meconium matrix when stored at 4°C and subjected to

multiple freeze-thaw cycles over a 72 hour period. Limits of detection ranged from 250 pg/mL
for methamphetamine, to 2.5 ng/mL for all four opiate analytes. Linear calibration for the
cocaine/benzoylecgonine, amphetamine/methamphetamine, and opiate methodologies was
achieved over the range of 10 – 250 ng/mL, 5 – 500 ng/mL, and 10 – 500 ng/mL, respectively.
Recent technological advances made in the field of particle chemistry mean that liquid
chromatographic separations can be performed at higher flow rates for increased speed without
sacrificing resolution or sensitivity. The increased speed, resolution, sensitivity, and separation
efficiency afforded by UPLC combined with the inherent selectivity and sensitivity of the
tandem mass spectrometer allowed for the accurate quantitation of all 8 analytes in the
meconium matrix in a time and cost effective manner. Development and validation of such
analytical methodologies will prove beneficial for the identification of prenatal substance abuse
which is an ongoing concern across socioeconomic lines.
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Chapter 1: Introduction to Prenatal Substance Abuse and Its Clinical and
Forensic Significance
1.1

Introduction
Prenatal substance abuse is an ongoing concern due to the characteristic physical and

mental developmental problems that result from drug abuse during pregnancy. Illicit drug
consumption continues to increase across geographical, social, and cultural groups worldwide
and in 2000 The World Drug Report estimated 180 million people, or 3% of the worlds
inhabitants to be drug users[1]. Substance abuse in the United States has reached epidemic
proportions during the past two decades and in 2006 an estimated 20.4 million Americans aged
12 years or older were users of illicit drugs[2, 3]. This estimation represents 8.3% of the
American population aged 12 years or older[2]. Females constitute approximately 30% of the
substance addicted population in the United States and most are of childbearing age[4]. Among
pregnant women aged 15 to 44 years who participated in the 2006 National Survey on Drug Use
and Health (NSDUH), 4.0% reported having used illicit drugs within 1 month of the survey[2].
National findings from the 2006 survey indicate that the rate of illicit drug use among pregnant
women aged 15 to 44 years has remained steady since 2003[2].
Estimating the prevalence of drug use among pregnant women based on maternal history
or broad scale surveys often proves unreliable due to guilt, embarrassment, fear of reprisal, or of
loss of custody[5]. As a result, identification of the drug exposed neonate is a difficult task and
even in the case of maternal admission, information regarding the type and/or extent of drug use
is often inaccurate[6]. One survey based on maternal report estimated that the prevalence of drug
abuse among pregnant women ranged between 0.4% and 27%[6, 7]. A survey conducted on
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infants delivered at a tertiary perinatal center illustrated the inaccuracy of estimations based on
maternal history. While only 10.5% of infants were birthed to mothers suspected of drug use
based on maternal history, subsequent drug testing revealed that 42% of infants had been
exposed to illicit drugs[8]. Another study of 3000 infants illustrated the inaccuracies associated
with maternal self-report. Of the 3000 infants monitored in the study, 43% were found to be
positive for illicit substances through toxicological analysis, while only 11% of these were
reported by the mother[9].
A study conducted on the prevalence of cocaine use during pregnancy in the early 1990s
reported that 37 out of 600 (6.25%) infants born across three metropolitan hospital nurseries in
the Toronto area tested positive for cocaine[10]. These findings were consistent with estimations
made by Birchfield et al who concluded that rates of infants exposed prenatally to cocaine range
between 2.6% and 11% of all live births[11]. A nationwide survey carried out in the early 1990s
at urban teaching hospitals indicated that 10-45% of the women cared for at those hospitals use
cocaine during pregnancy[12]. A separate survey of 36 hospitals reported that 11% of the women
studied had used illicit drugs during pregnancy[7]. A follow up report by the same authors in
1992 estimated that between 500,000 and 750,000 newborns are exposed to illicit drugs each
year[13].
Various neonatal health and developmental problems are thought to be directly related to
fetal exposure to drugs, alcohol, chemical agents, or other xenobiotics [6, 14-16]. Despite
extensive research and continued evidence of fetal and neonatal health risks, a large number of
pregnant women are involved in illicit drug use[5]. Drug use during gestation is associated with
higher risks for poor obstetrical outcomes, including placental abruption, premature labor, low

2

birth weight, microcephaly, congenital anomalies, necrotizing enterocolitis, neonatal withdrawal,
neurobehavioral effects, subarachnoid and intracerebral hemorrhage, and fetal death[17-25].
Due to the detrimental effects resulting from prenatal exposure to illicit substances,
correct diagnosis of drug use during pregnancy is essential. Correct diagnosis and early
intervention will allow the child to receive the specialized treatment and the care required to
ensure that their development is not further compromised. Successful diagnosis of drug abuse
during pregnancy will also assist in preventing the same mother from giving birth to subsequent
drug-exposed children[26]. It is extremely important to ensure that the early diagnosis of drug
abuse during pregnancy not only brings about beneficial changes in the environment of the
infant, but also aids in the successful rehabilitation of substance addicted mothers[27]. Although
the early identification of prenatal substance abuse will aid in the long term wellbeing of the
infant, without the implementation of a well defined intervention road map, such diagnosis also
have the potential to cause harm to mothers, children, and families alike[28]. Careful
consideration of the circumstances surrounding each and every positive result will ensure that a
mother who has used drugs or alcohol at some time during pregnancy is not mislabeled as a
substance abuser in the absence of true abuse. Review of positive results with mothers suspected
of substance abuse will help to ensure that infants are not separated from their mothers and
placed in living situations that offer no benefit[28].
Traditional identification of neonatal drug exposure is accomplished using a combination
of maternal history, newborn clinical symptoms and laboratory toxicology testing of the mother
and the infant[27]. Generally, toxicological testing of the mother and infant will only occur if the
consulting physician has reason to believe that prenatal substance abuse may be an issue based
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on maternal history, or if the infant’s physical features meet certain criteria which are commonly
associated with prenatal exposure to drugs.
Many states mandate toxicology testing of all mothers and infants regardless of maternal
history or certain physical features of the infant. Indiana’s Maternal & Children’s Special Health
Care (MCSHC) department mandates laboratory testing of meconium specimens to detect the
presence of controlled substances for those infants born in Indiana who meet selected criteria at
birth. Toxicology testing is performed on high-risk newborns (1) whose weight is less than 2500
grams and whose head circumference is smaller than the 10th percentile for the infant’s
gestational age when there is no other medical explanation for these conditions; or (2) when
there is maternal history of current or past drug use; or; (3) mother had no or inconsistent
prenatal care (frequently missed appointments, hospital hopping); or (4) infant shows
signs/symptoms suggestive of drug effects or withdrawal; or (5) unexpected abruption
placentae[29]. Approximately 1,600 newborn infants meet one or more of these criteria in
Indiana alone and many additional meconium specimens are submitted for analysis based on
recommendations from the consulting physician[29].
1.2

Drug Transfer in the Maternal-Fetal Complex
The placenta is a specialized organ which not only plays a lead role in fetal protection

during intrauterine life but also continuously adapts itself to meet developmental and nutritional
requirements of the fetus while in the uterus[30]. The role of the placenta as a transport organ is
crucial for fetal development as it is responsible for transferring oxygen and nutrients to the fetus
while simultaneously allowing for the efficient removal of fetal metabolism products by the
mother[30, 31]. Essential nutrients such as amino acids, vitamins, phosphate, iron, mono- and
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dicarboxylates, and glucose among others are transferred to the fetus throughout intrauterine life
via very specific transport mechanisms present within in the placenta[31].
The developing fetus is not only provided with essential nutrients and oxygen via specific
placental transport mechanisms but is also effectively protected through the placentas ability to
prevent the entry of various xenobiotics from the maternal blood supply[31]. Excluding drugs of
large molecular weight, such as heparin or insulin, most drugs are thought to cross the placental
membrane during pregnancy and are associated with varying degrees of fetal exposure[32]. In
general, un-ionized molecules with low molecular weights and high lipid solubility will diffuse
across the placental membrane more readily than large hydrophilic drug molecules[33]. Drugs
that are highly bound to proteins or contain ionized functional groups in plasma (pH 7.4) will
exhibit a much lower degree of placental diffusion than unionized, unbound drugs.
The placenta also facilitates the passage of various xenobiotics form the fetus to the
mother for elimination should they initially permeate the placental membrane. It is well
documented that various licit and illicit drugs can indeed cross the placental membrane which
represents the primary physiological link between mother and fetus [34-38].
While most xenobiotics cross the placental membrane and enter the fetal bloodstream via
passive diffusion, other potential transport mechanisms include facilitated diffusion, active
transport, and filtration. The mechanism by which certain drugs permeate the placental
membrane and enter the fetal bloodstream is dependent on the physicochemical properties of the
compounds such as molecular size, polarity, and pKa, as well as lipid solubility and protein
binding ability[32]. Maternal pharmacokinetics including the volume of distribution, rate of
metabolism and excretion, and the effect of haemodynamic changes in the mother during
pregnancy all impact the degree and severity of in utero drug exposure[32]. Maternal blood pH,
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which dictates the state of ionizable functional groups, will also play a significant role in the
drugs ability to cross the placenta[34].
Numerous transport systems which recognize a wide variety of pharmacologically active
drugs as substrates have been identified in the placenta, along with several additional transport
systems whose role in the placenta remains an enigma[31]. There is strong evidence to suggest
that several placental transport systems are direct targets for common drugs of abuse including
cocaine, amphetamines, nicotine, and cannabinoids[31]. Interference of drugs of abuse with the
transport function of the placenta can occur following a direct interaction of the drug with
specific transporters, or through an indirect modification of cell signaling pathways or
transmembrane ion gradients which subsequently influences transporter function[31].
Accompanying the recognition that drugs of abuse significantly affect placental transport
is the realization that maternal use of such drugs compromises the normal physiological function
of the placenta. Unnatural changes in placental physiology resulting from maternal drug use
produces deleterious effects in the mother as well as in the developing fetus[31].
1.3

Traditional Testing Procedures
Toxicological analysis of maternal and neonatal specimens is an objective means of

identifying prenatal drug exposure. Analysis of biological specimens obtained from the neonate
is necessary to document proof of the infant’s exposure to illicit drugs, even if the mother admits
to the use of illicit substances[39]. Positive toxicology testing in the infant facilitates court action
in the cases where authorities have recommended the child be removed from the mothers care
and placed in foster care[39].
Traditional toxicological analyses aimed at identifying prenatal exposure to illicit
substances have utilized various maternal and neonatal specimens over the years. Maternal blood
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is routinely analyzed for the presence of illicit substances in the mother. However, due to the
relatively short retention time of most drugs in blood, and the invasiveness of sample collection,
blood analysis is somewhat limited. Toxicological analysis of neonatal blood is rarely performed
as serum drug levels in the infant largely depend on the time interval between the mother’s last
drug intake and the subsequent collection of the neonatal blood. This time interval can be
substantial and as a result drug levels in the neonatal blood will likely fall below detection limits
for common screening techniques[39].
Neonatal urine is the most widely analyzed biological fluid for the determination of in
utero drug exposure and offers several distinct advantages over blood. Drug concentrations in
neonatal urine will be higher than those in corresponding blood (serum) specimens due to the
concentrating ability of the kidneys[40]. Neonatal urine also offers a slightly longer window of
detection than blood and should indicate the presence of any substances that the neonate was
exposed to in the last 3-7 days prior to delivery[41]. Urine also offers a larger volume for
collection than blood and from a toxicological standpoint it is easier to analyze than blood
because it is devoid of protein and cellular constituents that can complicate extraction and/or
analysis techniques[40].
Although neonate urine has been the most widely analyzed biological fluid for the
identification of in utero exposure to drugs, it does have several disadvantages which can
complicate collection and subsequent analyses. Neonatal urine collection is difficult, invasive
and must be performed as close to birth as possible as appreciable levels of drugs and/or
metabolites are expected to be present in the first specimen only[39, 41]. Drugs present in the
infant’s urine represent recent drug use by the mother and depending on the physicochemical
properties of the drug, the urine may test negative if the mother is an infrequent user or abstained
7

from use in the days leading up to delivery[39, 41]. Another common drawback to neonatal urine
analysis is the fact that most laboratories adopt pre-existing urine-based methodologies to screen
the infant’s urine for drugs of abuse. Unfortunately, neonatal urine is far from an ideal specimen
for such analyses. Pre-existing urine-based methodologies have been widely developed and
validated for use in workplace or forensic drug analysis[42]. Such screening techniques adopt
cutoff levels deemed suitable for their intended purpose and will most likely be too high for the
drug concentrations in clinical samples such as neonatal urine. Drug concentrations in neonatal
urine following in utero exposure would be expected to be lower than concentrations seen in
positive workplace or forensic samples due to maternal-fetal transfer kinetics, maternal
abstinence or infrequent use, and compromised sample collection at the time of birth. As a result
of these factors, several workplace drug testing thresholds have been shown to be too high for
clinical samples. The consequence of such false negatives is an underestimation of drug exposure
in the clinical setting. Multiple studies indicated that adopting lower cutoff levels for such assays
can dramatically improve detection rates[43, 44]. Due to the relative short detection window
offered by neonatal urine and a lack of recommended cutoff levels which take into account the
pharmacokinetics of drug transfer and elimination, the incidence of false-negative results in
neonatal urine analysis is high and can range from 32%-63%[41, 45].
Recently, meconium has become the specimen of choice for the detection of prenatal
exposure to several drugs of abuse[26, 46]. Meconium is the first blackish tarlike material passed
from the rectum by the newborn and is not fully evacuated until 125 hours post natal [47-49].
Meconium is a dark-green mass of water, epithelial cells, mucopolysaccharides, bile pigments,
and other lipids which begins to form between the 12th and 16th week of gestation and
accumulate until birth. Formation of meconium occurs in the fetal gut and results from
8

swallowed amniotic fluid and sloughed gastrointestinal epithelial cells[50]. Accumulation of
drugs and other xenobiotics occurs in the meconium as a result of fetal swallowing. This
phenomenon occurs when the fetus releases urine, containing drugs and metabolites, into the
amniotic fluid where it is subsequently swallowed and deposited into the meconium. Subsequent
exposure, excretion and reabsorption through fetal swallowing, combined with maternal
metabolism and elimination, and placental transfer results in the concentration of drugs and their
metabolites in meconium[51, 52]. At approximately the 16th week of gestation, the fetus
possesses fully functional liver enzymes capable of metabolizing drugs, allowing for excretion
into the bile and urine. Meconium is one of the most sensitive matrices for the detection of
prenatal drug exposure due to the accumulation of substances over several months of gestation.
The usefulness of meconium as an alternative toxicological specimen was first
demonstrated by Ostrea et al[53] in the late 1980’s, and its popularity as a tool for the
identification of prenatal exposure has continued to increase over the past two decades for
several reasons. The first reason is the relatively simple and non-invasive procedure used to
collect meconium samples, making it more successful than urine collection[54]. Meconium
analysis also extends the window of drug detection to approximately the last 20 weeks of
gestation as well as extending the window for specimen collection.
Meconium analysis has become an extremely important tool for the identification of
prenatal exposure to drugs of abuse. While the analysis of maternal and newborn blood or urine
can be useful for identifying recent (1-4 days) drug use, mothers who have abstained from use in
previous days will likely go undetected using these traditional matrices. However, due to nature
of meconium formation, which occurs over several months of gestation, isolated drug use during
the second and third trimesters will still be detectable through meconium analysis long after
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drugs have been metabolized and excreted from the blood and urine. While blood and/or urine
analysis proves useful for the identification of recent or chronic drug use, the extended detection
window afforded by meconium analysis aids in identifying infants exposed to drugs through
more isolated or recreational drug use which has previously gone undetected.
1.4

History of Meconium Analysis
The biochemical analysis of meconium for medical, clinical, and forensic purposes has

been widely reported in the scientific literature for over a century. While this review will focus
on the analysis of meconium for the purpose of identifying prenatal exposure to xenobiotics,
various scientific reports have utilized meconium analysis for alternative purposes. Meconium
analysis has been reported for the purpose of determining its metallic content[55], elucidating its
chemical composition in relation to blood-group-specific polysaccharides and abnormalities in
cases of meconium ileus[56], determining its tryptic activity in cases of congenital intestinal
obstruction[57], and isolating and preparing blood group substances for the purposes of
immunization studies[58].
One of the first reported uses of meconium as an alternate toxicological specimen was
published in 1956 by Kinsella and coworkers who wished to study the enteric excretion of
metabolites of steroid hormones in the human[59]. Although the estrogenic activity of meconium
had been previously reported by Gsell-Busse and coworkers[60], this was the first report of the
successful isolation and detection of estrogens in meconium. The authors theorized that the
isolation and detection of estriol should be possible due to the fact that meconium constitutes a
concentrate and a record of enteric excretion of metabolites throughout the fetal life. Results
indicated that estriol is present in the human intestinal content both as a free compound and as a
glucuronide conjugate, and its isolation and detection from meconium is feasible. The authors
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conclude that meconium should prove to be a fruitful biological material not only for the further
investigation of steroid hormone metabolism but for other compounds of pharmacological
interest[59].
Four years later, the same authors applied a similar methodology for the isolation and
determination of dehydroepiandrosterone from meconium[61]. While the determination of
dehydroepiandrosterone supported the authors earlier theory that meconium constitutes a record
of enteric excretion over the fetal lifetime, the absence of androsterone, a subsequent metabolite
of dehydroepiandrosterone, indicated that vast differences may exist between fetal and adult
intermediary metabolism.
The potential value of meconium, not only as an alternate biological material for
metabolic investigations, but also as a diagnostic tool to better understand the endocrinology of
the fetus was being realized by the early 1960s thanks largely in part to the work of Kinsella et
al. Following this work, several reports appeared in the scientific literature describing analytical
methodologies for the isolation and determination of steroid hormones and their conjugates in
human meconium for the purpose of endocrinology research [62-65]. Green and Shwachman
proposed the use of presumptive testing for the purpose of identifying cystic fibrosis on the basis
of high serum protein in meconium specimens[66]. The authors highlight the ongoing use of
protein analysis for the identification of meconium ileus and suggest that abnormal serum protein
levels in meconium may be a useful biomarker of cystic fibrosis in patients who did not have the
complication of meconium ileus[66].
Meconium was also utilized for the successful determination of listeria monocytogenes
for the purpose of identifying listeriosis in the newborn infant[67]. In 1968, Miettinen and
coworkers published one of the first studies on the application of gas chromatography and mass
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spectrometry for the detection of sterols in several fetal specimens including vernix caseosa,
amniotic fluid, and meconium[68].
The first reported use of meconium as an alternative toxicological specimen for the
detection of drug of abuse was published in 1987 by Ostrea et al who successfully detected
heroin, cocaine, and cannabinoid metabolites in the stools of infants born to drug dependant
mothers[69]. In the following year, Ostrea and coworkers described a method for the rapid
isolation and detection of morphine and benzoylecgonine in meconium using a simple liquid
extraction followed by radioimmunoassay screening and suggested that such a technique would
prove superior for the detection of drug metabolites in meconium due to the low incidence of
false positive results which tend to be common in urine analysis[41, 53].
Ostrea continued to publish methodologies for the detection of drugs of abuse in
meconium as alternatives to the more traditional urine analysis and in 1989 he and coworkers
analyzed 20 meconium specimens obtained from drug dependant mothers to compare the
analytical results with those obtained by urine analysis[45]. Of the 20 meconium specimens
analyzed in the study, all were positive for at least one drug metabolite using radioimmunoassay
(RIA) techniques. The widespread popularity of cocaine in the late 1980s was evident with 80%
of the specimens screening positive for benzoylecgonine while 55% of the specimens were
positive for morphine and 60% were indicative of cannabinoid use. Meconium specimens were
analyzed over the first three days of evacuation and while drug concentrations were highest
during the first two days of collection, positive determinations were still reported on the third day
of collection. Analysis of the urine only yielded positive results for 37% of the infants using
fluorescent polarization immunoassay (FPIA) and when paired urine and meconium specimens
were analyzed using RIA, higher concentrations of drug metabolites were detected in meconium.
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Interestingly, eight of the urine samples screened negative despite having a positive meconium
result indicating that meconium constitutes a very useful matrix for drug screening in the
neonate[45].
Maynard and Amoruso also investigated the usefulness of meconium as a matrix for
identifying prenatal exposure to drugs in abuse in 28 specimens collected from neonates born to
women suspected of drug abuse[70]. Urine collected from the newborn, the mother, or both,
along with meconium specimens were analyzed for the presence of cocaine, morphine, codeine
and marijuana. Results obtained through the analysis of meconium specimens were concordant
with urine analysis in 86% of the cases and in three cases meconium analysis yielded positive
results for cocaine while the newborn urine specimens were negative. The authors conclude that
due to the ease and reliable nature of meconium collection and the compatibility of this type of
screen testing with high throughput commercial laboratories, meconium is a useful specimen for
the detection of drugs in newborns[70].
In 1991, Ostrea and Welch reviewed current analytical methodologies for the
identification of maternal drug abuse and highlighted the importance of utilizing alternate
specimens such as meconium or hair as recent literature suggested that urine analysis may
seriously under diagnose the prevalence of fetal exposure to various drugs[71]. In the following
year, Ostrea and coworkers published the first large-scale, prospective, epidemiological study
into the prevalence and characteristics of maternal drug use in a high-risk, urban population by
analyzing the meconium from more than 3000 neonates delivered in a single perinatal center
over a ten month period[8]. Meconium specimens were analyzed were cocaine, morphine and
cannabinoids using RIA. Of the 3010 subjects, 44% were positive for one or more of the drug
classes while only 335 (11%) of the mothers actually admitted to maternal drug use. Of the 335
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mothers who admitted drug use, 52% of their newborns returned positive urine samples while
88% of the infants tested positive through meconium analysis. Due to the often normal
appearance of infants who have been prenatally exposed to drugs and whose mothers deny such
use, there is a growing need to more effectively identify the drug exposed child. The authors
conclude that improved identification of exposed newborns is possible with meconium drug
analysis[8].
Callahan and coworkers evaluated the sensitivity of meconium analysis compared
directly to hair and urine analysis for the detection of gestational exposure to cocaine[47]. The
meconium, hair, and urine of 59 infants who had been prenatally exposed to cocaine were
collected and analyzed using GC/MS, RIA and immunoassay, respectively. The authors
determined the most sensitive matrices for the identification of prenatal drug exposure to be
meconium or hair as traditional immunoassay analysis of the infants urine failed to identify 60%
of the cocaine-exposed infants. GC/MS analysis of the meconium or RIA analysis of the infants
hair appears to be capable of providing sufficient sensitivity required to identify fetal cocaine
exposure which occurred during the last two trimesters of pregnancy[47].
In 1992, Dahlem and colleagues published the results of yet another comparative study
aimed at assessing the suitability of meconium relative to infant urine for the identification of in
utero drug exposure[72]. The suitability of meconium relative to urine was assessed to identify
the most accurate way of determining maternal drug use as maternal admissions often prove
unreliable. Meconium and urine specimens were collected from twenty infants born to drug
dependant mothers and analyzed using RIA. Nineteen of the twenty infants (95%) tested positive
for drugs in meconium while only thirteen (65%) tested positive through immunoassay analysis
of the urine. Urine analysis failed to detect the presence of morphine in three specimens, cocaine
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in two specimens, and cannabinoids in three specimens. Results indicated that meconium is not
only easier and less invasive to collect, but it also constitutes a reliable alternate matrix to urine
for the detection of drugs in the neonate[72].
Yawn and coworkers employed meconium screening in combination with urine analysis
for the purpose of assessing substance use in rural Midwestern pregnant women[73]. Meconium
specimens screened positive for cannabinoids in 1.1% of subjects, opiates in 0.6% of subjects,
and cocaine in 0.1% of samples indicating that while substance use was relatively low in this
particular rural area, meconium analysis provides a reliable technique for the detection of such
use[73].
By the mid 1990s, meconium was widely recognized as a sensitive matrix for the
determination of prenatal drug exposure. The toxicological analysis of meconium specimens
became more common in studies aimed at determining rates of maternal substance use rather
than simply assessing the suitability of meconium for such analysis. In 1993, Dusick and
coworkers employed meconium analysis to determine the association between prenatal cocaine
exposure and intracranial ultrasonographic abnormalities, among other perinatal outcomes[74].
HPLC and GC/MS analysis of meconium specimens collected from 323 consecutively born very
low birth weight infants enabled the researchers to assign infants to either a cocaine-exposed
group, or a cocaine-nonexposed group to further study the relationship between prenatal
substance abuse and adverse perinatal outcomes. Studies indicated that while cocaine does not
appear to increase the incidence or severity of intracranial hemorrhage or periventricular
leukomalacia, it does increase the risk of abruptio placentae, surgical ligation of a patent ductus
arteriosus and seizures in very low birth weight infants. Meconium analysis will prove
instrumental in identifying infants predisposed to such outcomes[74].
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Rosengren and colleagues utilized meconium analysis to determine the prevalence of
cocaine use and assess the perceptions and pitfalls associated with current predictors of maternal
use[75]. Results indicated that meconium analysis is necessary to positively identify cocaine
exposed infants as the more traditional predictors, such as the opinion of the nurse, can be
frequently inaccurate. Lombarderoa and colleagues reported a sensitive GC/MS methodology for
the detection of cocaine, benzoylecgonine and ecgonine methyl ester (EME) in meconium
extracts taken directly from diapers of exposed infants[76]. The authors report a LOD of 11
ng/mL and conclude that GC/MS analysis of meconium provides an attractive alternative to
urine for the detection of cocaine and its metabolites as meconium collection is less invasive and
less discomforting for the neonate[76].
In 1994, following the publication of several methodologies for the detection of drugs in
meconium specimens, Wingert and colleagues conducted a large scale study aimed at comparing
meconium, maternal urine, and neonatal urine as matrices for the detection of maternal drug use
during pregnancy[77]. Meconium, maternal urine and neonatal urine were collected from 423
consecutive deliveries at a large, metropolitan obstetric hospital. Specimens were screened for
cocaine, cannabinoids, codeine, morphine, and methadone using EMIT and positive screens were
confirmed using GC/MS. Of the three matrices under investigation, meconium proved more
reliable than maternal or neonatal urine for the detection of benzoylecgonine and was equally
effective for the determination of codeine, morphine, cannabinoids and methadone[77]. Similar
publications highlighting the usefulness of meconium for the sensitive detection of drugs of
abuse lead to the widespread application of meconium analysis in both academic and health
institutions worldwide [44, 46, 78-88].
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Many early methodologies employed GC/MS for the determination of analytes in
meconium. This was largely due to the complex nature of the meconium matrix which meant that
chromatographic separation was required to isolate the analytes and mass spectral information
was required for unequivocal identification. Chromatographic techniques coupled to mass
spectrometric detectors have continued to find widespread use in forensic toxicology laboratories
for the detection of drugs of abuse in meconium.
1.4.1

Instrumental Methodologies Employed for the Analysis of Meconium
A large majority of analytical methodologies reported in the literature describing the

detection of xenobiotics in meconium have utilized GC/MS. Recent advances in analytical
technologies have allowed for the application of even more sensitive and selective assays to the
problem of identifying prenatal drug exposure in the neonate. In 2003, Pichini et al described a
sensitive methodology for the detection of arecoline in meconium using high performance liquid
chromatography (HPLC) coupled to a quadrupole mass spectrometer which was equipped with
an electrospray ionization (ESI) source[89]. Chromatographic separation was achieved using a
reversed phase column and the mass spectrometer was operated in single ion monitoring (SIM)
mode allowing for a lower limit of quantitation (LLOQ) of 5 ng/g.
One of the earliest applications of tandem mass spectrometry for the detection of xenobiotics was
published in 2005 by Choo and coworkers who employed LC-APCI-MS/MS for the
quantification of methadone and its metabolites following solid phase extraction (SPE) from
human meconium[90]. The authors report a LLOQ of 5 ng/g, highlighting the enhanced
sensitivity of the tandem mass spectrometer.
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In 2006, Kato and colleagues reported a HPLC-MS/MS methodology employing isotope dilution
and an on-line SPE for the sensitive determination of phthalate metabolites in meconium[91].
The efficiency of the solid phase extraction combined with the inherent sensitivity of tandem
mass spectrometry enabled the authors to achieve LLOQs of between 0.2 and 0.7 ng/g. Since the
appearance of these early studies in the scientific literature, tandem mass spectrometry has
allowed for the low level detection of various analytes of forensic interest such as codeine,
morphine, hydrocodone, hydromorphone, oxycodone, 6-acetylmorphine[92], amphetamine, 4hydroxy-3-methoxyamphetamine, 4-hydroxy-3-methoxymethamphetamine, methamphetamine,
3,4-methylenedioxyamphetamine, 3,4-methylenedioxyethylamphetamine, 3,4methylenedioxymethamphetamine, norephedrine, p-hydroxyamphetamine, phydroxymethamphetamine[93], alpha-hydroxyalprazolam, alpha-hydroxyethylflurazepam, alphahydroxytriazolam, alprazolam, desalkylflurazepam, diazepam, lorazepam, midazolam,
nordiazepam, oxazepam, temazepam, clonazepam, 7-aminoclonazepam[94], nicotine, cotinine,
trans-3'-hydroxycotinine, nornicotine, norcotinine[95], buprenorphine, and
norbuprenorphine[96].
While meconium analysis is today performed largely for the purpose of identifying prenatal drug
exposure, it also finds widespread application in the early identification of cystic fibrosis,
identifying prenatal exposure to neurotoxicants such as organic pesticides, detection of
cytomegalovirus, and as an indicator of the mineral nutritional history of the fetus [66, 97-99].
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Chapter 2: Introduction to the Laboratory Analysis of Toxicological
Specimens
2.1

Introduction
The analytical methodology employed for the toxicological analysis of biological

specimens depends largely on whether the testing aims to provide qualitative or quantitative
information. Although the specifics of testing procedures may vary slightly from laboratory to
laboratory, the process of measurement is usually divided into an initial screening test followed
by a confirmation test. Most laboratories perform an initial screening test when asked to analyze
any specimen for the presence of a certain drug or drug class. Screening tests provide the analyst
with a relatively quick and cost effective way to determine whether a drug or drug class is likely
to be present in a given specimen. Screening tests may be designed to detect the presence of a
certain drug class, such as benzodiazepines, or may be a broad drug screen performed on a
GC/MS which enables the analyst to screen for many drugs based on retention times and mass
spectral data. Following a positive screen result, the presence of a drug or drug class should be
confirmed using a second technique which draws on a different chemical principle. Confirmatory
tests should be more selective for the target analyte than the initial screen.
Forensic toxicology laboratories routinely offer specific testing panels aimed at detecting
and quantifying specific drugs such as ‘drugs of abuse’, ‘analgesic medications’, ‘drug facilitated
sexual assault (DFSA) drugs’, or ‘drugs capable of causing impairment’. Obviously the total
number of drugs encountered in any one forensic case can be large and while certain drugs will
provide important toxicological information, many of the drugs will not be relevant to the case at
hand. By offering panels consisting of selected analytes, forensic toxicology laboratories can
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provide the most relevant information without the cost of testing for additional analytes with
little significant to the case.
Confirmation assays are designed to identify and quantify only target analytes. The
number of analytes included in each confirmation assay is often less than the number of
compounds capable of generating a positive screen. Confirmation assays are generally designed
to identify and quantify all analytes included in a specific panel. While positive screening results
are possible due to cross reacting interferences, positive confirmations only arise when one or
more target analytes are present in the sample. Table 1 outlines the common analytes and testing
procedures for a typical ‘drugs of abuse’ testing panel.
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Table 1: Common analytes detected during ‘drugs of abuse’ screening and confirmation analysis.
Drug class
Analytes detected in screen testing
Analytes detected in
confirmation testing
• Amphetamine derivatives
• Amphetamine
Amphetamines
• Cross reactants (ranitidine, bupropion)

Cannabinoids
Cocaine
Methadone
Barbiturates

• Cannabinoids (THC and metabolites)
• Cross reactants (pantoprazole, omeprazole)
• Cocaine and metabolites
• Cross reactants
• Methadone and metabolites
• Cross reactants (doxylamine)
• Barbiturates and metabolites
• Cross reactants (Phenytoin)

Benzodiazepines • Benzodiazepines and metabolites
• Cross reactants (oxaprozin, sertraline)

Opiates

• Opiate derivatives
• Cross reactants (fluoroquinolones, ofloxacin)

• Methamphetamine
• MDMA
• TCH
• THC-COOH
• Cocaine
• Benzoylecgonine
• Cocaethylene
• Methadone
• EDDP
• Butalbital
• Phenobarbital
• Pentobarbital
• Amobarbital
• Butabarbital
• Diazepam
• Nordiazepam
• Clonazepam
• Temazepam
• Alprazolam
• Morphine
• Codeine
• Hydrocodone
• Hydromorphone
• Oxycodone
• Oxymorphone
• 6-monoacetylmorphine

Mass spectrometry (MS) has long been the recommended technique for confirmatory
testing and should be employed where possible and practical. Mass spectrometry provides the
analyst with unique structural information making the unequivocal identification of individual
drugs possible, even in the presence of chemically similar compounds. Confirmation analysis
employing mass spectrometry is generally performed following a positive immunoassay screen.
Both instrumentation and sample preparation procedures required for mass spectrometric
analysis can be cost ineffective. Initial presumptive screening employing more cost effective
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immunoassay techniques identifies a large majority of negative samples. This reduces the
number of required confirmations and therefore the overall cost of analysis.
Mass spectrometers coupled to either gas chromatographic (GC/MS) or liquid
chromatographic (LC/MS) systems are the most commonly employed analytical techniques for
confirmatory testing in the toxicology laboratory. Gas chromatography coupled with mass
spectrometry has long been the most commonly employed confirmation technique in the
toxicology laboratory. In recent years however, the coupling of liquid chromatography with mass
spectrometry has found widespread use due to its decreased sample preparation requirements and
increased sensitivity. Liquid chromatography also alleviates thermal complications associated
with GC analysis. Many compounds do not naturally lend themselves to GC analysis as they are
either too polar or insufficiently volatile. By chemically derivatizing the target analyte to either
increase its overall volatility or decrease its polarity, it is possible to increase the suitability of a
certain compound for GC analysis. While chemical derivatization alleviates some of the thermal
complications associated with GC analysis, sample preparation requirements and long run times
can prove time and cost ineffective in high throughput toxicology laboratories. Thermal stability
also presents a problem when analyzing small drug molecules, as thermally labile compounds
may undergo degradation in the injection port of the GC.
Liquid chromatography offers the analyst the advantage of introducing samples in
aqueous solvents and eliminates the need for chemical derivatization, thus greatly reducing
sample preparation time and cost. Liquid chromatography employing tandem mass spectrometry
has recently become the preferred technique for toxicological analyses due to its superior
selectivity and sensitivity which enables the analyst to quantify lower levels of analyte in more
complex matrices with reduced sample preparation.
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2.2

Sample Preparation Techniques
Sample preparation refers to a series of steps which are performed to transform a sample

into a form that is suitable for analysis. There are numerous ways to prepare samples for
chemical analysis and the method of choice depends on the nature of the sample, the method of
chemical analysis that will follow preparation, and whether the testing is presumptive or
confirmatory. Sample analysis in the forensic toxicology laboratory is typically chromatographic
which requires more extensive sample cleanup than immunoassay or spectrophotometric based
techniques.
Due to the complex nature of biological specimens and the low concentrations of drug
commonly encountered in forensic analysis, analytes of interest are often isolated or extracted
from the sample matrix and concentrated prior to instrumental analysis[100]. Direct
chromatographic analysis of biological specimens is not practical due to the large number of
naturally occurring compounds present in specimens such as whole blood, urine, and meconium.
Biological specimens are so rich in endogenous interfering species that any attempts to identify
or quantify low levels of xenobiotics without prior isolation would prove inaccurate. Isolation
and concentration of an analyte from a biological matrix prior to chromatographic analysis
allows for a more accurate identification/quantitation and ensures instrument longevity.
Chemical extractions, for the purpose of isolating and concentrating an analyte of interest
from a biological matrix, are most commonly achieved using either liquid-liquid extractions
(LLE) or solid-phase extractions (SPE).
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2.2.1

Liquid – Liquid Extraction (LLE)
Liquid-liquid extractions utilize differences in the pH and solubility characteristics of an

analyte to effectively remove the compound from an aqueous matrix such as blood or urine.
Liquid-liquid extractions are achieved by introducing an immiscible organic solvent to an
appropriately buffered aqueous specimen. Compounds in a non-ionized form will prefer the
lipophilic environment of the organic solvent while ionized species will remain the aqueous
environment of the biological sample. By appropriately buffering the biological sample
according the pH characteristics of the analyte, and introducing an immiscible organic solvent,
un-ionized drug molecules will transfer to the organic layer while many of the biological
components such as proteins remain in the aqueous layer. It is on this basis that liquid-liquid
extractions allow for the effective removal of analytes from the surrounding biological
matrix[100].
Developing an efficient LLE requires knowledge of the physicochemical properties of the
target analyte. Basic compounds are routinely extracted into organic solvents by first buffering
the sample with an appropriate base or basic buffer solution. Under alkaline conditions, basic
compounds will be unionized and will readily transfer into the organic environment of solvents
such as hexane, toluene, dichloromethane or chloroform. Similarly, acidic analytes may be
extracted into such solvents by first buffering the aqueous sample with an acid or acidic buffer
solution to ensure that the target analyte is present in an un-ionized form. Target analytes are
generally extracted into organic solvents with densities less than that of the aqueous layer to
allow for easy transfer and subsequent concentration of the analyte through simple dry down and
reconstitution steps.
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2.2.2

Solid Phase Extractions (SPE)
Solid phase extractions also aim to isolate and concentrate target analytes by removing

sample impurities. Solid-phase extractions (SPE) were originally developed for the purpose of
alleviating some of the time-related problems associated with multi-step liquid-liquid
extractions[100]. In SPE, appropriately buffered samples are applied to a silica gel based packing
material which is contained within a syringe barrel cartridge. Extractions are based on the
physicochemical interaction between the packing material and the target analyte.
Sample preparation using SPE usually consists of four basic steps; which include column
conditioning, sample loading, wash steps, and analyte elution. The first step of a solid phase
extraction is referred to as column conditioning which aims to make the subsequent extraction
easier and more efficient. Conditioning the column with a non-polar solvent not only removes
any impurities in the cartridge but also ensures maximum contact of the liquid and solid phases.
Conditioning of the column with a solvent similar in nature to the sample solvent ensures that the
sample will experience similar pH conditions when loaded onto the column. Failure to condition
the column can result in poor recoveries and irreproducible results[101].
Following column conditioning, the sample is loaded onto the SPE column in a solvent
that is weak for the sorbent being used[101]. If the solvent is too strong for the analyte of
interest, the analyte will not be retained on the sorbent and will simply pass through the column
into waste. Once the sample has been loaded onto the column, several wash steps are generally
performed to wash all remaining sample onto the sorbent and remove any undesirable sample
components. Wash steps are generally performed with a weak solvent similar in nature to the
loading solvent to ensure that no analyte is eluted during the wash process. Analyte elution is the
final step of SPE and is achieved using a solvent that is strong for the sorbent being used.
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While all SPE are performed using a similar sequence of events as the ones described
above, the nature of the packing material may be varied to provide different retention
mechanisms. Normal phase SPE involves the use of a solid phase consisting of polar functionally
bonded silica with short carbon chains. In normal phase SPE, the polar sorbent acts to retain
polar analytes while less polar components are washed through the sorbent into waste. Analyte
elution is then achieved with a highly polar solvent. Reversed phase SPE utilizes a non-polar
solid sorbent which generally consists of silicon derivatized with hydrocarbon chains. Retention
is based on the hydrophobic effect and only non-polar or weakly polar analytes will retain on the
sorbent surface. Analyte elution is achieved using non-polar organic solvents which disrupt the
hydrophobic interaction between the sorbent and the analyte.
While normal phase and reversed phase SPE separate analytes based on polarity, ionexchange SPE separates analyte based on electrostatic interaction existing between a charged or
ionized analyte and a charged sorbent. Ion-exchange SPE requires that both the analyte of
interest and the functional groups bonded to the solid phase are charged. Special consideration
must therefore be given to the solvents of choice and their respective pH.
Anion exchange sorbents are derivatized with positively charged functional groups and
act to retain negatively charged analytes. Anion exchange SPE is well suited for the extraction of
acidic compounds following buffering with a base to ensure that the analyte is negatively
charged. Sample elution is performed through the addition of an organic solvent containing a
concentrated acid (1-2% v/v) which acts to neutralize the molecule and increase its solubility in
the organic elution solvent.
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Cation exchange sorbents are derivatized with negatively charged functional groups and
act to retain positively charged analytes. Cation exchange SPE is well suited for the extraction of
basic compounds following buffering with an acid to ensure that the analyte is positively
charged. Sample elution is performed through the addition of an organic solvent containing a
concentrated base (1-2% v/v) which acts to neutralize the molecule and increase its solubility in
the organic elution solvent.
2.3

Chromatographic Separations in Forensic Toxicology
The term chromatography defines the analytical separation technique in which the

components of a mixture are carried through a stationary phase by the flow of a mobile phase.
Subsequent separation of the individual components is based on the differences in migration
rates among the sample components[102]. The two general categories of chromatography most
commonly employed in forensic toxicology are liquid chromatography (LC) and gas
chromatography (GC). In the former, the mobile phase is a liquid; in the latter it is a gas.
Chromatographic separations play an integral role in forensic toxicology as traditional
toxicological specimens commonly encountered in post mortem analysis require extensive
sample separation to isolate the compound of interest from matrix interferences and other drugs.
Gas chromatographic separations are performed by vaporizing and injecting a small
volume of sample (typically 1µL) onto the head of a chromatographic column. The sample
components are swept along the stationary phase by an inert carrier gas such as helium and the
differing degrees of interaction between the gaseous analytes and the stationary phase causes the
individual sample components to elute at different times. Stationary phases are comprised of a
microscopic layer of liquid or polymer coated onto an inert solid support and contained within a
metal capillary column maintained in a temperature-regulated oven[103]. Following injection of
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a sample mixture onto the chromatographic column, each component partitions between the
stationary phase and the mobile phase as it is continuously swept toward the detector. Sample
components that have a high affinity for the stationary phase spend more time in that phase and
take longer to reach the detector. As the individual components begin to elute from the
chromatographic column, the detector produces a signal that is proportional to the amount of
substance that passed through it[103]. Individual components that elute from the column are
identified by a characteristic retention time which is a reproducible measure of the time interval
between sample injection onto the column and peak detector response. Gas chromatographs are
commonly interfaced with mass spectrometers because the low flow rates employed for capillary
GC allow the column eluent to be directly fed into the ionization chamber of the mass
spectrometer making for easy coupling.
Liquid chromatographic separations are achieved by injecting a small volume of sample
onto a column which is tightly packed with stationary phase particles. Sample components are
carried through the column by a continuous flow of a liquid mobile phase solution. Individual
compounds pass through the column at different rates due to the differences in their partitioning
behavior between the mobile liquid phase and the stationary phase. Unlike gas chromatographic
separations where there is no direct interaction between the mobile phase (carrier gas) and the
analyte, each sample component experiences differing degrees of both chemical and physical
interactions with the stationary phase and mobile phase as it traverses the LC column. Analytes
are identified by a characteristic retention time which is an accurate measure of the time interval
between sample injection onto the column and peak detector response.
Before the development and implementation of sophisticated LC/MS interfaces, high
performance liquid chromatography (HPLC) was the fastest growing and most widely employed
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analytical separation technique due to its suitability for separating nonvolatile or thermally labile
species not amendable to GC. Traditional HPLC systems were coupled to one of several
detection systems that proved compatible with the liquid phase separation technique such as
refractive index detectors, UV/VIS (fixed wavelength, variable wavelength, diode array)
detectors, fluorescence detectors, and electrochemical detectors. The successful coupling of
liquid chromatography to mass spectrometry required the development of sophisticated
interfaces capable of combining the liquid phase separation technique, with the gas phase mass
spectrometry technique carried out under vacuum.
2.4

Ultra Performance Liquid Chromatography (UPLC)
Ultra performance liquid chromatography (UPLC) is an emerging analytical technique

which draws upon the principles of chromatography to run separations at higher flow rates for
increased speed, while simultaneously achieving superior resolution and sensitivity. Ultra
performance liquid chromatography was developed through the recognition that a reduction in
the stationary phase particle size will have the greatest benefit to any chromatographic
process[104-106]. While the increased efficiency of small particle chromatography has long been
recognized, development of techniques utilizing this science is complicated by the large
increases in system backpressures encountered when pumping mobile phase through sub 2µm
particles. Traditional HPLC systems are unable to operate at backpressures typically afforded by
small particle chromatography. While there is no single separation parameter that distinguishes
between ‘high performance’ and ‘ultra performance’ liquid chromatography, UPLC refers to
chromatographic separations employing sub 2µm stationary phase particles of high mechanical
strength.
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The evolution of packing materials designed and employed to directly affect
chromatographic separations has been based on the underlying principles of the van Deemter
equation (Equation 1)[104] [107].
H = A + B/µ + Cµ

Equation 1

The van Deemter equation is an empirical formula that describes the relationship between mobile
linear velocity (µ) and column efficiency (HETP or H) (Equation 1)[104]. The van Deemter plot
(Figure 1) illustrates the principles of the van Deemter equation and is used to predict and
determine the mobile phase flow rate where column efficiencies will be maximized[108].
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Figure 1: Van Deemter plot (Adapted from Waters, 2004).
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Figure 1 illustrates how particle diameter can significantly reduce the HETP resulting in higher
separation efficiencies. The extended minimum of the sub 2 µm particles seen in Figure 1
indicates that increases in mobile phase flow rates do not have the same negative influences on
separation efficiency as seen with the larger particles. This means that increased efficiencies are
available over a much wider range of flow rates and the speed of analysis can be increased
without sacrificing efficiency or resolution[104, 106].
Column efficiency is used to evaluate the performance of a stationary phase through its ability to
accomplish particular separations. Such evaluation entails how well the column is packed and its
kinetic performance. Column efficiency is commonly measured by the number of theoretical
plates (N) in a stationary phase. This measure of column efficiency is easily calculated by
obtaining an analytes retention time (tR) and peak standard deviation (σ) from a chromatogram
and substituting the values into Equation 2.
N = (tR/σ)2

Equation 2

The more theoretical plates a column has, the more efficient it is deemed. Although plate number
is still an accurate way to determine column efficiency, a more appropriate parameter for
measuring efficiency is the plate height or the height equivalent to a theoretical plate (HETP)
which is calculated from the column length (L) and the number of theoretical plates (N)
(Equation 3).
H = L/N

Equation 3

Measuring column efficiency based on the height equivalent to a theoretical plate (HETP) allows
for the normalization of plate number for columns of different lengths. Plate height is
traditionally measured in millimeters and as plate height decreases, column efficiency increases
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as there will be more equilibrations along the column length, leading to a more efficient
separation.
Efficiency is the primary separation parameter behind UPLC since it relies on the same
selectivity and retentivity as HPLC[107]. Review of the fundamental resolution (Rs) equation
(Equation 4) reveals that chromatographic resolution is directly proportional to the square root of
column efficiency.
Rs = (√N)/4 ((α-1)/α) (k/(k+1))

Equation 4

Increasing column efficiency will not only result in greater resolving power but also gives rise to
narrower peaks due to the fact that column efficiency is inversely proportional to the square root
of the peak width (Equation 5).
N α 1/w2

Equation 5

Narrower peak width would be expected to contribute to increased resolving power because
narrower peaks are easier to separate[107]. Increased efficiency also leads to an increase in
sensitivity, according to Equation 6, which states that peak height, and therefore sensitivity, is
inversely proportional to peak width (Equation 6).
H α 1/w

Equation 6

Yet another benefit to the chromatographer is the concomitant increase in peak capacity
per unit time in gradient separations that accompanies the taller, narrower peaks[105].
Recognition that increases in column efficiency lead to subsequent increases in resolution and
sensitivity has long existed and as a result analysts commonly employ various methods to
maximize column efficiency. According to Equations 2 and 3, gains in column efficiency can be
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achieved by increasing the number of theoretical plates or by reducing the height of the
theoretical plates. Increasing the number of theoretical plates through the employment of longer
columns may not always be desirable as this leads to increases in retention time and band
broadening. This especially holds true for high throughput forensic toxicological analysis where
sample run time must be minimized to minimize sample turnaround time, and losses in
sensitivity through band broadening are not affordable due to the already low concentrations of
analyte present in typical samples. As a result, increases in column efficiency are more
commonly achieved through the reduction of theoretical plate height.
The van Deemter equation describes the relationship between linear flow velocity (µ) and
column efficiency (H), where A, B, and C are constants related to the mechanistic components of
band broadening (Equation 1). Maximizing separation efficiencies through the reduction of
theoretical plate height (H) requires a thorough understanding of the van Deemter equation and
its individual components which all contribute to band broadening.
Eddie diffusion, also known as multiple flow path diffusion, is a phenomenon which
contributes to zone spreading and is represented by the constant ‘A’ in the van Deemter equation.
When a mobile phase moves through a porous medium such as a packed column, parts of the
stream take a more tortuous path than others. Zone spreading is the result because some solute
molecules take longer paths and lag behind the average, while others take shorter paths and move
ahead of the average[109]. Longitudinal diffusion is another phenomenon which contributes to
band broadening and can is represented by the constant ‘B’ in the van Deemter equation. When
solutes are contained in a fluid such as a mobile phase stream, they will naturally diffuse and
spread based on the concentration gradient that exists. Regardless of how discrete the solute
band, once in the mobile phase, solutes will diffuse from the center of the band to more dilute
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regions resulting in zone spreading. Due to the fact that diffusion coefficients of mobile phases
are orders of magnitude smaller in liquids than they are in gases, the longitudinal diffusion
constant (B/µ) approaches zero in the van Deemter equation as it is directly proportional to the
mobile phase diffusion coefficient. Mass transfer processes that occur in the mobile phase also
result in zone broadening and this phenomenon is represented by the constant ‘C’ in the van
Deemter equation. Such broadening occurs because both the flowing stream of the mobile phase,
and the stationary phase particles have finite widths and time is required for solute molecules to
diffuse from the interior of these phases to the interfaces which is where transfer can occur. As a
result, analyte molecules at the front of the band are swept ahead before they have time to
equilibrate with the stationary phase and molecules at the trailing edge of the band are left behind
by fast moving mobile phase[109]. Table 2 outlines the components of the Van deemter equation
and their relationship to column and analyte properties.
Table 2: Components of the Van deemter equation and their relationship to column and analyte
properties
Process
Term in equation Relationship to column and analyte
properties
Eddie diffusion
A
A = 2λdp
Longitudinal diffusion

B/µ

B/µ = (2γDM)/µ

Mass transfer in mobile phase

CMµ

CMµ = (fM(k’)d2pµ)/DM

Careful examination of the relationships existing between the three diffusion phenomena and the
column properties, leads to the conclusion that a reduction in the diameter of stationary phase
particles will have the greatest impact on theoretical plate height, and therefore separation
efficiency. Zone spreading, as a result of Eddie diffusion and mass transfer effects, is directly
proportional to stationary phase particle diameter. Reducing the diameter of the stationary phase
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particle will maximize separation efficiency through the reduction of Eddy diffusion and
diffusion resulting from mass transfer effects. Although stationary phase particle diameter does
not directly affect the phenomena of longitudinal diffusion, the higher linear velocities affordable
with smaller particles (see below) act to minimize longitudinal diffusion effects and further
maximize separation efficiency.
Reducing stationary phase particle size has been exploited as the driving force for
increasing separation efficiencies for more than forty years, however until the introduction of
UPLC, the scope of this technique was somewhat limited. Not only are traditional HPLC system
designs unable to operate at the high backpressures associated with small particle
chromatography, but traditional detection systems lack the speed required to generate sufficient
data when working with peaks that may only be a few seconds wide[107].
Examination of some fundamental chromatographic equations helps to illustrate the new
levels of speed, sensitivity and resolution provided by the three fold decrease in particle size
from 5µm (HPLC scale) to 1.7µm (UPLC scale). According to the van Deemter plot, (Figure 1)
column efficiency (N) is inversely proportional to particle size (dp) (Equation 7) due to
decreased zone broadening with smaller particles.
N α 1/dp

Equation 7

As a result, a decrease in particle size from 5µm to 1.7µm will result in a threefold increase in
efficiency. The fundamental resolution equation (Equation 4) tells us that resolution is
proportional to the square root of efficiency meaning that the threefold increase in efficiency
afforded by the 1.7µm particles also provides a 70% increase in resolution. Efficiency is also
inversely proportional to the square root of peak width (Equation 5) meaning that peak widths
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will be 70% narrower as a result of the reduced particle size. A 70% reduction in peak width
results in a 70% increase in peak height and therefore sensitivity. Reduced peak width also
provide the chromatographer with a greater peak capacity per unit time in gradient
separations[107]. Smaller particles also enable extraordinary increases in analysis speed without
sacrificing resolution[110]. According to Equation 8 column length can be reduced
proportionally as particle size is decreased without losing efficiency[110].
N = L/dp

Equation 8

This enables the chromatographer to perform separations in one third of the analysis time.
Moreover, van Deemter theory states that the optimum flow rate (Fopt), corresponding to
maximum separation efficiencies, increases as particle size decreases, according to Equation 9.
Fopt α 1/dp

Equation 9

As can be seen from the van Deemter plot (Figure 1), as particle size decreases, the
corresponding HETP also decreases, resulting in higher efficiencies. It is also evident from the
van Deemter plot that the highest efficiencies are available over a much wider range of flow rates
with smaller particles than with larger particles.
The separation efficiency of HPLC increased as the particle size of column packing
decreased from 10 µm in the 1970s down to 3.5 µm in the 1990s[111]. One consistent
observation with all of these particles sizes, as well as the 2.5 µm particles used in the early
2000s was that HETP decreased to a minimum value and then increased with increasing flow
rate[111] (Figure 1). When employing 1.7 µm stationary phase particles such as those used in
UPLC, the resulting van Deemter plot not only exhibits a decreased HETP relative to the larger
particles but also offers an extended minimum over a wider range of linear velocities[104, 111].
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As a result, flow rate or speed of analysis can be optimized without sacrificing resolution. This
means that when transitioning from 5µm to 1.7µm particles, not only can column length be
reduced by a factor of 3, but the separation can be run at three times the flow rate. This translates
to a nine fold increase in throughput with no loss in efficiency or resolution[110].
Since backpressure is proportional to flow rate, achieving small particle, high peak
capacity separations requires fully redesigned HPLC systems capable of operating at
backpressures beyond the capabilities of today’s system designs[112]. To take full advantage of
the increased speed, superior resolution and sensitivity afforded by smaller particles, instrument
technology had to be fully redesigned[112].
To fully realize the potential speed, sensitivity and resolution of UPLC separations, new
pressure – tolerant reversed phase particle had to be developed. Production of extremely small,
efficient particles with high mechanical strength would allow the analyst to surpass the
performance standards of current HPLC column technology. Early investigations into the use of
sub 2 µm particles for ultrahigh-pressure reversed phase chromatography were reported by
MacNair and coworkers who employed 1.5 µm nonporous octadecyl-silane-modified silica
particles to achieve theoretical plate counts as high as 300,000 for lightly retained
compounds[113]. In more recent years, Waters Corporation has utilized a bridged
ethylsiloxane/silica hybrid (BEH) structure with a narrow particle size distribution, produced by
the condensation of 1,2-bis(triethoxysilyl)ethane and tetraethoxysilane[114]. This new hybrid
material was developed in a 1.7 µm particle to improve efficiency, ruggedness, pH range, peak
shape and loading capacity, as well as the ability to run at elevated backpressures and
temperatures[112, 114]. The interconnection of silica atoms with ethyl groups whilst maintaining
a silica backbone has proven to be a key success factor for Waters UPLC columns because it
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means maintaining the strength of silica, while achieving reduced silanol activity and improved
resistance to alkaline conditions[114]. Peak shape is further optimized using trifunctional C18
bonding chemistry and a proprietary end-capping procedure[114].
High efficiency separations employing 1.7 µm solid phase particles routinely produce
peaks with a half-height width of less than 1 second which poses significant challenges for the
detection system[110]. One major concern when operating with very narrow peaks is the ability
of the mass spectrometer to obtain a sufficient number of data points across a peak to perform
peak integration and data-dependant MS/MS analysis[115]. To accurately and reproducibly
quantify analyte peaks with half-height widths of less than one second, detection systems capable
of rapid data acquisition are required to ensure that sampling rates are high enough to capture
sufficient data points across such narrow peaks.
2.5

Mass Spectrometry (MS)
Mass spectrometry describes the analytical technique in which components of a sample

or mixture are converted into rapidly moving gaseous ions and subsequently separated and
identified based on their mass-to-charge ratios. Mass spectrometry provides both qualitative
(structural) and quantitative (molecular mass or concentration) information about analyte
molecules following their conversion into gaseous ions[116]. Mass spectrometry is typically
preceded by a chromatographic separation such as gas chromatography (GC) or liquid
chromatography (LC) to resolve the molecules of interest from possible matrix interferences.
Following elution from the chromatographic column, molecules of interest are introduced into
the ionization source of the mass spectrometer.
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Ionization can be achieved using a variety of mechanisms which are referred to as either
“hard” or “soft” ionization techniques as described my McLafferty et al[117]. Hard ionization
techniques produce ions which possess appreciable internal energies and tend to undergo
fragmentation, whereas soft ionization techniques produce ions with low internal energy which
reduces the propensity for fragmentation. Efficient ionization produces either positive or
negative ions of interest which then travel through the mass analyzer where they are separated
and/or filtered according to their mass-to-charge (m/z) ratio. Following mass analysis, stable ions
make contact with the detector where a signal is generated describing the relative abundance of
each signal according to the mass-to-charge ratio[116].
Mass spectrometry is recommended as the confirmatory technique in forensic
toxicological analysis because of its ability to generate a unique mass spectrum for most
compounds which can be used to characterize the sample[118]. Strong recommendations for the
use of mass spectrometry exist because of its ability to both determine molecular weight and
elucidate structural information[119].
Although direct mass spectrometric analysis is feasible through injection without prior
chromatographic separation, traditional toxicological analyses have utilized mass spectrometers
coupled to gas chromatographs. Chromatographic separations are often required prior to mass
spectrometric analysis due to the complex biological matrices typically encountered in the
forensic toxicology laboratory. Due to the ease at which gas chromatographic systems are
interfaced with mass spectrometers, GC/MS analysis has become the most common technique
for toxicological screening and confirmation in the forensic and clinical industries.
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Electron ionization (EI) is a hard ionization technique commonly employed in GC/MS
experiments. EI induces significant fragmentation of the analyte giving rise to characteristic
fragments which are subsequently used for structural information. The masses of these fragments
are characteristic of the original analyte molecule and the way in which it fragmented under EI
conditions. Confirmation analysis by GC/MS has traditionally offered superior sensitivity,
selectivity, speed and precision and remains the method of choice for the detection and
quantification of drugs and poisons volatile under GC/MS conditions[120]. GC/MS is still
widely employed in many toxicology laboratories for a number of reason including; (1)
instrumentation is readily available and reasonably inexpensive, (2) laboratory staff have
extensive working knowledge of both the hardware and software, (3) electron impact ionization
(EI) provides structural information through ‘hard’ ionization, (4) extensive searchable mass
spectral libraries exist to assist with identification of unknowns, and (5) GC/MS interfaces are
relatively simple and easy to maintain[121].
While gas chromatographs represent an almost ideal inlet device for a mass spectrometer,
the chromatographic separation itself is not suited to all molecules and hence limits both the
capabilities and applications of GC/MS in the toxicology laboratory. In order for a compound to
be amendable to GC analysis it must possess sufficient volatility so that its molecules exist in the
gas or vapor phase at temperatures at or below 400°C. Gaseous analyte molecules need also be
thermally stable to avoid sample degradation in the injection port of the gas chromatograph.
Many drugs of forensic importance such as the benzodiazepines, tricyclic antidepressants, and
acetaminophen are not naturally amendable to GC as a result of their high polarity, thermal
lability or low volatility[122]. As a result LC has acquired a role of growing importance due to
its separation capabilities for such compounds[123].
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Early in development, conventional detection systems for LC did not include mass
spectrometry. This was because solutes eluting from an LC column are dissolved in a liquid
mobile phase at atmospheric pressure, and mass spectrometers are configured to detect gas phase
ions under vacuum. Due to the incompatibility of LC with MS detection, unequivocal
identification of analytes was not always possible due to the possibility of co-elution and falsepositives associated with ultra violet (UV) detection. While the potential capabilities and
advantages of coupling LC with mass spectrometry (LC/MS) were well recognized, design and
development of sophisticated interfaces for devices having different strategies proved both time
consuming and expensive.
2.6

The Rise of Liquid Chromatography – Mass Spectrometry (LC/MS)
Research and long-term development over the last 35 years has produced seven major

interfacing techniques that have made LC/MS experiments both possible and suitable for the
field of analytical and forensic toxicology[124]. In 1969 Tal’roze and coworkers employed a
capillary inlet interface in one of the earliest reported attempts at developing an LC/MS
experiment[125]. Since the early work of Tal’roze et al., various interfaces have been designed
to achieve both chromatographic solvent evaporation and analyte ionization. Elimination of the
chromatographic solvent prior to MS detection, flow rate incompatibilities, the inability of mass
spectrometers to handle non-volatile buffers, and achieving efficient and reproducible ionization
of non-volatile and/or thermally labile analytes all arose as problematic complications during the
development of LC/MS interfaces. Several interfaces, each providing a variety of technological
solutions to the problems listed above, have transformed LC/MS into a robust, widely applicable
and wide-spread analytical technique[126].
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2.7

LC/MS Interfaces
Recent reviews have indicated that of the 25 different LC/MS interfaces that have been

described in the literature over the past 20 years, only 5 are actively used today and even fewer
are the subject of any further developmental research efforts[127, 128]. Interfaces most
commonly employed today include thermospray (TS), particle beam (PB), fast atom
bombardment (FAB), atmospheric pressure chemical ionization (APCI), and electrospray
ionization (ESI).
2.7.1

Thermospray Interface (TP)
The original thermospray interface introduced by Vestal and co-workers in 1983 used a

heated vaporizer tube to generate a jet of vapor and small droplets from the LC column
effluent[129, 130]. The pressurized solution flows through the heated capillary at flow rates
approaching 2 mL/min where it undergoes almost complete volatilization. It is then nebulized
into an expansion chamber where it is ionized at low pressure by the solvent buffer (solventmediated chemical ionization), a filament, or by a discharge electrode[124].
Following ionization and complete desolvation, analyte ions are transferred to the mass
spectrometer by means of a repeller electrode which can have varying voltages applied to it to
enhance fragmentation of the analyte. Application of a higher voltage to the repeller electrode
increases the acceleration of the analyte ions so that subsequent collisions with residual solvent
molecules will result in fragmentation.
Mass spectra resulting from thermospray ionization usually yield little structural
information and prove less useful for the identification of unknown compounds. Because of this,
TS ionization is generally employed for target compound analysis[130]. A review in 1997
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highlighted the widespread use of the thermospray interface in the early 1990s, in particular, for
the sensitive detection of steroids, drugs of abuse, thiourea pesticides, mycotoxins, indolic
compounds and tricyclic antidepressants[124]. The introduction of more sensitive and robust
approaches to mass spectrometric analyses based on atmospheric-pressure ionization techniques
have largely replaced thermospray applications[131].
2.7.2

Particle Beam Interface (PB)
The original particle beam (PB) interface was introduced as the ‘mono-disperse aerosol

generating interface for chromatography’ (MAGIC-LC-MS) in 1984 by Willoughby and
Browner[132]. In PB ionization experiments, the chromatography effluent is nebulized either
pneumatically or by thermospray nebulization at atmospheric pressure into a slightly heated
desolvation chamber. The desolvation chamber is connected to a momentum separator which is
the principle component of the PB interface. Following desolvation, analytes are transferred into
the low-pressure ion source through a two-stage jet separator where the high mass analytes are
preferentially transferred to the MS ion source while the low mass solvent molecules are
essentially pumped away[126]. Subsequent ionization occurs via EI, CI, or fast atom
bombardment (FAB). The PB interface offers the advantage of compatible coupling to any mass
spectrometer with minor (if any) modification. Such compatibility means that the PB interface
enables the coupling of a wide range of LC separations to conventional CI or EI MS procedures.
Offsetting the advantage of accommodating EI for structural information are the
disadvantages of low sensitivity, non-linear responses due to matrix effects, and possible
discrimination of low mass, volatile samples in the jet-separating region [124, 130, 132].
Although the PB interface has been sparsely used for the confirmation of ivermectin in bovine
milk and liver[133] and human metabolites of nicotine in serum and serum[134], its
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susceptibility to matrix effects significantly limits the useful linear dynamic range of the
technique[131].
2.7.3

Fast Atom Bombardment Interface (FAB)
In a continuous flow or dynamic fast-atom bombardment (CF-FAB) interface, a small

liquid stream (5-15µL/min) is mixed with a FAB matrix solvent such as glycerol, sulfolane,
diethanolamine, or triethanolamine and introduced into the low-pressure ion source of the mass
spectrometer through an open-ended or frit-terminated (frit-FAB) capillary[124]. Ions are
generated by bombardment of the resulting liquid film with accelerated atoms of an inert gas
such as argon or neon. Generated ions are extracted by an electrode and subsequently transferred
to the mass analyzer.
FAB is a relatively soft ionization technique primarily producing intact molecular ions.
Dynamic FAB alleviates many of the problems associated with static FAB such as differing
responses for hydrophobic and hydrophilic analytes and low detection limits due to background
signal from matrix related ions[126]. Secondary ions mass spectrometry (SIMS) experiments can
also be performed using the same type of interface when using ions rather than atoms for
bombardment ionization[124]. Although easy to implement, FAB interfaces are finding limited
use in modern literature, primarily due to the introduction of atmospheric pressure ionization
(API) techniques.
2.7.4

Atmospheric Pressure Ionization (API) Techniques
Atmospheric pressure ionization techniques have quickly become the most widely

employed LC/MS interfaces for the analysis of a variety of analytes in forensic and clinical
toxicology since their introduction in the mid 1980s. The two most common API techniques
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include atmospheric pressure chemical ionization (APCI) and electrospray ionization (ESI). API
interfaces consist of five principle components (Figure 2): (1) the liquid introduction device or
spray probe, (2) the atmospheric-pressure ion source region, where ions are generated by means
of electrospray ionization (ESI), or atmospheric-pressure chemical ionization (APCI), (3) an ion
sampling aperture, (4) an atmospheric-pressure to vacuum interface, and (5) an ion optical
system which is responsible for transferring the generated ions into the mass analyzer[135, 136].

Figure 2: Schematic of an electrospray interface (ESI) (Adapted from Slobodnik 1995).
Specialized design of the last two components is crucial as they determine whether or not
the analyst achieves the high ionization efficiencies that are possible with such techniques. Ion
losses during transfer from the atmospheric ionization region to the high vacuum region of the
mass spectrometer are inevitable, however, proper design of the vacuum interface and ion optics
will act to minimize these losses and ensure optimal sensitivity[135].
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Both ESI and APCI operate by first generating a fine, continuous spray from the liquid
chromatographic effluent. Nebulization into the atmospheric-pressure ion source region is
achieved pneumatically (APCI), by the action potential of strong electrical field (ESI), or by a
combination of the two (pneumatically assisted ESI)[135]. Following generation of the aerosol,
gas phase ions are formed by one of several mechanisms explained in more detail below (see
sections 2.7.5 and 2.7.6), and these ions, along with solvent vapor and nitrogen bath gas are
sampled into a first pumping stage by an ion sampling device. As the mixture of analyte ions,
solvent vapors and gases supersonically expand into this first low pressure region, the ions of
interest along with other high molecular mass molecules populate the core of this expansion. By
employing an appropriate skimmer to sample these core components, analyte ions are transferred
into a second pumping stage which is equipped with an ion focusing device and transfer optics
which subsequently transfer the ions of interest to the mass analyzer region of the mass
spectrometer (pressure <10-3 Pa)[136].
API techniques such as APCI and ESI offer several advantages over the earlier LC/MS
interfaces, four of which were noted by Voyksner as being: (1) Techniques such as APCI and
ESI can handle liquid flow-rates that are typically used in LC because the sampling orifice
actually acts as the restrictor between the atmospheric-pressure region and the first pumping
stage, (2) API techniques are suited to the analysis of highly polar, non-volatile, and thermally
labile species typically separated in the liquid phase, (3) API-MS techniques exhibit high
sensitivities due to the soft nature and high efficiency of the ionization mechanisms, (4) API-MS
techniques are comparatively robust and relative easy to use[137]. LC/MS interfaces relying on
the formation of ions at atmospheric-pressure also prevents the problem of vaporized solvent
entering the vacuum system of the mass spectrometer[123].
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APCI and ESI are both soft ionization techniques giving rise to ions which possess
minimal internal energies and thus undergo little fragmentation[138]. Ionization of analytes
using either APCI or ESI results in the formation of primarily singly-charged ions (“quasi
molecular ions”) through the addition or subtraction of a proton giving rise to [M+H]+ and [MH]- ions respectively[139]. While the formation of singly charged molecular species using API
techniques provides little structural information in comparison to hard ionization techniques such
as EI, the ease of identification based on, or information pertaining to, the molecular weight of
the analyte is maximized.
2.7.5

Atmospheric Pressure Chemical Ionization (APCI)

APCI describes the chemical ionization of compounds in an ion source operated at
atmospheric-pressure conditions[140, 141]. A typical APCI source requires the following
components for successful operation:
•

A capillary out of which the chromatographic effluent is sprayed by means of a
concentric nebulizer gas.

•

A heated vaporizer tube which desolvates the analyte molecules.

•

A corona discharge needle which ionizes the molecular mist exiting the vaporizer tube.

•

Ion focusing and entrance optics for ion transfer into an area of intermediate vacuum,
followed by further focusing elements and skimmers which transport the ions into the
high vacuum mass analyzer[142].
Nebulization of the LC effluent into the atmospheric-pressure ion source is performed by

a heated nebulizer with pneumatic assistance. Nebulizer temperatures of up to 500°C induce
solvent evaporation and ions are generated through subsequent gas-phase ion-molecule reactions.
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Reagent ions responsible for the ionization of analyte species are normally created by means of a
corona discharge and the subsequent ionization mechanisms are the same as those encountered in
traditional medium-pressure chemical ionization (CI)[126, 135]. Positive ion formation takes
place following proton transfer, adduct formation or charge exchange reactions while negative
ion formation is achieved by proton abstraction, anion attachment, or electron-capture
reactions[126].
APCI is widely employed for the analysis of low to moderately polar compounds. Unlike
ESI, solvent evaporation in APCI experiments occurs prior to analyte ionization and the two
processes are separate. Solvent evaporation during APCI experiments is supported by the
application of high temperatures to the nebulizer while a discharge electrode subsequently acts to
ionize solvent molecules, which, after several ion molecule interactions, transfer a charge to the
analyte molecule resulting in ionization[124, 139]. APCI is slightly harder than ESI and can
induce some degree fragmentation of the molecular species due primarily to the high
temperatures employed for the purpose of solvent evaporation[139]. APCI allows for the
sensitive determination of analytes possessing moderate polarity and molecular mass (Figure 3)
and exhibits high sensitivity for large lipophilic molecules which are not amendable to ionization
by other techniques[124, 142].
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Figure 3: Relationship between molecular mass and analyte polarity for analytes suited to
GC/MS and different LC/MS interfaces (Adapted from Maurer 1998).

2.7.6

Electrospray Ionization (ESI)
Electrospray ionization (ESI) has quickly become one of the most important and widely

employed ionization techniques for the on-line coupling of liquid phase separation
methodologies with mass spectrometry (MS). Such coupling has paved the way for numerous
electrospray ionization mass spectrometric (ESI-MS) methodologies which have revolutionized
the capabilities of clinical and forensic laboratories to detect low levels of analytes in complex
biological matrices. Coupling of electrospray ionization with modern mass analyzers provides
the analyst with a sensitive, robust and reliable tool for the analysis of femto-mole quantities of
non-volatile and thermally labile biomolecules which are not amendable to analysis by
traditional techniques[116].
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The electrospray ionization process employs electrical energy to assist the transfer of
ionic species from solution into the gas phase before they are subjected to mass spectrometric
analysis (Figure 4). The process of transferring ionic species from a solution into gas phase ions
can be described by a three step process:
1. Nebulization of a sample solution into electrically charged droplets (Figure 4).
2. Solvent evaporation (Figure 4).
3. Ion ejection from the highly charged droplets (Figure 4)[116].

1.)

2.)

3.)

Figure 4: Schematic of electrospray ionization (ESI) showing the three steps of ionization: 1.)
Nebulization of a sample solution into electrically charged droplets, 2.) Solvent evaporation, and
3.) Ion ejection from the highly charged droplets (Adapted from Lam 2003).

The initial formation and dispersion of a fine mist of charged droplets is achieved through
electrospray nebulization. When a liquid is exposed to a high electrical field, a mist of highly
charged droplets is formed in a process termed electrospray nebulization. Electrospray
nebulization is achieved by pumping a continuous sample solution through a stainless steel or
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quartz silica capillary tube at a very low flow rate (0.1-10 µL/min). A high voltage (2-5 kV) is
applied to the capillary relative to the wall of the surrounding chamber[116]. The high electrical
field at the tip of the capillary tube acts to pull like charge toward the liquid front resulting in
charge deposition on the surface of the emerging liquid. As charge accumulates at the liquid
front, electrostatic repulsions at the exit of the electrospray tip also increase. When the
electrostatic repulsion becomes stronger than the surface tension, a highly charged droplet with
the same polarity as the capillary voltage is generated[116, 143]. The point at which droplets
emerge from the liquid solution is referred to as the Rayleigh limit and is defined as the point at
which coulombic repulsion of the surface charge is equal to the surface tension of the
solution[144].
Electrically charged droplets generated at the tip of the capillary tube through
electrospray nebulization then pass through the surrounding gas, down a potential gradient, to the
counter-electrode. Positively charged droplets are generated when the capillary is held at a more
positive potential than the counter-electrode causing positive charge to accumulate at the
capillary tip. A reversal of the electric field will result in the formation of negatively charged
droplets travelling down a potential gradient to a counter-electrode being held at a more positive
potential. The formation of micrometer-sized droplets depends on the liquid’s flow rate, surface
tension and electrolyte concentration[143]. A significant increase in any one of the three
aforementioned variables can greatly decrease the ability of the electric field to generate the
desired aerosol required for ion transfer to the mass spectrometer. Small increases in a liquid’s
flow rate, surface tension or electrolyte concentration may be overcome by increasing the
electrical field at the tip of the capillary however care must be taken to ensure that the increase in
electric field energy does not give rise to an electrical discharge[143].
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The second step in the process of transferring condensed phase ion into gas phase ions
suitable for mass spectrometric analysis involves solvent evaporation. Electrospray nebulization
produces electrically charged droplets when charge repulsion exceeds the cohesive force that
holds the liquid together. Electrically charged droplets then traverse down a potential gradient
toward the entrance to the mass spectrometer, and generate analyte ions by one of several
proposed mechanisms.
The coulomb fission mechanism proposes that the increased charge density due to solvent
evaporation causes large droplets to undergo size reduction into successively smaller droplets
which eventually consist of a single analyte ion[145]. Solvent evaporation is aided by elevated
source temperatures and/or the introduction of a stream of nitrogen drying gas. The reduction in
droplet size through solvent evaporation results in an increase in charge density at the surface of
the droplet. Further deformation of the droplet occurs as a result of the shear forces experienced
by the droplet during its flight through a dense desolvation gas toward the counterelectrode[143]. As the droplets evaporate, the increasing coulomb forces exceed the surface
tension causing the droplet to undergo fission (Figure 4). Successive fissions ultimately give rise
to droplets containing a single analyte molecule possessing and retaining the droplet charge as
the remaining solvent evaporates[146]. A second mechanism for the formation of single analyte
ions assumes that the increase in charge density resulting from solvent evaporation eventually
results in coulombic repulsions that exceed the liquid’s surface tension and as a result, ions are
released from the droplet surfaces[147]. This mechanism is termed ion evaporation and theorizes
that microdroplets with an approximate radius of 10nm resulting from successive fissions, do not
experience further disintegration to smaller droplets but rather emit ions from their surface in
order to alleviate charge repulsion[116, 143].
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While ionization of analytes during ESI experiments occurs predominantly through
condensed phase equilibrium or charge transfer complexation in solution, gas phase interactions,
occurring after the analyte has been released from solution also exist[148]. Gas phase
interactions occur following droplet emission and prior to the analyte reaching the mass analyzer.
As a result, such reactions can have a significant effect on MS response[149]. Gas phase
interactions which result in analyte charging during ESI experiments occur through gas-phase
proton-transfer reactions. Such a phenomenon exists primarily because the gas phase basicity,
and therefore proton affinity, of certain molecules can be markedly different to their basicity in
solution. Initial charging of molecules during ESI experiments occurs in the condensed phase
through equilibrium and charge transfer according to the molecules solution-phase basicity.
Following electrospray nebulization into the gas phase, molecules that were protonated in
solution can yield their protons to solvents or analytes with greater gas-phase basicity[149]. Such
gas-phase proton transfer reactions take place when there is an inversion in the order of basicity
among a series of molecules proceeding from solution into the gas phase[150]. Analyte
molecules which are sprayed and ejected as neutrals can become positively charged through gasphase interactions with solvent ions which exhibit a higher basicity in solution but possess
inferior gas-phase basicity. As a result of this basicity inversion, the protonated solvent molecule
yields its proton to the more basic gas-phase analyte resulting in gas-phase charging. Increased
signal through gas-phase analyte charging can greatly increase sensitivity in ESI-MS
experiments however analyte response may also be completely suppressed in situations where
the electrospray solvent has a higher gas-phase proton affinity than the analyte[151]. It is
therefore imperative to select an electrospray solvent which possesses a lower gas-phase proton
affinity than the analyte of interest.
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Of the above interface technologies, most research and further development efforts are
focused around the atmospheric pressure ionization (API) techniques, specifically, atmospheric
pressure chemical ionization (APCI) and electrospray ionization (ESI).
2.8

LC/MS/MS and its Applications in Forensic Toxicology
The vast majority of LC/MS instrumentation employs APCI or ESI due to the large

number of compounds which are amendable to soft ionization techniques, regardless of their
polarity or molecular weight (Figure 3). API techniques produce characteristic ions depending on
the ion mode in which the spectra are obtained. In positive-ion mode the base peak is normally
the protonated molecular ion [M+H]+ which is often accompanied by less abundant metal
adducts such as [M+Na]+ and [M+K]+[152, 153]. When spectra is obtained in negative-ion
mode, the deprotonated molecular species [M-H]- generally constitutes the base peak[152].
While soft ionization techniques such as APCI and ESI provide abundant ions of the molecular
species, leading to increases in sensitivity, they yield very few, if any, fragments and therefore
provide relatively little structural information and limited selectivity[154]. To order to increase
the selectivity of experiments employing soft ionization techniques, tandem mass spectrometry
(MS/MS) is applied to induce fragmentation of the molecular species and give rise to structurally
significant product ions[155].
Tandem mass spectrometry employs two stages of mass analysis to examine the
fragmentation of analyte ions within a mixture of ions. The increased selectivity afforded by
tandem mass spectrometry has been widely utilized in the fields of forensic and clinical
toxicology where analyte identification can prove challenging due to the complex nature of
biological matrices[154]. Tandem mass spectrometers provide an added dimension of mass
spectral information by creating ionic species from a sample, mass selecting a precursor ion,
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inducing fragmentation of that selected ion and obtaining the mass spectrum of the structurally
significant fragments[156]. The goal of tandem mass spectrometry is to provide the analyst with
additional structural information not normally yielded by soft ionization techniques, while
simultaneously retaining the sensitivity afforded by the soft ionization. By employing two or
more mass spectrometers with a collision cell positioned in between, tandem mass spectrometry
ensures increases in selectivity by providing characteristic molecular fragments generated by
collision-induced dissociation (CID)[157]. Tandem mass spectrometers allow for the selective
determination of multiple analytes within a single run by monitoring multiple ions or
fragmentation transitions characteristic to individual analytes. In addition, the baseline separation
of analytes from matrix interferences, which is a must for HPLC employing UV or MS detection,
is not required in MS/MS experiments because of its inherent selectivity[157].
Tandem mass spectrometry is achieved using a variety of instruments which can be
classified into two categories of tandem mass spectrometers. The first category is made up of
instruments in which two mass spectrometers are assembled in tandem such tandem massanalyzing quadrupoles, tandem time-of-flight analyzers or a combination of the two (QTOF).
The coupling of several different analyzers for the purpose of MS/MS experiments have been
described in the literature. The sequential combination of mass analyzers is generally intersected
by a collision cell which is designed to induce dissociation of the precursor ions through
collisions with an inert gas such as argon. Product ions resulting for CID are then analyzed in the
second quadrupole. Experiments performed using the sequential combinations of mass analyzers
are referred to as tandem-in-space mass spectrometry. Tandem mass spectrometry experiments
can also be performed using another category of instruments which are characterized by their
ability to store ions. Mass analyzers which are capable of storing ions for subsequent analysis
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include the ion cyclotron resonance (ICR) and the quadrupole ion trap mass[154]. Mass analysis
is performed by creating precursor ions and storing them in a radio frequency (rf) trapping field.
Following ion production, separation and storage, precursor ions can be excited and caused to
fragment during a selected time period by the application of additional rf waveforms.
Fragmentation of the precursor ions leads to the generation of characteristic product ions which
can be observed in a mass spectrum by utilizing the highly efficient ion manipulation capabilities
of such analyzers[154, 158]. This process may be repeated to obtain the mass spectrum of
fragments over several generations without the need to transfer ions from one vacuum chamber
to the next, rather, a single chamber utilizing a quadrupole rf field is used for all analyses[154,
158]. Experiments performed using mass analyzers capable of ion storage are referred to as
tandem-in-time mass spectrometry. Tandem mass spectrometry combined with the appropriate
chemical separation technique such as liquid chromatography or gas chromatography provide
analysts with impressive selectivity and sensitivity by eliminating a large majority of chemical
noise, resulting in superior selectivity and limits of detection relative to single mass spectrometry
experiments[158]. The majority of tandem mass spectrometric experiments performed in recent
times have employed a “tandem-in-space” approach and the most widely used tandem mass
spectrometer of this category is the triple quadrupole.
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2.9

Triple Quadrupole Mass Spectrometer

2.9.1

Introduction
The triple quadrupole assembly was first introduced by Yost and Enke in 1978 for the

purpose of mixture analysis and structural elucidation[156]. A quadrupole is a mass analyzer
consisting of four co-linear rods, set parallel to each other (Figure 5).

From ion source

To detector

Figure 5: Schematic of a quadrupole mass analyzer.

Each opposing pair of rods is connected electrically and an RF voltage is applied between the
two rod pairs. A DC voltage is then superimposed onto the RF voltage and it is the ratio of these
two voltages that enables the quadrupole to perform mass analysis. Depending on the exact
potential applied to the rods, only ions with a certain m/z ratio will pass through the quadrupole
and reach the detector because the applied voltages affect the trajectories of ions travelling down
the flight path which is centered between the two sets of rods. Ions with unstable trajectories in
the oscillating electric fields will collide with the rods and exit the system through vacuum. For a
given voltage, only ions with a certain m/z ratio will pass through the quadrupole and reach the
detector while all other ions are essentially filtered out. Quadrupole mass analyzers were
employed in the first desktop LC/MS systems and are still the most commonly employed and
least expensive mass analyzers used in LC/MS instruments[159].
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The stability and motion of ions in a quadrupole is significantly different from those
observed in field-free regions and in magnetic and electrostatic sectors[160]. Ion trajectories in
dynamic instruments such as quadrupole devices are influenced by time-dependant forces which
complicate their mathematical prediction relative to sector instruments. The motion of ions in a
quadrupole field can be mathematically described by solutions to the second-order linear
differential Mathieu equation (Equation 10).
((d2u)/(dζ2)) + (au – 2qucos2ζ)u = 0

Equation 10

Mathieu was able to describe solutions in terms of regions of stability and regions of instability
while investigating the mathematics of vibrating stretched animal skins[160]. The Mathieu
equation can be applied to describe the regions of stability and instability during ion trajectory in
a quadrupole device. The Mathieu mass stability diagram shown in Figure 6 is derived from the
Mathieu equation and illustrates regions of stable and unstable trajectory for two ion masses (A
and B) entering a quadrupole at the same time.
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Figure 6: Mathieu stability diagram of two masses (A and B) in a quadrupole mass filter. Voltage
coordinates corresponding to points under the stability curve represent stable trajectories while
all other voltage conditions result in unstable ion trajectory in the quadrupole device.
Any of the RF/DC conditions under the stability curve represent conditions of stable
trajectory during which that mass will pass through the quadrupole to the detector. RF/DC
conditions appearing only under the left hand curve will allow only mass A to pass through the
quadrupole while mass B will experience unstable trajectory and be removed from the
quadrupole through vacuum. Similarly, any of the RF/DC condition appearing only under the
right hand curve will only allow mass B to pass through the quadrupole. Figure 6 shows three
dotted lines which represent typical quadrupole scan lines which pass through the stable regions
of each curve under different RF/DC conditions. If the slope of the RF/DC scan is steep, similar
to the top line in Figure 6 the spectral peaks will be narrow and well separated due to the smaller
regions of stability encountered by those scan conditions. If the slope of the RF/DC scan is
shallow, as represented by the middle line in Figure 6, spectral peaks will be wider and poorly
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separated leading to less resolving power. If the slope of the RF/DC scan is too shallow, as
represented by the bottom line in Figure 6, masses A and B will pass through the quadrupole
without being separated due to significant overlap in regions of stability[161].
Understanding the principles of the Mathieu equation and corresponding stability plots
enables the analyst to monitor the presence and abundance of a particular mass or scan the mass
range by varying the rf and dc voltages applied across the rods and obtaining the corresponding
mass spectrum. Only the first (Q1) and third (Q3) quadrupoles are operated using a combination
of rf and dc voltages necessary for mass analysis, while the second quadrupole (Q2) is operated
with a fixed rf voltage only and therefore allows ions of all masses to pass through it. Q1 and Q3
both have the ability to perform mass analysis while Q2 is employed as a collision cell with ion
focusing properties in which precursor ions, having already passed through Q1, undergo collision
induced dissociation (CID) into characteristic product ions which can then be scanned or
transmitted using Q3 (Figure 7)[154]. Collision induced dissociation is achieved by selecting a
parent mass to pass through Q1 and into the quadrupole collision cell where it collides with
atoms of an inert gas, usually argon, and acquires energy which leads to its subsequent
decomposition into characteristic product or daughter ions[118]. CID is widely employed to
obtain structurally characteristic fragmentation patterns which are used for the unequivocal
identification of analytes in complex matrices[162]. The reproducibility of CID is dependent
upon the chosen collision gas, collision energies, and collision gas flow. While specific
parameters may be optimal and constant on one instrument, significant variation is common
between instruments meaning that CID product ions may also be instrument and laboratory
dependant. Variations in CID parameters, and therefore product ions, between laboratories
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complicate the development of reference spectral libraries. For this reason LC-MS/MS does not
currently possess the same discriminative power as GC/MS employing EI.

Figure 7: Schematic representation of a triple quadrupole mass spectrometer.
2.9.2

MS Operating Modes
Mass analysis can be performed utilizing one or both of the mass analyzers when

employing triple quadrupole instruments as they have the ability to operate in the single mass
spectrometry (MS) mode or tandem mass spectrometry (MS/MS) mode. Single mass
spectrometry experiments are performed using one of three main MS scan modes (Table 3). The
most widely employed MS mode is the MS1 mode in which the first quadrupole (MS1) is
employed as a mass filter while the collision cell and MS2 allow all masses exiting MS1 to pass
through to the detector. MS1 mode is the most sensitive method for performing MS analysis and
it is directly analogous to experiments employing a single-quadrupole mass spectrometer for the
purposes of scanning a mass range[163]. The MS2 mode of operation is also employed for MS
experiments however it provides optimum performance with scan speeds greater than 2000
Da/s[163]. MS2 is achieved by allowing ions of all masses to pass through MS1 and Q2 while
employing the fast MS scanning capabilities of MS2. The SIR (selected ion recording) mode of
operation is employed as a quantitative tool for MS analysis when no suitable or reproducible
fragmentation pattern of the parent molecule can be identified to allow for a more selective
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MS/MS analysis[163]. SIR (or SIM) is directly analogous to single quadrupole mass
spectrometry experiments in which a single ion of interest is pre-selected to oscillate through the
quadrupole.
Table 3: MS operating modes using the triple quadrupole mass spectrometer.
Operating mode
MS1
Collision cell
MS1

Resolving (scanning)

MS2
SIR

2.9.3

MS2

Pass all masses

Pass all masses
Resolving (static)

Resolving (scanning)
Pass all masses

MS/MS Operating Modes
By operating in tandem mass spectrometry (MS/MS) mode by utilizing the mass analysis

capabilities of Q1 and Q3, an additional dimension of mass spectral information is provided. The
combination of two mass analyzers provides the analyst with the option to acquire information
using additional operating modes not amendable to traditional single-quadrupole MS analysis.
Because both analyzers can be operated in the scan or selected-ion mode (SIR), the number of
possible combinations and therefore operating modes is extended to four (Table 4)[120].
Table 4: MS/MS operating modes of the triple quadrupole mass spectrometer.
Operating mode
MS1
Collision cell

MS2

Product

Static

Pass all masses

Scanning

Precursor

Scanning

Pass all masses

Static

MRM

Static

Pass all masses

Static

Constant neutral loss

Scanning

Pass all masses

Scanning

When operating in product (daughter) ion scan mode, the first quadrupole is static and allows
only ions with a specific m/z (precursor ions) to pass through into the collision cell. The collision
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cell operates as normal by inducing fragmentation of the precursor ions through energetic
collisions with atoms of an inert gas such as argon. Fragmentation produces characteristic
product ions which are then scanned by the third quadrupole which is set to scan over an
appropriate mass range. A product ion spectrum (formerly referred to as a daughter ion
spectrum) is obtained when operating in product ion scanning mode. (Figure 8)[163]. Product
ion scanning is most commonly employed in method development to identify fragmentation
patterns of a specific analyte. Optimization of CID conditions is achieved using product scanning
by identifying collision parameters which maximize the yield of specific product ions passing
through Q3 and reaching the detector. Product scanning is also employed for structural
elucidation as product ions are characteristic of precursor ions. Product ion scanning is widely
employed for the unequivocal identification of drugs and their metabolites in complex biological
matrices. Chemical separation of the analyte from the complex matrix is achieved by the
chromatographic separation and the first quadrupole, while fragmentation of the analyte in the
second quadrupole provides structural information[120, 163]. A product ion spectrum displays
the ions produced by fragmentation of a known parent ion[118].

Ionization chamber

MS1
Static (at precursor mass)

Collision cell
(Pass all masses)

Figure 8: Schematic representation of product (daughter) ion scanning mode.
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MS2
Scanning

Precursor ion scanning is achieved by scanning the first quadrupole over a chosen mass range
while the third quadrupole is set to pass only ions with a particular m/z (product ions) (Figure 9).
Precursor scanning allows all ions to pass through Q1 and undergo CID in the second quadrupole
however only desired product ions will be allowed to pass through the third quadrupole. By
constantly scanning the first quadrupole, precursor ions which fragment into the desired product
ions will be identified. Ions which pass through the first quadrupole will only be detected if they
produce the pre-selected product ions through fragmentation in the collision cell[154]. Precursor
scanning is typically employed to corroborate information obtained from product scans during
structural elucidation experiments. Precursor scanning is also employed to identify possible
precursors of a common product ion[163].

Ionization chamber
MS1
Scanning

Collision cell
(Pass all masses)

MS2
Static (product ion)

Figure 9: Schematic representation of precursor ion scanning mode.

Multiple reaction, or selected reaction monitoring (MRM or SRM) mode is a highly selective
tandem mass spectrometry equivalent of SIR. MRM experiments are performed by setting Q1
static to only transmit ions with specific m/z corresponding to the precursor ion of interest.
Following fragmentation in the collision cell, only characteristic product ions of the precursor are
transmitted through Q3 which is also held static (Figure 10). MRM experiments can only be
performed when fragmentation patterns for the analyte have been determined. Once
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characteristic product ions have been identified and CID parameters have been optimized, Q3
can be programmed to allow only product ions with certain m/z values through to the detector.
MRM mode is widely used for quantitative analysis is MS/MS experiments. Dwell times can be
maximized because both Q1 and Q3 are held static to only allow through ions with pre-selected
m/z values (precursor and product ions respectively), meaning that enhanced sensitivity is
achieved compared to single mass spectrometry experiments performed in the scanningmode[163]. MRM is most commonly employed to quantify target analytes in complex matrices
such as drugs and /or metabolites in biological samples. Because individual transitions are
monitored in both SIR and MRM the product of such scans is not a mass spectrum, rather a
chromatogram[163]. While the number of MRM transitions required for an unequivocal
identification is still largely debated, most laboratories monitor two transitions and require
product ions to be present at a predetermined ratio. Ion ratios are generally determined using
quality control standards which are analyzed prior to patient samples. Increasing the number of
MRM transitions enhances selectivity at the cost of sensitivity due to decreased dwell times.

Ionization chamber

MS1
(Static at precursor mass)

Collision cell
(Pass all masses)

MS2
Static (at product mass)

Figure 10: Schematic representation of multiple reaction monitoring (MRM) mode.

Neutral loss tandem mass spectrometry experiments identify the loss of a specific neutral
fragment (eg. expulsion of H2O) or functional group from an unspecified precursor (Figure
65

11)[163]. Neutral loss scanning requires that both Q1 and Q3 are scanned simultaneously with a
constant m/z difference between them corresponding to the mass of the lost fragment or
functional group[154]. When the scanning of Q1 and Q3 is synchronized, Q3 determines
whether precursor ions transmitted through Q1 have lost a fragment corresponding to the mass
difference between the two scanning spectrometers. If Q3 detects a fragment loss corresponding
to the mass of the neutral fragment of interest, the loss registers at the detector and the mass
spectrum displays all precursor ions that experienced a mass loss corresponding to the fragment
of interest[164]. Neutral loss scan mode is most commonly employed to screen for a certain class
of compounds by identifying all ions which undergo the loss of a given neutral fragment through
fragmentation[154, 164]. Screening for a certain class of compounds which are known to follow
a characteristic fragmentation pathway, involving the loss of a certain neutral fragment or
functional group, could be achieved by employing a neutral loss scan. Neutral loss scanning is
commonly employed in early drug discovery for the identification of drug classes. An example is
the identification of glycerol phosphatidylcholine phospholipids (GCP) using a constant-neutralloss scan of m/z 59. Under certain CID conditions the dominant fragmentation of GCP’s is the
loss of trimethylamine (m/z 59) from the polar head group. Detection of a neutral loss of mass 59
Da at Q3 would indicate the presence of a GCP and allow for differentiation of this class from
other phospholipid classes present in complex mixtures[165].
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Ionization chamber

MS2

MS1
Scanning (synchronized with MS2)

Collision cell
(Pass all masses)

Scanning (synchronized with MS1)

Figure 11: Schematic representation of neutral loss scanning mode.

2.10

Mass Spectral Criteria for a Positive Identification
Prior to the introduction of atmospheric pressure ionization techniques such as ESI, and

APCI, a large majority of toxicological analyses were performed using GC/MS employing EI.
Electron ionization (EI) yields fragment ions which are very characteristic of, and therefore
provide significant information pertaining to, molecular structure. This is due primarily to the
ability of EI to produce odd electron molecular ions. Dissociation of odd electron molecular ions
produces fragment ions which are significantly more characteristic of molecular structure than
are even electron molecular ions[117]. The extensive fragmentation of odd electron molecular
ions into structurally significant fragment ions under EI conditions provides the analyst with an
EI mass spectrum possessing an unusually high content of structural information. This additional
structural information afforded by EI mass spectra has allowed for the development of EI
reference spectral libraries. Identification of unknown compounds is achieved by ‘library
matching’ which involves matching the EI spectrum of an unknown compound with one or
several contained within the library database. Library matches are made by comparing molecular
ions, relative abundances of fragment ions, and isotope patterns of the unknown compound with
reference spectra contained in the library. EI spectral libraries are readily available and can be
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installed into instrument software to allow for automatic library matching following data
acquisition of an unknown compound. For this reason, EI remains the method of choice for the
routine, efficient, identification of unknown compounds at trace levels[166].
Identification of unknown compounds using API techniques is achieved using a different
approach due to the relatively small amount of structural information afforded by soft ionization.
While the protonated molecular ions produced during API experiments assist in molecular
weight determinations, little information is provided to assist with structural elucidation. As a
result, ESI or APCI spectral libraries are not practical and do not currently exist to aid with
unknown identification. Due to the lack of structural information provided by soft ionization,
API techniques are not commonly employed for broad based, general unknown screening.
General unknown screening in complex biological matrices employing API techniques would
prove impractical as identifications would be based solely on the presence or absence of
protonated molecular ions. For this reason, GC/MS employing EI remains the most commonly
employed technique for broad based drug screening. Identifications are based on full EI spectra
containing characteristic information that can be automatically matched with reference spectra.
While API techniques do not naturally lend themselves to general unknown screening
applications, several tandem mass spectrometric screening techniques employing soft ionization
have been reported in the literature [167-170]. The identification of analytes using APILC/MS/MS is normally achieved using retention times and by monitoring the presence of 2-3
multiple reaction monitoring (MRM) ion channels. Unlike GC/MS screening in which
identifications are made based on pre-existing spectral libraries, API-MS/MS methods must be
developed through the analysis of standards. A reference standard of each analyte must first be
infused into the mass spectrometer to obtain ionization, and CID fragmentation information.
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Following optimization of the mass spectral conditions, standards must be injected onto the LC
to determine individual retention times. The screening method is then built by designating each
analyte a characteristic retention time and a minimum of one characteristic MRM transition
which is monitored during the analysis of unknowns. Screening methods based on monitoring
MRM transitions present additional problems as the number of analytes increase. Monitoring the
presence of analytes based on MRM transitions requires the mass spectrometer to continuously
scan the appropriate mass range. As the number of analytes increase, dwell times and therefore
sensitivity decreases. Additional screening selectivity may be achieved by monitoring more than
one MRM transitions for each analyte, however, the addition of more MRM transitions to the
MS/MS method further limits dwell times and decreases overall method sensitivity. Care must be
taken when optimizing dwell times to ensure that sufficient data points are obtained across each
chromatographic peak. Many forensic samples contain very low concentrations of analytes and
attempts to increase screening sensitivity by increasing dwell times may result in an inability to
accurately characterize chromatographic peaks as a result of insufficient data points.
Due to the nature of data acquisition, API-MS/MS techniques are better suited to, and
more commonly employed for confirmation analysis. Confirmation methods employing APIMS/MS are generally employed to confirm the presence of, and quantitate a specific drug. These
confirmation methods may be designed to detect and quantitate a single analyte or several
members of a certain family of drugs, such as the opiates. Specific LC-MS/MS methods are
again developed through the analysis of standards and positive identification criteria normally
include retention times, and the presence of 2-3 MRM transitions in the correct abundance.
During the analysis of reference standards, the most abundant MRM transition for each analyte is
routinely employed at the quantifying ion, while the second most abundant transition is
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employed for qualitative identification purposes. Confirmation methods are rarely designed to
detect and quantify more than a few drugs at any one time meaning that dwell times, and
therefore sensitivity can be maximized. Confirmation methods employing API-MS/MS combine
the increased sensitivity afforded by soft ionization with the inherent selectivity of tandem mass
spectrometry.
2.11

Mass Range and Resolution
The mass range of any mass spectrometer refers to the range of m/z values that can be

characterized with sufficient resolution to characterize adjacent peaks. Mass resolution refers to
the ability of the mass spectrometer to distinguish between two peaks of differing m/z values
within a single mass spectrum. A numerical expression of resolution can be obtained from the
ratio m/∆m, where ‘m’ is the nominal m/z value of one of the compounds and ‘∆m’ is the
difference in m/z values between the two peaks. If two peaks at a nominal m/z of 100 are
observed on separate channels of an oscilloscope sweep and offset by 0.100 mass units then the
resolving power of the mass spectrometer would be 1,000 (100/0.1)[118]. Measuring peak
separation can be done using the peak width definition method or the valley width definition
method. According to the peak width definition, the value of ∆m is the width of the peak
measured at a designated peak height level and m is again the m/z value of the peak.
The valley width definition method evaluates resolution by calculating the degree of
overlap between two peaks. This method defines ∆m as the closest possible spacing of two peaks
of equal intensity where the height of the valley between them is less than a certain specified
fraction of the peak height. When calculated using this method, resolution is generally reported
as a certain resolving power with a percentage valley definition. If we take the previous example
of a mass spectrometer where m/∆m is equal to 1,000 and we find that the height of the valley
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between the two peaks is 10% of the peak height, the mass spectrometer has a resolving power of
1,000 with a 10% valley definition[118].
The ability of a quadrupole device to resolve different masses depends on several factors
including the shape and diameter of the rods, the applied RF/DC voltages and the kinetic energy
of ions entering and exiting the quadrupole[161]. Figure 6 in section 2.9.1 shows a Mathieu
stability diagram of two masses entering a quadrupole at the same time. The three dotted lines
passing through the plot represent RF/DC scan rates and while all three lines pass through
regions of stable trajectory for both masses, resulting signals and ion abundances will be
significantly different for each scan. The top line represents a high resolution scan as resulting
spectral peaks will be narrow and well separated. If the mass range is scanned according to the
middle line, peaks will be much wider and poorly separated resulting in decreased resolving
power. Finally, if the mass range is scanned according to the bottom line, the spectral peaks will
overlap and pass through the quadrupole without being separated. This results in inadequate
resolution due to significant overlap of the spectral peaks[161].
It can also be seen in Figure 6 that the slope of the RF/DC scan rate can have a significant
effect on sensitivity. The sensitivity of a certain scan rate for an ion of interest depends on how
many of the variable RF/DC conditions fall within the regions of stability for that ion. If we
again use Figure 6 as an example, it can be seen that while the top scan line represents a high
resolution scan, the total number of ions that reach the detector will be quite low due to the
minimal number of RF/DC combinations corresponding to stable trajectory. Conversely, the
RF/DC scan slope represented by the bottom line will provide greater sensitivity as more area of
the stable trajectory curve is covered by the scan, however, spectral peaks will be wide and
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poorly separated. Because of this phenomenon, increased resolution is always accompanied by a
sacrifice in sensitivity when using quadrupole mass filters.
2.12

Waters TQD
The Waters TQ Detector is a tandem quadrupole, atmospheric pressure ionization (API)

mass spectrometer designed specifically for tandem mass spectrometric analyses following ultra
performance liquid chromatographic (UPLC) separations[163]. The TQ Detector has been
designed for compatibility with the ACQUITY UPLC™ system and can be employed for both
qualitative and quantitative analyses. The Waters TQD utilizes technological advances made in
ion source configuration, T-Wave™ collision cell technology and data acquisition speed to take
full advantage of the UPLC separation. The TQ detector utilizes a Z-Spray dual orthogonal ion
source which acts to protect critical source and analyzer elements from the harmful effects of
contamination by non-ionic species in complex biological matrices such as meconium (Figure
12)[171].

Figure 12: Schematic representation of the Waters TQD ion optics.
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Dual orthogonal sampling achieved with the Z-spray technique utilizes the same principles as
conventional electrospray sources except that the trajectory of ions entering the analyzer is not a
straight line, rather an approximate Z-shape[172](Figure 12). This trajectory deflects many
neutral molecules which can build up on the orifice of skimmers in conventional sources. The
final skimmer in the Z-spray ion source is set off to one side eliminating much of this material
build up[172]. Protection of the source from matrix contamination through dual orthogonal
sampling provides inherent sensitivity by not only decreasing background noise but also
allowing for an increase in cone orifice size. Decreased background noise is achieved by the
more effective removal of non-ionized contaminants by the dual orthogonal sampling technique.
Due to the more effective removal of matrix contaminants, the sampling size of the cone orifice
can be increased to allow more analyte ions to pass through to the mass spectrometer. By
decreasing the background noise and increasing the number of analyte ions reaching the mass
spectrometer, the Z-Spray dual orthogonal ion source ensures inherent sensitivity. The detection
system has also been redesigned to accommodate the narrow (2-3 seconds) peaks typical of
UPLC separations. Accurate quantitation of such narrow peaks demands fast acquisition speeds
to ensure that sufficient data points are obtained across each chromatographic peak. Failure to
couple the UPLC with a detection system capable of rapid acquisition would result in the
inability to accurately characterize chromatographic peaks. Table 5 outlines select system
specifications of the TQD.
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Table 5: Select system specifications of the Waters triple quadrupole detector (TQD).
Details
System specification
Acquisition modes
Mass range

Full scan; Selected ion recording (SIR); Product ion scan;
Precursor ion scan; Constant neutral loss/gain; Multiple reaction
monitoring (MRM)
2 to 2000 m/z

Scan speed

Up to 10,000 Da/s

MRM acquisition cycle time Minimum dwell time of 5 ms per channel
Mass resolution

2.13

Valley between 2034.63 Da and 2035.63 Da peaks is <12% of
the average height of the two peaks

Application of Tandem Mass Spectrometry in Forensic Toxicology
The fields of forensic and clinical toxicology require confirmatory testing techniques

which are capable of providing the most reliable and accurate information possible. The
importance of superior selectivity, sensitivity, precision, robustness and speed may be more
pronounced in the fields of forensic and clinical toxicology than any other. Analytical
methodologies employed for the purposes of identifying and quantifying analytes in these fields
need offer the highest selectivity and sensitivity as analyses commonly involve the determination
of trace level xenobiotics in complex biological matrices rich in interferences.
The hyphenation of gas chromatography with mass spectrometry (GC/MS) has been
widely employed in forensic and clinical laboratories worldwide since its introduction in the
mid-twentieth century. The separation power, speed and cost effectiveness of gas
chromatography, combined with the sensitivity and selectivity of mass spectrometry alleviated
many of the problems associated with the detection of xenobiotics in complex samples of
biological origin. GC/MS has long been the most widely employed technique for the selective
determination and accurate quantification of drugs and their metabolites in biological

74

samples[120]. Review of the scientific literature indicates a significant shift in the popularity and
employment of confirmation techniques from largely GC/MS based methodologies to LC-MS
and LC-MS/MS assays.
Early studies into the applications of tandem mass spectrometry were published by
pioneering research groups such as Cooks and colleagues at Purdue University[173], Hunt and
colleagues at the University of Virginia[174], and Enke et al at Michigan State University[175],
however much of the earlier work utilized the selectivity and sensitivity of MS/MS without prior
chromatographic separation. Reports of liquid chromatography-tandem mass spectrometry
methodologies for the selective and sensitive determination of drugs in biological matrices
consistently began to appear in the literature in the mid 1990s as a direct result of advances made
in the design and commercial availability of sophisticated LC-MS interfaces.
Verweij and colleagues described a quantitative LC-MS/MS methodology for the
determination of some analgesics and tranquilizers of the methadone, butyrophenone, or
diphenylbutylpiperidine groups in whole blood. The authors employed a SRM mass
spectrometric technique to monitor daughter ions produced by CID following thermospray (TS)
ionization[176]. The same authors described a LC-MS/MS technique employing thermospray
ionization for the quantitative analysis of several drugs with hypnotic, sedative and tranquillizing
properties in whole blood in the following year. Quantitation was performed using a triple
quadrupole mass spectrometer operating in the SRM mode following HPLC separation. The
authors report detection limits in the range of 0.05 – 0.5 ng/mL for most analytes[177].
The potential of the atmospheric pressure ionization techniques was realized from the
beginning and the mid 1990s saw a large increase in the number of published applications while
alternative ionization techniques such as thermospray, fast atom bombardment, and particle
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beam ionization began to disappear from the literature[131].Cai and Henion employed a triple
quadrupole mass spectrometer interfaced with an electrospray ionization source for the trace
analysis of LSD and analogues in human urine following on-line immunoaffinity extraction.
Coupling of the on-line extraction to the tandem mass spectrometric analysis provided the Cai
and Henion with detection limits as low as 2.5 ppt which represented a 20 fold increase in
sensitivity relative to their previous solid phase extraction technique[178]. Cai and Henion also
describe a technique for the elucidation of LSD metabolism pathways in vitro by employing the
precursor and neutral loss scanning modes of the triple quadrupole mass spectrometer (see
section 2.9.4) following separation by LC and capillary electrophoresis. Although the precursor
and neutral loss scanning modes employed here are seldom used for the quantitation of target
drugs, Cai and Henion were able to positively identify two new in vitro metabolites of the
hallucinogen whose structures were unequivocally established through comparisons with
reference standards[179]. Constanzer and colleagues employed a triple quadrupole mass
spectrometer interacted with positive ion APCI for the determination of cyclobenzaprine in
human plasma and urine. The sensitivity of the LC-MS/MS method was compared to a
previously established GC/MS method and a HPLC separation employing UV detection. The
authors concluded that the LC-MS/MS technique allowed for a ten-fold increase in sensitivity
relative to the GC method and a five-fold increase in sensitivity relative to the HPLC-UV
methodology[180]. Kleinschnitz and co-workers also employed APCI interfaced with a triple
quadrupole mass spectrometer for the analysis of 1,4-benzodiazepines in serum and urine
allowing detection quantification limits of 2 ng/mL[181].
In the years following these early studies, reported applications of LC-MS/MS, in
particular, liquid chromatography coupled to triple quadrupole instruments, for the determination
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of drugs or toxins in sample of biological origin increased exponentially. The current role of LCMS/MS in forensic and clinical toxicology has been the focus of several reviews [120, 131, 182].
Several LC-MS/MS techniques with forensic significance are reviewed here, focusing primarily
on the detection and/or quantification of drugs of abuse in biological samples.
Hegstad and co-workers validated a triple quadrupole mass spectrometry method
employing positive ion mode ESI for the purpose of screening nicotine, cotinine, morphine, 6monoacetylmorphine, codeine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine, cocaine, benzoylecgonine, 7-aminonitrazepam, 7-aminoclonazepam, 7aminoflunitrazepam, oxazepam, diazepam, alprazolam, zopiclone, zolpidem, carisoprodol,
meprobamate, buprenorphine, and methadone in hair samples. Following validation, the ESIMS/MS method was implemented for the analysis of authentic samples[183]. Concheiro et al
recently employed positive mode electrospray chemical ionization (ESCI) interfaced with a triple
quadrupole mass spectrometer for the determination of morphine, codeine, 6monoacetylmorphine, methadone, amphetamine, methamphetamine, 3,4methylenedioxyamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxy-Nethylamphetamine, benzoylecgonine, cocaine, delta-9-tetrahydrocannabinol, zolpidem,
zopiclone, alprazolam, clonazepam, oxazepam, nordiazepam, lorazepam, flunitrazepam,
diazepam, diphenhydramine and amitriptyline in preserved oral fluid specimens. Detection limits
of 0.5µg/L were achieved using the tandem-in-space mass spectrometry method[184]. Gaulier et
al reported a tandem mass spectrometry method for the sensitive determination of acepromazine
for the purpose of identifying drug facilitated sexual assault (DFSA) crimes. The authors
employed a TSQ tandem mass spectrometer equipped with an orthogonal electrospray ionization
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source and determined the presence of acepromazine in a sample of the victims hair at a
concentration of 31 pg/mg[185].
Ojanpera and co-workers reported a sensitive tandem mass spectrometry technique for
the detection of the highly potent opioid designer drug 3-methylfentanyl (TMF) in post-mortem
specimens. Analysis was performed using a QTrap LC-MS/MS operated in triple quadrupole
mode allowing for the unequivocal identification of the drug at lethal levels in 117 cases over a
two year period[186]. Roman et al investigated the potential of tandem mass spectrometry
following liquid chromatographic separation for the detection of seven antipsychotic drugs
commonly dosed at low levels. Analysis was performed on a triple quadrupole instrument
equipped with an electrospray interface and the authors conclude that the enhanced sensitivity
and selectivity afforded by LC-MS/MS is fast becoming essential for the determination of such
drugs to properly assess their role in post-mortem cases[187].
Liu et al describe a method employing the fast scanning capabilities of a triple
quadrupole mass spectrometer operating in the MRM mode for the purpose of screening 22
poisonous alkaloids in human blood. Positive ion ESI followed by MS/MS analysis enabled the
authors to selectively identify 22 compounds in human blood based on two fragmentation
transitions for each analyte. The authors achieved detection limits in the range of 0.1ng/mL to
20ng/mL[188]. Concheiro and co-workers utilized a triple quadrupole mass spectrometer
equipped with a Z-spray ion source for the simultaneous determination of ecgonine methyl ester,
benzoylecgonine, morphine, codeine, 6-acetylmorphine, amphetamine, methamphetamine, 3,4methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA),
methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and d-lysergic acid
diethylamide (LSD) in human urine and highlighted the importance of ion ratios in the
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identification criteria. The authors suggest that additional research efforts should be focused on
determining satisfactory variations in ion ratios following fragmentation by the softer LCMS/MS ionization techniques[189].
Castaing and co-workers capitalized on the sensitivity, selectivity and multi-analyte
detection capabilities of a triple quadrupole mass spectrometer equipped with an ESI source to
simultaneously screen and quantify selective serotonin reuptake inhibitors (SSRIs) (fluoxetine,
paroxetine, sertraline, fluvoxamine, and citalopram), serotonin noradrenergic reuptake inhibitors
(SNaRIs) (milnacipram and venlafaxine), mirtazapine and five of their active metabolites in
whole blood. The authors describe the first method in the literature for the simultaneous
screening and quantification of all aforementioned drugs using LC-MS/MS and highlight that the
more traditional analytical techniques lack the capability to detect and quantify drugs from the
SSRI, SNaRI and related classes simultaneously[190].
Castro and co-workers successfully combined a solid phase extraction and LC separation
into a single system to allow for the direct injection of plasma samples for the simultaneous
determination of 14 antidepressants and their metabolites by positive ion ESI and tandem mass
spectrometry. The authors’ state that the minimal sample preparation required for LC-MS/MS
analysis, its high selectivity and sensitivity in combination with good precision and accuracy
over a wide dynamic range, allow for the development of much more efficient and rapid
analytical methodologies. In particular the authors state that the application of LC-MS/MS for
the separation and detection of multiple antidepressants in a single sample eliminates the need
for lengthy sample preparation steps such as fluorescence derivatization which is required for the
more traditional HPLC with fluorescence detection approach[191].
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The enhanced sensitivity of tandem mass spectrometry was employed by Quintela et al
for the detection of low concentrations of 21 benzodiazepine, metabolites and analogues in urine
using a triple quadrupole mass spectrometer equipped with an ESI interface. Successful detection
was achieved by monitoring two fragmentation transitions for each analyte in the MRM mode.
The authors conclude that the increased sensitivity afforded by tandem mass spectrometry assists
in the detection of low concentrations of benzodiazepines used in drug facilitated sexual assault
crimes[192].
Almost 15 years on from the first reported applications of API techniques for the
ionization of analytes prior to tandem mass spectrometric analysis, ESI and APCI find
widespread use in routine toxicological analysis worldwide[120, 131, 182]. Just as API
techniques have become common practice in toxicological analysis, triple quadrupole mass
spectrometers have been the focus of the vast majority of studies involving the detection and
quantitation of xenobiotics in toxicological specimens. Tandem mass spectrometry employing
hybrid mass analyzers for the purpose of qualitative and/or quantitative determination of
xenobiotics in toxicological specimens became the focus of many research groups in the early
twenty first century.
Ballard and co-authors described a novel analytical strategy for the analysis of quaternary
ammonium neuromuscular blocking agents in a wide variety of biological specimens using a
tandem quadrupole orthogonal acceleration time of flight (Q-TOF) instrument. The authors
exploit the qualitative power of the modern quadrupole/time-of-flight (Q-TOF) mass
spectrometer by using the full scan product-ion spectra to unequivocally identify several
neuromuscular blocking agents at levels as low as 2-10 ng/g in various biological matrices.
Concluding remarks highlight the superiority of the modern Q-TOF instrument relative to the
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commonly employed tandem quadrupole for forensic analyses in which qualitative findings are
of the utmost importance[193].
Frison et al recently employed an ion trap mass spectrometer equipped with an
electrospray ionization source (ESI) for the sensitive determination of citalopram and its (S)
enantiomer, escitalopram, along with their demethylated metabolites in neonatal hair samples.
The authors reported a quantification limit of 25pg/mg for all analytes using the tandem-in-time
mass spectrometry approach[194].
Deviation from conventional tandem quadrupole mass spectrometers for forensic
screening and confirmation was also demonstrated by Sauvage and co-workers who developed a
comprehensive screening method for 1250 exogenous compounds in human blood and urine
using a triple quadrupole linear ion trap mass spectrometer. The authors developed a general
unknown screening procedure based on linear ion trap MS/MS using advanced computer
programming capabilities for the analysis of clinical and forensic samples. By storing product
ions in the linear ion trap following CID, the authors demonstrated superior identification
capabilities in a direct comparison with GC/MS and HPLC-DAD[167]. Favretto et al employed
an ion trap mass spectrometer for the sensitive determination of buprenorphine and
norbuprenorphine in urine, blood and hair samples and comparatively investigated the use of an
ion trap for the purposes of collision induced dissociation rather than the in-source fragmentation
techniques previously reported in the literature. The authors report a much higher CID efficiency
through the use of an ion trap which appears to generate not only more product ions but also a
higher abundance of each. Collective data suggests that ion trap MS/MS experiments for the
determination of buprenorphine and its active metabolite are not only superior to the previously
reported LC/MS experiments employing in-source collisions and a single quadrupole, but also
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offer enhanced sensitivity relative to triple quadrupole mass spectrometers employing a CID cell.
Variations in sensitivity between the two instruments were attributed to the high collision
energies required to produce any appreciable fragmentation in the triple quadrupole CID,
combined with the losses in sensitivity associated with ion transfer through tandem-in-space
instruments[195].
In 2005, Herrin and co-workers utilized the large database of multiple reaction
monitoring transition ions for drugs amendable to LC/MS/MS to create a tandem mass
spectrometry technique for the screening of drugs in post mortem specimens. Herrin et al
employed a QTrap LC-MS/MS for the purpose of unequivocally identifying over 100 drugs,
many of which are not amendable to enzyme immunoassay (EIA) screening techniques.
Qualitative determinations were made based on the detection of MRM transition ions and the
enhanced product ion (EPI) scans produced by the linear ion trap. Enhanced product ion scans
are produced when Q3 is employed as a linear ion trap while simultaneously performing the role
of Q3 for the MRM experiments. Identifications based on the detection of one MRM transition
ion and a matching EPI scan enabled the authors to unequivocally identify over 100 drugs in
post-mortem specimens using dwell times in the range of 1-25 ms[168].
Prior to the studies of Herrin et al, several groups published methodologies describing the
application of quadrupole-linear ion-trap mass spectrometry for the broad based screening of
forensically significant drugs in post-mortem specimens[167, 169, 196, 197]. The number of
published methodologies describing the use of liquid chromatography coupled to tandem mass
spectrometry for the forensic analysis of drug or other xenobiotics continues to increase each
year as the instrumentation capable of performing LC-MS/MS analysis continues to become
more affordable and intuitive (Figure 13).
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Figure 13: Number of LC-MS/MS articles appearing in pubmed from 2001 - 2008 for the
forensic analysis of drugs or other xenobiotics.
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Chapter 3: Analytical Method Validation
3.1

Introduction
Analytical methodologies play an integral role in many fields of the life sciences and as a

result, produce data that is subsequently interpreted to provide pivotal information which is then
used to make medical, legal, clinical, and environmental decisions. Correct interpretation and
evaluation of analytical data is obviously a crucial component in the decision making process,
however, preliminary procedures must also be implemented by analytical chemists to ensure that
such methodologies are generating reliable analytical data at all times. Analytical data of high
quality and integrity can only be produced by an analytical method which has demonstrated both
suitability and reliability for its intended purpose. Careful method development followed by a
thorough bioanalytical method validation is required for analytical methodologies whose
intended use is to quantify the concentration of an analyte in a particular biological matrix for the
purpose of forensic and/or clinical toxicology analysis[198].
Bioanalytical method validation for analytical techniques intended for forensic
toxicology analysis is of extreme importance as it objectively demonstrates the inherent quality
of the analytical method for its intended purpose by fulfilling minimum performance and
acceptance criteria[198]. Failure to validate a bioanalytical methodology for its intended purpose
may unknowingly generate unreliable data which will not only be questioned in a court of law,
but may result in unjustified legal consequences or the inappropriate treatment of patients[198].
Unreliable data generated during analytical studies to assess the pharmacological efficacy of a
new drug or patient compliance in pain management toxicology can have detrimental effects on
both the patient and the toxicology laboratory responsible for generating the data. All appropriate
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steps must be taken to ensure that the data generated by bioanalytical methodologies in the
forensic toxicology laboratory is both accurate and reliable.
The first step in validating a bioanalytical method is to identify and define its intended
purpose as this will largely determine which method parameters require validation. As there is no
one single guideline on bioanalytical method validation, it is routinely customized by individual
laboratories by the identification and validation of only select performance criteria which have
been chosen based largely on the intended purpose of the test. Selection of relevant performance
criteria is made easier by first identifying the intended purpose or application of the method. For
example, certain validation parameters such as precision and accuracy are vital performance
criteria which need be addressed during the validation of a quantitative bioanalytical method
whereas validation of certain qualitative assays may not incorporate the assessment of such
parameters. Bioanalytical method validation procedures show significant variation from
laboratory to laboratory and although there is no single guideline describing the processes for full
method validation, several guidance documents addressing the bioanalytical analysis of drugs
and poisons in biological samples exist in the literature [119, 198-202]. In the present study,
analytical methodologies were developed for the purpose of quantifying drugs of abuse in
meconium. All analytical method validation protocols were designed and followed according to
validation guidelines set out in documents such as the bioanalytical method validation guidance
for industry document published by the US Food and Drug Administration in 2001, and the
Forensic Toxicology laboratory guidelines published by the Society of Forensic Toxicologist
(SOFT) and American Academy of Forensic Sciences (AAFS).
Full bioanalytical validations should be completed when developing and implementing a
method for the first time or if the method is intended for the detection of drugs and/or
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metabolites in novel matrices. Guidance presented in these documents applies to the validation of
bioanalytical procedures such as gas chromatography (GC), high-pressure liquid chromatography
(LC), combined GC and LC mass spectrometric procedures such as LC-MS, LC-MS/MS, GCMS, and GC-MS/MS performed primarily for the quantitative determination of drugs and their
metabolites in various biological matrices such as blood, serum, plasma, or urine.
The present study describes the development of three UPLC-MS/MS methodologies for
the quantitative determination of several drugs of abuse in human meconium. Implementation of
this technique for the intended purpose has not occurred previously and because of this, all three
UPLC-MS/MS methodologies were subjected to full analytical method validation procedures.
Fundamental parameters for a full bioanalytical method validation include accuracy,
precision, selectivity, sensitivity, reproducibility, and stability. Method validation was performed
for each confirmation assay by determining and assessing (1) selectivity, (2) accuracy, (3)
precision, recovery, (3) calibration curve, (4) Limit of detection, and (5) stability. Validation of
each analytical method involved documenting the performance of each of these criteria during
laboratory experiments designed specifically for that purpose. Each performance parameter was
designated certain acceptance criteria which had to be satisfied in order to deem the method
suitable and reliable for its intended purpose. Table 6 provides an overview of bioanalytical
method validation terms, abbreviations, and definitions.

86

Table 6: Overview of bioanalytical method validation terms and definitions.
Term

Definition

Selectivity

The ability of an analytical method to differentiate and quantify the
analyte of interest in the presence of other components in the sample

Accuracy

The closeness of mean test results obtained by the method to the true
concentration of the analyte

Precision

The closeness of individual measures (degree of scatter) of an analyte
concentration when the procedure is applied repeatedly to multiple
aliquots of a single standard

Recovery

Recovery pertains to the extraction efficiency of an analytical method
within the limits of variability

Calibration curve

Represent the relationship between instrument response and known
concentrations of an analyte

Stability

Pertains to the stability of an analyte in a biological matrix during sample
collection, and storage

Limit of detection (LOD)

The lowest concentration or amount of analyte in a sample that can be
unequivocally identified but not necessarily quantified

Lower limit of quantitation (LLOQ)

The lowest concentration of an analyte in a sample that can be quantitated
with suitable accuracy and precision

3.2

Bioanalytical Validation Parameters

3.2.1 Selectivity
Selectivity is the ability of an analytical method to differentiate and quantify the analyte
of interest in the presence of other components in the sample[199]. Selectivity is an extremely
important validation parameter in forensic toxicology due to the complex nature of biological
specimens such as blood, urine, tissue, and meconium. Complex matrices such as meconium are
expected to be rich in interfering species of both endogenous and exogenous origin. This means
that bioanalytical methods intended to quantify small amounts of analyte, must be capable of
unequivocal identification and accurate quantification in the presence of additional sample
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components such as xenobiotics, metabolites, impurities, degradants, and endogenous
interferences[198].
Chemical extractions are routinely employed in forensic toxicology to aid in the removal
of interfering species from the biological matrix prior to instrumental analysis. While various
chemical extractions (SPE, LLE, protein precipitations) have been shown to selectively extract
common drugs of abuse while simultaneously removing matrix components, many of these
techniques are validated only for blood or urine. Meconium presents a significantly different
matrix of biological origin and the application of pre-existing extraction techniques may not
necessarily provide extracts of the same purity.
Selectivity studies for alternate matrices such meconium, are important for determining
whether or not the chosen chemical extraction is suitable and sufficient. To determine the extent
of sample cleanup, and therefore the suitability of the extraction technique, multiple (n=5) blank
matrices should be subject to chemical extraction and analyzed for the analyte(s) of interest. Any
analyte response generated by endogenous compounds in the blank matrix should correspond to
an analyte concentration below the LLOQ. Five blank biological matrices should be subject to
chemical extraction and analyzed for the analyte of interest to ensure that any analyte response
generated by endogenous compounds could not result in a confirmed positive result.
Selectivity of the instrumental detection system is also paramount to ensure that the
analyte(s) of interest are accurately identified in the presence of chemically similar exogenous
interferences. Chemical extractions are often sufficient for the removal of endogenous
compounds which are chemically and physically distinct from the analyte(s) of interest, however,
xenobiotics with similar physicochemical properties will likely not be removed during chemical
extraction. For this reason, detection systems must be capable of accurate and unequivocal
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analyte identification in the presence of chemically similar compounds. Mass spectral
characteristics of chemically similar compounds commonly encountered in forensic specimens
should be studied to ensure that they are distinguishable from the analyte of interest. In order to
evaluate the selectivity of the methodology, several blank matrices should be spiked with the
analyte of interest at a concentration corresponding to the LLOQ and also with various
exogenous interferences. Samples should be analyzed to ensure that the methodology is capable
of accurately identifying and quantifying the analyte of interest in the presence of chemically
similar compounds.
3.2.2

Accuracy
The accuracy of an analytical methodology describes the closeness of mean test results

obtained by the method to the true concentration of the analyte[199]. The accuracy of an
analytical methodology should be determined by preparing and analyzing five replicate standards
in the matrix under investigation at three concentrations spanning the calibration range of the
method. Five standards containing a known amount of the analyte should be prepared at
concentrations representing the upper limit of quantitation (ULOQ), the LOQ, and a
concentration point midway between the two. Replicate analysis of the standards should produce
mean values within 15% of the expected nominal value, except at the LLOQ where the mean
value should be within 20% of the expected nominal value. The degree of deviation of mean
values from the true values serves as the measure of method accuracy[199].
3.2.3

Precision
The precision of an analytical method describes the closeness of individual measures

(degree of scatter) of an analyte concentration when the procedure is applied repeatedly to
multiple aliquots of a single standard[199]. The precision of an analytical methodology should be
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determined by preparing and analyzing five replicate standards in the matrix under investigation
at three concentrations spanning the calibration range of the method. Precision of the analytical
method should not exceed 15% of the coefficient of variation (CV) except at the LLOQ where is
should not exceed 20% of the CV. Precision studies can be further subdivided into intra-batch
precision and inter-batch precision. Intra-batch precision evaluates the method precision during a
single analytical run or single batch. Inter-batch precision evaluates the method precision over
multiple batches and provides an indication of method repeatability with time. Inter-batch
precision experiments may be as simple as analyzing replicates under identical conditions over
several days or may involve using different analysts, instruments, reagents, or laboratories to
determine the robustness of the methodology. Mathematically determining the precision of
replicate analysis at any one concentration involves calculating the standard deviation of the
replicate concentrations and dividing by their mean.
3.2.4 Recovery
Recovery of an analytical methodology should be evaluated to determine the extraction
efficiencies for each analyte from the matrix of interest. Recovery pertains to the extraction
efficiency of an analytical method within the limits of variability. Recovery is not among the
validation parameters regarded as essential for quantitative assays unless the sensitivity of the
assay is poor[198].
Analyte recovery pertains to the detector response obtained from a known amount of
analyte added to and then extracted from a biological matrix, compared to the detector response
obtained for the same concentration analyzed as a pure authentic standard[199]. While the
recovery of an analyte and its respective internal standard need not be 100%, the extent of
recovery should be reproducible at concentrations spanning the calibration range.
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3.2.5

Calibration Curves
Calibration curves consist of a number of standards prepared at known concentrations in

the same matrix as the unknown specimens. Following accurate preparation, calibration
standards are analyzed to determine how the instrumental response changes with analyte
concentration. Once this relationship has been established, unknown samples can be analyzed
and quantified by measuring the analyte response and interpolating to find the concentration of
the analyte. Calibration curves are the most commonly employed internal standard method for
forensic toxicological analysis. Preparation of calibration curve standards in appropriate matrices
for the purpose of quantifying unknown analytes is typical across toxicology laboratories.
Calibration curves should be generated and assessed for each analyte encompassed in the
analytical method. A sufficient number of calibrator concentrations should be employed to cover
the entire calibration range and should be evenly spaced to accurately and adequately define the
relationship between analyte concentration and detector response[119, 198, 199].
Calibration standards used to construct calibration curves should be constructed from
blank biological matrices which have been spiked with a known amount of analyte and internal
standard. Detector responses are generally calculated as the area ratio of analyte versus internal
standard for bioanalytical methods[198].
3.2.6

Stability Studies
Analyte stability in a biological matrix is a function of the storage conditions, the

physicochemical properties of the drug itself, and the matrix in which the drug is present[199].
Stability studies should be performed to assess the stability of each analyte in the matrix of
interest and in the storage container to be used. Stability studies are specific to the matrix,
storage container, storage conditions, and the analyte investigated during validation studies and
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results should not be extrapolated or applied to other matrices or conditions. Stability studies
should be designed to evaluate the stability of each analyte during collection, pre-testing storage,
analysis procedures, and post-testing storage. Studies should also be designed to investigate
analyte stability during and after several freeze and thaw cycles. Stability of the analyte
following several freeze-thaw cycles is important to establish as samples are routinely subject to
such conditions during retesting. Investigations into analyte stability should be performed by
spiking the appropriate blank matrix with each analyte at concentrations within the expected
range. Samples prepared at a high and low concentration relative to the calibration curve are
most appropriate. Spiked samples should then be subject to various conditions representative of
sample collection, storage and preparation. Samples should also be subject to several freeze-thaw
cycles and analyzed following each cycle to ensure stability over the time course. Mean values
obtained after subsequent freeze-thaw cycles should be within 20% of the expected nominal
values if the analytes are indeed stable in the matrix of interest. The stability of analytes and
internal standards during and prior to analysis, but following extraction may also be investigated.
These studies are important for high throughput production laboratories as samples are often
batched and loaded into sample organizers for subsequent analysis. If multiple batches are to be
analyzed over a significant period of time, prepared extracts may experience significant
residence time in the autosampler. Stability of the analyte in such an environment should be
established in such cases.
3.2.7

Limit of Detection (LOD) and Lower Limit of Quantitation (LLOQ) Studies
The limit of detection (LOD) for an analytical methodology is defined as the lowest

concentration or amount of analyte in a sample that can be unequivocally identified but not
necessarily quantified. It corresponds to the lowest concentration of analyte that the analytical
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methodology can reliably differentiate from background noise[201]. The LOD can be determined
either by a statistical approach based on measuring replicate blank (negative matrix) samples or
by an empirical approach which consists analyzing progressively more dilute concentrations of
analyte until reliable identification can no longer be made[203]. Statistical determination of the
LOD is achieved by analyzing a series of blank samples (appropriate matrix with no analyte) and
obtaining the mean blank value (µ) and the standard deviation (σ) of those values. The LOD is
then determined using Equation 11.

LOD = µ + 3σ

Equation 11

The statistical approach assumes that the standard deviation of the blank is roughly equivalent to
the standard deviation of the concentration that actually corresponds to the LOD[203]. Similar to
the statistical approach is the method for determining the LOD based on the signal to noise (S/N)
ratio. The signal to noise is defined as the height of the analyte peak (signal) and the amplitude
between the highest and lowest point of the baseline (noise)[198]. The LOD is normally accepted
as the concentration at which the S/N ratio is equal to, or greater than 3 for triplicate analyses.
The empirical or experimental approach to determining the LOD involves analyzing serially
dilute samples of analyte until the LOD is determined. The LOD corresponds to the lowest
concentration of sample at which the identification of the analyte still satisfies predetermined
acceptance criteria[203]. Concentrations below the LOD do not satisfy such criteria and
identification of the analyte would not be justified. The limit of detection was determined
empirically for all confirmation methodologies by analyzing serially dilute samples until the
methodology was unable to reliably identify the analyte as a result of shifts in retention times or
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inaccurate ion ratios. Acceptance criteria for retention times were within 2% of calibrators and
ion ratios were required to be within 20% of calibrators to positively identify the analyte.
Evaluation and determination of the LOD for instrumental methods designed for forensic
analysis may not always be necessary. While it is good practice to understand instrument
limitations, forensic laboratories rarely report positive results at concentrations corresponding to
the LOD. This is because most chromatographic methodologies employed in the toxicology
laboratory are confirmatory assays aimed at quantitating an unknown analyte. As quantitation at
the LOD is not feasible, many laboratories do not consider it a vital validation parameter. A more
important validation parameter in the forensic toxicology industry is the lower limit of
quantitation.
The lower limit of quantitation (LLOQ) is defined as the lowest concentration of an
analyte in a sample which can be accurately and precisely quantitated[199]. The LLOQ is an
important parameter in toxicology as all chromatographic assays are designed to accurately
quantitate an unknown analyte. As accurate quantitation below the LLOQ is not feasible, any
sample that contains an analyte below the established LLOQ is generally considered negative in
the toxicology laboratory. There are several approaches to determining the LLOQ and the most
appropriate depends largely on the intended purpose of the analytical methodology. The LLOQ
can be determined statistically using the same technique as the LOD method and substituting µ
and σ into Equation 12.

LLOQ = µ + 10σ

Equation 12
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Similar to this approach is the method of determining the LLOQ based on the signal to noise
(S/N) ratio. The signal to noise is defined as the height of the analyte peak (signal) and the
amplitude between the highest and lowest point of the baseline (noise)[198]. The LLOQ
normally corresponds to the concentration at which the S/N ratio is equal or greater than 10.
Laboratory guidelines published by SOFT/AAFS state that for chromatographic assays, the
LLOQ may be defined as the concentration of the lowest calibration standard. The LLOQ is the
concentration at which the analytical methodology can still quantify the analyte with acceptable
accuracy and precision.
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Chapter 4: Introduction and Overview to the Development and Validation of
UPLC-MS/MS Methodologies for the Quantitative Determination of Cocaine,
Amphetamine, and Opiate Derivatives in Human Meconium.
4.1

Introduction
Cocaine, amphetamines, and opiates continue to find widespread abuse among users

worldwide. Due to the detrimental effects of prenatal drug exposure, there is a growing need for
methodologies capable of assisting with the identification of maternal drug use. Traditional
methods for identifying maternal drug use have relied on the analysis of maternal and/or infant
blood and urine. Due to the relatively short retention time of drugs in blood and urine, these
analyses aid only in the identification of recent maternal drug use. Development of sensitive and
selective methodologies capable of detecting drugs of abuse in human meconium will aid in
identifying prenatal drug exposure occurring during the second and third trimesters which has
previously gone undetected. Implementation of such methodologies will ensure that the correct
intervention and treatment is made available to both the mother and the newborn.
Development and full analytical method validation of three UPLC-MS/MS
methodologies for the quantitative determination of cocaine, amphetamine, and opiate
derivatives in human meconium is described. Methodologies were developed for the purpose of
selectively determining and accurately quantifying cocaine, benzoylecgonine, amphetamine,
methamphetamine, codeine, morphine, hydromorphone, and 6-monoacetylated morphine in
meconium specimens. All experiments were performed using the Waters TQD triple quadrupole
mass spectrometer equipped with an electrospray ionization (ESI) source operating in the
positive ion mode. Chromatographic separations prior to mass spectrometric detection were
achieved using the Waters ACQUITY UPLC™ chromatograph. Methodologies were validated
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according to full analytical method validation guidelines published in the ‘Bioanalytical Method
Validation Guidance for Industry’ document published by the US Food and Drug Administration
in 2001, and the ‘Forensic Toxicology Laboratory Guidelines’ published by the Society of
Forensic Toxicologist (SOFT) and American Academy of Forensic Sciences (AAFS)[119, 199].
Tables 7 provides an overview of the three analytical methodologies including the number of
analytes detected by each methodology, sample preparation method, and figures of merit such as
the calibration range, the limit of detection (LOD), and the lower limit of quantitation (LLOQ).
Table 7: Overview of three UPLC-MS/MS methodologies developed and validated for the
purpose of detecting and quantifying several cocaine, amphetamine, and opiate derivatives in
human meconium.
UPLC
methodology
Methodology
#1.
Chapter 5

Analyte
1. Cocaine

Sample preparation

Calibration
range

LOD

LLOQ

1.Protein precipitation

10 – 250 ng/mL

1 ng/mL

10 ng/mL

10 – 250 ng/mL

1 ng/mL

10 ng/mL

2. SPE
2. Benzoylecgonine

1.Protein precipitation
2. SPE

Methodology
#2.
Chapter 6

Methodology
#3.
Chapter 7

1. Morphine

Supported-liquid
extraction (SLE)

10 – 500 ng/mL

2.5 ng/mL

10 ng/mL

2. Codeine

Supported liquid

10 – 500 ng/mL

2.5 ng/mL

10 ng/mL

extraction (SLE)
3. Hydromorphone

Supported liquid
extraction (SLE)

10 – 500 ng/mL

2.5 ng/mL

10 ng/mL

4. 6-monoacetylmorphine

Supported liquid
extraction (SLE)

10 – 500 ng/mL

2.5 ng/mL

10 ng/mL

1. Amphetamine

Supported liquid
extraction (SLE)

5 – 500 ng/mL

1 ng/mL

5 ng/mL

2. Methamphetamine

Supported liquid
extraction (SLE)

5 – 500 ng/mL

250 pg/mL

5 ng/mL
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4.2

Experimental
Experimental sections 4.2.1 & 4.2.2 describe method development steps common to all

three UPLC-MS/MS methodologies. These sections are designed to provide the reader with an
overview of the steps taken and processes followed during preliminary method development.
Pease refer to individual experimental sections in chapters 5, 6 and 7 for specific instrumental
conditions and detailed experimental designs. Section 4.3 describes the details of method
validation experiments for each of the three UPLC-MS/MS methodologies. Please refer to
chapter 3 for definitions of validation parameters and generalized experimental approaches.
Please refer to the individual results and discussion sections in chapters 5, 6, and 7 for discussion
and interpretation of individual validation experiments.
4.2.1

Development and Optimization of MS/MS Parameters
Mass spectrometric detection was performed using a Waters TQD triple quadrupole mass

spectrometer (Waters Corp., Milford, MA, USA) equipped with an electrospray ionization (ESI)
source operating in positive ion mode. Method development was initiated by identifying
appropriate quantifier and qualifier mass transitions for each analyte. Concentrated (10 µg/mL)
solutions each analyte were directly infused into the mass spectrometer ionization source at a
flow rate of 20 µL/min. The flow paths of the concentrated analyte solutions were modified with
a T-mixer to allow mixing of the solution with mobile phase (Figure 14). This allowed for the
simultaneous infusion of analyte solution and initial mobile phase into the mass spectrometer.
Simultaneous infusion of the sample with the initial mobile phase ensured that any subsequently
optimized tune page parameters were compatible with the initial mobile phase. Optimizing the
tune page parameters under these conditions also ensured that analytes were being introduced
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into the ESI source in an environment that was representative of an authentic sample. This
ensured the most accurate optimization of ionization parameters specific to both the sample and
the mobile phase.

Figure 14: Schematic representation of the ‘T-mixing’ mode which allows for the simultaneous
infusion of analyte solution from reservoir A and mobile phase eluting from the UPLC column.

Concentrated (10 µg/mL) solutions of each analyte were concomitantly infused with the initial
mobile phase composition at a flow rate of 0.6 mL/min. During infusion of each analyte, the
collision gas was turned off to allow the protonated molecular ion of each compound to reach the
detector and produce a recordable signal. Following identification of the molecular ion signal, an
auto tune was completed for each analyte which involved adjusting the capillary voltages, cone
voltages, and collision energies to maximize the signal for both the precursor ions and the
product ions generated in the collision cell. Auto tuning of the protonated molecular ion of each
compound yielded information necessary to collect data in the MRM mode. The mass transition
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from the protonated molecular ion [M+H]+ to the most abundant product ion was designated the
quantifying ion transition while the second most abundant mass transition was designated as the
qualifying ion transition for each analyte. The most abundant product ion for each deuterated
internal standard was also monitored and used to calculate the response ratio between internal
standards and analytes for all experiments. Following auto tuning of each analyte and internal
standard, the optimized parameters were used to construct the MS/MS method which was then
used to acquire data in the MRM mode.
4.2.2

Development of UPLC Separation Conditions
Following development of the MS/MS detection method, analytes were individually

injected onto the UPLC to optimize chromatographic separation conditions. Analytes were
individually injected onto the column to obtain and record characteristic retention times and to
optimize chromatographic conditions. Chromatographic conditions were optimized to ensure that
all peak shapes were Gaussian in nature and baseline resolution was achieved, allowing for
accurate and reliable identification. All liquid chromatographic separations were performed on a
Waters ACQUITYTM ultra performance liquid chromatograph (UPLC™) (Waters Corp.,
Milford, MA, USA). Separations were achieved on one of several ACQUITY UPLC™ columns
(see individual experimental sections for column dimensions). All mobile phases consisted of
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1%
formic acid (solvent B). Analytes elution was achieved using step-wise binary elution gradients
and all flow was directed into the ESI source of the mass spectrometer.
4.2.3

Considerations for UPLC-MS/MS Method Development
Analytical separation and detection of xenobiotics in complex biological matrices can

prove difficult when employing detection systems that lack the selectivity of mass spectrometry.
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Traditional techniques such as HPLC equipped with UV detection require baseline separation of
analytes from any endogenous interferences, xenobiotics, or sample contaminants with similar
UV absorbance. UV detection systems measure the UV absorbance of column eluates at a
particular wavelength or over a range of wavelengths. Compounds with similar chromatographic
properties to the analyte of interest, which absorb UV radiation at the chosen wavelength may
co-elute with the analyte making any subsequent attempts at integration and quantification
inaccurate and unreliable. The problem of co-elution can be overcome by modifying sample
extraction techniques, reconstitution solvents, mobile phase components, flow rates,
chromatographic columns or detection wavelengths.
Depending on the complexity of the biological extract, lengthy, complex
chromatographic separations employing various mobile phase additives may be required to
successfully resolve the analyte of interest from sample interferences. Mass spectrometry, in
particular tandem mass spectrometry, offers the analyst enhances selectivity for the identification
of low levels of analyte in complex biological matrices rich in interferences. According to the
SOFT/AAFS forensic laboratory guidelines, the detection or initial identification of drugs or
toxins should be confirmed whenever possible by a second testing technique based on a different
chemical principle. Due to its superior sensitivity, mass spectrometry is the recommended
confirmatory technique, where possible and practical[119].
Confirmation assays in the forensic toxicology laboratory which employ mass
spectrometry are generally performed in the single ion monitoring (SIM) mode for MS analysis
and in the multiple reaction monitoring (MRM) mode MS/MS analysis. This is the general
occurrence due to the sequence of testing procedures performed in the routine toxicological
analysis of blood, urine, or alternate specimens. Confirmation techniques employing mass
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spectrometry are generally developed and optimized to identify individual components of a drug
class whose presence was indicated by the presumptive screen test.
Due to the finite number of analytes monitored during a confirmation assay, data
acquisition can be performed in either the SIM mode for single mass spectrometry experiments
or MRM for tandem mass spectrometry techniques. SIM and MRM scanning during
confirmation analysis provides the analyst with inherent selectivity for the analyte/s of interest
and due to the reduction in background signal, sensitivity is also enhanced. Tandem mass
spectrometry experiments employing the MRM mode do not produce mass spectrums, rather
chromatograms as the data output is reflective of only one mass transition corresponding to the
analyte of interest rather than a complete mass spectrum obtained by scanning a certain mass
range. While chromatographic separations still play an integral role in LC-MS/MS assays,
baseline chromatographic resolution is often not required when employing mass spectrometry as
a detection technique because of its ability to monitor mass transitions specific to an individual
analyte. When operating in MRM mode, mass spectrometers are constantly acquiring data for
one or more mass transitions. Although co-elution may exist between transitions on the total ion
chromatogram (TIC), data pertaining to each transition is being acquired individually and
extraction of the individual trace allow for the accurate and reliable quantification of the analyte
corresponding to that transition. Figure 15 shows the TIC for the chromatographic separation of
eight tricyclic antidepressants on a Waters Acquity TQD. It can be seen from the TIC, which
only contains five peaks, that the individual analytes are not chromatographically resolved.
When operating in MRM mode however, triple quadrupole instruments are constantly acquiring
data for individual ion traces. This information can be extracted from the TIC and used to
quantify each analyte. Figure 16 shows the extracted ion traces for each analyte. While
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chromatographic resolution was not achieved, all eight analytes can be accurately quantified
using individual MRM ion traces (Figure 16).
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Figure 15: TIC for the chromatographic separation of eight tricyclic antidepressants on a Waters
Acquity TQD. Analytes are not chromatographically resolved but can be quantified using their
individual MRM ion traces.
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Figure 16: Extracted in traces for each analyte. Individual ion traces are acquired in the MRM
mode and eliminate the need for chromatographic resolution.

There are however, circumstances in which baseline resolution is required for tandem
mass spectrometric detection to enable accurate and reliable quantitative results. One such
instance arises when the detection of two or more co-eluting compounds is performed by
monitoring the abundance of product ions with identical masses. Chromatographic resolution is
required in such cases to eliminate the detrimental effects of ‘cross-talk’ which is caused by the
slow removal of ions from the collision cell. Cross-talk may occur when two co-eluting
compounds with identical product ion masses are monitored by successive transition scans[196].
Cross-talk occurs when fragment ions from a certain mass transition scan event have not fully
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cleared the collision cell before a second scan event takes place in which the same fragment ion
is monitored. Residual fragment ions from the first scan event contributing to the analyte
response for the second scan event lead to signal artifacts which impact the quantitation of the
co-eluting analytes.
The effects of cross talk can be minimized by introducing an inter-scan delay between the
two transitions to ensure optimal clearance of the collision cell, however this increases the
method ‘dead time’ and significantly affects the scan cycle time. Increasing the scan cycle time
by introducing an inter-scan delay, decreases the number of data points obtained over a
chromatographic peak which can also have a detrimental effect of quantitation accuracy[196]. In
such cases, chromatographic resolution is the preferred option for alleviating the problems
associated with ion cross-talk. Chromatographic resolution may not always be feasible for
methods designed to detect a large number of analytes in a relatively short chromatographic
run[196, 197] and in such cases, the effects of cross-talk on quantitation accuracy should be
assessed during validation experiments.
4.3

Experimental Design for Method Validation
Preliminary method development experiments described in section 4.2 involved

developing and optimizing a chromatographic separation which allowed for the accurate and
reliable identification of each analyte and deuterated internal standard based on retention times.
Experiments also involved developing and optimizing a mass spectral method capable of
obtaining data in the multiple reaction monitoring (MRM) mode for each analyte and deuterated
internal standard. Following the development and optimization of UPLC and MS/MS conditions
using concentrated drug standards, each UPLC-MS/MS methodology was subject to a full
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analytical method validation. Validation experiments were designed and carried out to determine
the suitability of each method for its intended purpose.
Scientific validation of the UPLC-MS/MS methodologies included performance studies
assessing matrix equivalence, linearity, selectivity, accuracy, intra- and inter-run precision,
recovery, stability and limit of detection (LOD). Method validation studies were performed over
a ten day time period and methodologies were deemed suitable for the analysis of authentic
samples if, and only if, validation studies had were completed and acceptance criteria were met
for each validation parameter. Several validation experiments required the replicate analysis of
standards prepared at concentrations spanning the concentration range for that specific analyte.
With the exception of matrix equivalence experiments (see section 4.3.1) standards were
prepared at the LLOQ, the ULOQ, and a concentration midway between the two. Table 8 lists
the concentrations of all standards used during validation experiments.
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Table 8: Concentrations of standards used in all validation experiments. Concentrations of
standards spanned the calibration range of each method.
Method

Methodology #1
Chapter 5

Methodology #2
Chapter 6

Methodology #3
Chapter 7

4.3.1

Analyte

Conc of Std. 1
(LLOQ)

Conc of Std. 2
(midway point)

Conc of Std. 3
(ULOQ)

Cocaine

10 ng/mL

50 ng/mL

250 ng/mL

Benzoylecgonine

10 ng/mL

50 ng/mL

250 ng/mL

Morphine

10 ng/mL

50 ng/mL

500 ng/mL

Codeine

10 ng/mL

50 ng/mL

500 ng/mL

Hydromorphone

10 ng/mL

50 ng/mL

500 ng/mL

6-monoacetylmorphine

10 ng/mL

50 ng/mL

500 ng/mL

Amphetamine

5 ng/mL

50 ng/mL

500 ng/mL

Methamphetamine

5 ng/mL

50 ng/mL

500 ng/mL

Equivalence Studies for Calibration Curves
Certified drug free meconium cannot be purchased for the purpose of constructing

calibration curves. In order to alleviate this problem, initial equivalence studies were performed
to determine the suitability of using calibration curves constructed in blood for the quantitation
of meconium specimens.
Experiments were performed by quantitating five high quality control (HQC) standards
and five low quality control (LQC) standards using a calibration curve constructed in blood and a
calibration curve constructed in meconium which had previously screened negative at AIT
Laboratories employing a cutoff of 50 ng/g. Equivalence studies were performed to ensure that
calibration curves prepared in blood were able to accurately quantify quality control standards,
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and therefore authentic samples, in meconium. Quantitative values obtained for QC standards
using the calibration curve constructed in blood were required to be within 15% relative error
(%RE) of the quantitative values obtained using the calibration curve constructed in meconium.
If equivalence studies indicated that calibration curves constructed in blood were capable of
accurately quantitating QC standards prepared in meconium, certified drug free whole blood
would be employed for the remainder of validation for the purpose of constructing calibration
curves.
Preliminary equivalence studies were performed on the first day of validation to assess the
suitability of calibration curves constructed in certified drug-free blood for the purpose of
quantitating meconium specimens. High and low quality control specimens were prepared
according the calibration range of each assay. The concentration of standards used in matrix
equivalence studies varies slightly from those used in the remainder of validation experiments.
Table 9 lists the concentration of all standards used for equivalence studies.
Table 9: Concentrations of all LQC and HQC standards used in preliminary matrix equivalence
studies.
Analyte
Cocaine

LQC used for equivalence studies

HQC used for equivalence studies

15 ng/mL

125 ng/mL

Benzoylecgonine

15 ng/mL

125 ng/mL

Morphine

10 ng/mL

500 ng/mL

Codeine

10 ng/mL

500 ng/mL

Hydromorphone

10 ng/mL

500 ng/mL

6-monoacetylmorphine

10 ng/mL

500 ng/mL

Amphetamine

10 ng/mL

500 ng/mL

Methamphetamine

10 ng/mL

500 ng/mL

Quantitative values obtained for QC standards using a calibration curve constructed in blood
were required to be within 15% relative error (%RE) of the quantitative values obtained using a
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calibration curve constructed in negative meconium. Relative error was calculated according to
Equation 13.
%RE = [(value from blood curve/value from meconium curve)-1] x 100%

Equation 13

4.3.2 Selectivity
The selectivity of each LC-MS/MS assay was assessed by analyzing five blank
meconium samples which had previously screened negative at AIT Laboratories using a cutoff of
50 ng/g. Negative meconium samples were analyzed as blanks because certified drug free
meconium is not commercially available. Blank samples (n=5) were analyzed using each of the
three confirmation methods employing appropriate internal standards, calibration curves and
quality control standards to ensure that the method would be selective for the analytes of interest
in the presence of any endogenous interferences. Methods were deemed selective if, and only if,
the blank matrices did not generate an analyte response in excess of the LLOQ (see Table 8 for
method LLOQs). Following the analysis of blank sample matrices for the presence of possible
interferences, selectivity was established at the LLOQ for each analyte. In order to deem the
methodology selective, negative meconium specimens were spiked with the analyte/s of interest
at a concentration corresponding to the LLOQ. Specimens were then spiked with varying
concentrations of potential interfering species to ensure that the method was selective for the
analyte/s of interest in the presence of other endogenous matrix components. Samples were again
analyzed by each of the confirmation methods using appropriate internal standards, calibration
curves and quality control standards. Individual methodologies were deemed selective if, and
only if, they were capable of quantifying the analyte/s of interest within +/-20% of the expected
nominal value for 80% of the prepared samples.
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4.3.3

Accuracy
Accuracy of the analytical methodology was assessed by preparing and analyzing five

replicate samples prepared in negative meconium at concentrations covering the calibration
range of the method. Samples prepared at the LLOQ, and ULOQ and a concentration midway
between the two were analyzed to assess the accuracy of the quantitation. The method was
deemed accurate if, and only if, the values obtained for each specimen were within 15% of the
expected nominal values, except at the LLOQ where values were expected to be within 20% of
the expected nominal value. Table 8 lists the concentration of all standards used for accuracy
experiments.
4.3.4

Precision
The precision of each confirmation assay was assessed by analyzing five replicates at

three different analyte concentrations corresponding to the LLOQ, the ULOQ and a
concentration point midway between the LLOQ and the ULOQ. Methodologies were deemed
precise if, and only if, the relative standard deviation (RSD) did not exceed 15%, except for the
LLOQ, where the RSD was required to be less than 20%. Intra batch precision was assessed by
analyzing five replicates at three different concentrations within a single analytical run and inter
batch precision was assessed by analyzing replicates over a four day/four batch period. Inter
batch precision was assessed to determine the methods precision with time, and to provide an
indication of method robustness. Intra batch precision was calculated by determining the
standard deviation (σ) and the mean (µ) for each the five replicate analyses at each concentration.
The absolute value of the coefficient of variation or the relative standard deviation (RSD) was
then calculated according to Equation 14.
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R.S.D = (σ/µ) x 100%

Equation 14

Inter batch precision was calculated in the same manner using standard deviation (σ) and mean
(µ) values calculated from values obtained over the four day period for each concentration.
4.3.5 Recovery
Recovery was evaluated to determine extraction efficiencies of each analyte from the
meconium matrix. Recovery was determined by directly comparing the detector response (mean
peak area) for extracted samples prepared and analyzed in triplicate at concentrations
corresponding to the LLOQ, the ULOQ and a concentration midway between the two, with
detector responses for unextracted samples at the same concentrations which represented 100%
recovery[199]. Unextracted samples were prepared directly in mobile phase and injected.
Recoveries were determined as a percentage (Equation 15) and although a high percent recovery
was not necessary for validation, percent recoveries were required to be consistent and
reproducible within triplicate samples and over the three concentrations studied.

% Recovery = (response for extracted) / (response for unextracted) x 100%
4.3.6

Equation 15

Limit of Detection (LOD) and Limit of Quantitation (LOQ)
Limit of detection studies were performed by analyzing serially dilute standards of each

analyte until retention time shifts or inaccurate ion ratios prevented accurate and unequivocal
identification. A series of blank meconium specimens were spiked with each analyte at serially
dilute concentrations beginning with the LLOQ. Samples were analyzed by the appropriate
confirmation method using internal standards, calibration curves and quality control standards.
The LOD for each methodology was determined by evaluating analyte responses, retention time
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accuracy, and ion ratio accuracy for each analyte at each concentration. The limit of detection
was identified as the lowest concentration of analyte which could be accurately identified but not
necessarily quantified. The increased sensitivity of the UPLC-MS/MS methodology meant that
analyte responses were observed at concentrations lower than the LOD, however, retention time
shifts and inaccurate ion ratios meant that unequivocal identifications could not be made. The
limit of detection was identified as the lowest concentration of analyte which could be identified
using established retention time windows and ion ratio abundances.
In order for a methodology to be considered accurate and precise, quantifications at the
LLOQ are generally required to exhibit precision within 20% of the coefficient of variation (CV)
RSD and accuracy within +/- 20% of the expected nominal concentration [198]. The lowest point
of each calibration curve was subject to these exact criteria for acceptance during all validation
experiments and as a result, the LLOQ was subsequently defined as the concentration of the
lowest calibration standard for each confirmation assay.
4.3.7 Stability
In order to assess the stability of each analyte in meconium, freshly made stock solutions
of each analyte were prepared and used to spike blank meconium specimens which were then
subject to several freeze and thaw cycles and subsequently analyzed. Blank meconium
specimens which had previously screened negative at AIT Laboratories using a cutoff of 50 ng/g
were spiked with analyte at concentrations corresponding to the LLOQ and the ULOQ (Table 8).
Specimens were then frozen for 24 and subsequently thawed unassisted at room temperature.
Once thawed, the specimens were again frozen under the same conditions for another 24 hours
after which they were thawed again at room temperature. This cycle was completed a total of
three times and specimens were analyzed upon thawing on the third freeze thaw cycle. Each
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analyte was deemed stable during storage if, and only if, the quantitative values obtained were
within 20% of the expected nominal concentration.
4.3.8 Data Analysis
Analytical data was analyzed using Masslynx version 4.1 software. Criteria for a positive
result included accurate chromatographic retention time, presence of both the qualifying product
ion and the quantifying product ion, and product ion ratios within acceptable limits[119, 199].
Chromatographic retention times are initially established for each analyte and deuterated internal
standard during method validation through the analysis of reference standards. Retention times
are updated following the analysis of calibration standards in each batch to account for minor
drifts in daily retention times. Retention times for each analyte of interest were required to be
within 5% of those determined with control samples. The ratio of the quantifying product ion
peak area to the qualifying product ion peak area was required to be within +/- 20% of the ion
ratio determined for calibrators. Quantitation was performed using a working standard
calibration curve and comparing the ratio of quantifying ion peak area to internal standard peak
area. Authentic samples were required to exhibit sufficient recovery of the internal standard.
Internal standard response was required to be between 10% and 200% of the calibrator/control
average. Calibration curves were required to comprise at least 50% of the original curve points
and any specimens with quantitative values above greater than the upper calibrator were required
to be rerun at an appropriate dilution. The analytical run is considered acceptable if the
calculated concentrations of analyte/s in control samples are within 20% of the expected nominal
value.

113

Chapter 5: Detection and Quantification of Cocaine and Benzoylecgonine in
Meconium Using Solid Phase Extraction and UPLC-MS/MS
5.1

Abstract
A methodology for the selective determination and quantification of cocaine and its

major metabolite benzoylecgonine in meconium using ultra performance liquid chromatographytandem mass spectrometry (UPLC-MS/MS) is described. Past studies indicate that up to 40% of
neonates dying within two days of birth with no apparent cause of death have cocaine and/or
benzoylecgonine in their blood, and rates of infants exposed to cocaine prenatally has been
estimated to be between 2.6% and 11% of all live births. Ultra performance liquid
chromatography (UPLC) is an emerging analytical technique which draws upon the principles of
chromatography to run separations at higher flow rates for increased speed, while simultaneously
achieving superior resolution and sensitivity. Extraction of both analytes was achieved using a
preliminary protein precipitation followed by solid-phase extraction (SPE). Limits of detection
for both analytes were 4 ng/g and the lower limit of quantitation (LLOQ) was 40 ng/g. The
working calibration range was 40-1000 ng/g. The methodology exhibited high intra-run precision
with CV values ranging from 1.6-9.2% for cocaine and 5.3-11.8% for benzoylecgonine. Inter run
precision was evaluated and experiments produced CV values ranging from 3.9-5.0% for cocaine
and 4.4-6.2% for benzoylecgonine. The increased speed and separation efficiency offered by
UPLC, allowed for the separation and subsequent quantification of both analytes in less than 2
minutes. Dramatic increases in separation speed such as those afforded by UPLC translate into
increased samples per unit time in high throughput toxicology laboratories. Development of
sensitive analytical methodologies capable of detecting low levels of such drugs in meconium
will prove beneficial for the identification of prenatal substance abuse.
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5.2

Introduction
Cocaine belongs to the tropane alkaloid family and is obtained from the leaves of the

plant Erythroxylon coca. Although the leaves of Erythroxylon coca and other related species
have been used by the Peruvian Indians for centuries to increase endurance and improve wellbeing, the active ingredient cocaine, was not isolated until the mid nineteenth century. Albert
Niemann, a graduate student at the University of Gottingen was the first person to devise and
report a technique for the isolation of cocaine in 1860[204]. In 1884, 24 years after the first
reported isolation of cocaine, Dr Karl Koller discovered that cocaine was an effective local
anesthetic. In the years following Koller’s discovery, physicians around the world were
employing cocaine as an anesthetic in ophthalmologic, dental, and general surgical procedures.
Although analogues of cocaine such as procaine and lidocaine are still employed as anesthetic
agents, the free distribution of cocaine was banned by the Harrison Narcotics Act in 1914. By the
mid twentieth century the recreational use of cocaine had become a significant concern across
socioeconomic lines.
Cocaine is available on the street in either the base form (crack, free base) or as the
hydrochloride salt. Although both forms of the drug are available in high purity for a similar
street value, the free-base ‘crack’ cocaine is predominately used for smoking while cocaine
hydrochloride is mainly employed for intravenous injection and nasal insufflation.
The prevalence of cocaine use has increased substantially over the past two decades and
in 1989 it was estimated that 50 million Americans has used cocaine at least once and
approximately 8 million people were regular users of the drug[205]. More recent findings from
the 2006 National survey on drug use and health (NSDUH) estimates 2,700 initiates to cocaine
use per day based on the 977,000 persons aged 12 years or older who admitted to using cocaine
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for the first time within the past twelve months[2]. The NSDUH estimates that in addition to the
2.4 million frequent (i.e., at least twice weekly) users of cocaine, there are approximately 4.6
million occasional users (i.e., once a month or less) of the drug, excluding individuals already in
prison[2].
Although it is difficult to accurately determine the number of women who use cocaine
during pregnancy, there is evidence to suggest that cocaine represents a significant proportion of
the illicit substances which 4% of pregnant women admitted using during pregnancy in the 2006
NSDUH [2, 8, 11, 206]. One such study, performed at a high-risk tertiary perinatal, reported that
38% of infants tested positive for drugs, and 90% of those 773 infants were positive for
cocaine[207]. In 1991 the Los Angeles County Office of Chief Medical Examiner-Coroner (LAC
CMEC) reported that 40% of neonates dying within two days with no apparent cause of death
had cocaine and/or benzoylecgonine in their blood[208]. Rates of infants exposed to cocaine
prenatally has been estimated to be between 2.6% and 11% of all live births[11].
Chemical extraction of benzoylecgonine from biological matrices is complicated by the
amphoteric nature of the compound. While cocaine exists as a basic molecule and is easily
extracted into organic solvent under alkaline conditions, benzoylecgonine exists as a zwitterion
making it difficult to extract. Extraction of target analytes from biological matrices generally
occurs following neutralization with an appropriate acid or base depending on the properties of
the drug. Benzoylecgonine possesses two ionizable centers, one with acidic properties and one
with basic properties making its neutralization difficult. Extraction design is further complicated
by the need to simultaneously extract cocaine for analysis meaning that the method of choice
must provide satisfactory recovery of both analytes.
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Table 10 provides the chemical structures of cocaine and its primary metabolite,
benzoylecgonine and describes certain physicochemical properties of each compound including
molecular weights, molecular formulas, and pKa’s.
Table 10: Chemical structures, molecular weights, molecular formulas, and pKa's of cocaine and
benzoylecgonine.
Cocaine
Benzoylecgonine
Chemical structure

Chemical structure

Molecular weight

303.353 g/mol

Molecular weight

289.33 g/mol

Molecular formula

C17H21NO4

Molecular formula

C16H19NO4

pKa

5.3

8.72

pKa 1

3.15

pKa 2

10.14

Mechanism of Action
Cocaine is a naturally-occurring central nervous system (CNS) stimulant that interferes

with the actions of dopamine, norepinephrine and serotonin in functioning nerves. Cocaine is
classed as a sympathomimetic agent due to its ability to activate the sympathetic nervous system
both centrally and peripherally[209]. Central stimulation of the sympathetic nervous system
results from cocaine’s ability to selectively bind dopamine reuptake transporters (DATs) in the
brain[204]. Clearance of dopamine at the synapse and subsequent termination of dopaminergic
neurotransmission is achieved through reuptake into the presynaptic neuron which is mediated
by DATs[210]. By binding to DATs, cocaine impairs the reuptake of dopamine into the
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presynaptic neuron resulting in elevated dopamine levels in the central nervous system. Direct
stimulation of the central nervous system by cocaine and other sympathomimetic agents also
results in increased norepinephrine release from peripheral synapses. Cocaine not only facilitates
increased release of norepinephrine peripherally it also acts to inhibit its reuptake at the synapses
causing it to remain in the synaptic cleft for a prolonged period of time. As a result of cocaine’s
ability to inhibit the reuptake of dopamine centrally and norepinephrine peripherally, the natural
effect of these neurotransmitters is amplified. Excessive levels of CNS dopamine and peripheral
norepinephrine account for the feelings of euphoria and increased alertness associated with
cocaine use[209].
5.4

Effect of Prenatal Exposure
Due to the popularity and prevalence of cocaine use in the USA, the vast majority of

research conducted into the effects of maternal drug use has focused on cocaine. Prenatal cocaine
use has been associated with premature labor, placental abruption, low birth parameters (weight,
head circumference, length), microcephaly, congenital malformations, increased risk of sudden
infant death syndrome (SIDS), spontaneous abortion, acute hypoxic-ischemic encephalopathy,
cerebral hemorrhage or infarction, abnormal neonatal behavior, limb deformities[75, 83, 211,
212].
5.5

History of Cocaine and Benzoylecgonine Detection in Meconium Specimens.
The detrimental outcomes of prenatal cocaine exposure on developing children have long

been realized. As a result of the widespread use of cocaine during pregnancy, many analytical
methodologies describing the detection of cocaine and its inactive metabolite, benzoylecgonine,
in meconium have appeared in the literature.
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Browne and colleagues described a method for the detection of cocaine and its
metabolites in meconium using HPLC and GC-MS. First-day meconium samples were subject to
solid phase extraction followed by chromatographic separation and detection by either UV or
MS. Although the authors reported the presence cocaine at concentrations ranging from 0.1µg/g
to 0.78µg/g, no benzoylecgonine, ecgonine or ecgonine methyl ester was detected, prompting the
authors to speculate that the metabolizing capabilities of the neonate may be limited[52].
Callahan and co-workers employed GC/MS for the identification of gestational cocaine exposure
in the infants of 59 women who had been previously identified as cocaine users through hair
analysis. The authors concluded that GC/MS analysis of meconium proved more sensitive than
immunoassay analysis of urine and can detect fetal cocaine exposure which occurred in the last
two trimesters of pregnancy[213].
Clark et al employed solid phase extraction and GC/MS for the determination of cocaine
and benzoylecgonine in methanolic extracts of meconium which had been screened using
fluorescence polarization immunoassay (FPIA). The enhanced sensitivity of GC/MS enabled the
authors to identify cocaine at concentrations as low as 0.25µg/g and benzoylecgonine at
concentrations of 0.5µg/g[214]. Murphey and co-workers employed solid phase extraction
columns with both cation exchange and hydrophobic properties for the simultaneous extraction
of cocaine, benzoylnorecgonine, benzoylecgonine and norcocaine from meconium. Following
extraction, analytes were identified using HPLC and limits of detection were 50ng/g for all
analytes[215].
Many of the reported methodologies for the determination of cocaine and its metabolites
in meconium utilized solid phase extraction followed by GC/MS analysis. Solid phase extraction
is generally required due to the complex nature of the meconium matrix. Liquid-liquid
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extractions fail to remove many of the endogenous interferants present in the sample. GC/MS
analysis was routinely utilized following SPE throughout the 1990s due to the separating power
of gas chromatography and the unequivocal mass spectrometric identifications afforded my MS.
Early reports of LC-MS/MS methods for the determination of cocaine and its metabolites in
meconium began to appear in the literature at the turn of the century. Xia and colleagues
employed a triple quadrupole mass spectrometer equipped with an electrospray ionization source
for the determination of cocaine and several of its metabolites following LC separation. The
authors conclude that the utilization of MS-MS both increases the selectivity of the assay and
reduces sample preparation time as several metabolites of cocaine which are directly amendable
to LC separation require additional derivatization for GC analysis[216]. Pichini and co-workers
employed an ESI-LC/MS assay operating in SIM mode for the simultaneous determination of
cocaine and opiates in meconium. Analytes were extracted using an initial liquid extraction into
methanol or ammonium hydrogen carbonate buffer followed by a solid phase extraction for
subsequent sample clean-up. Method validation included a linear dynamic range of 0.005 –
1.00µg/g[217]. The same authors re-applied the validated LC-MS method two years later for the
determination of two additional cocaine metabolites in meconium[218].
To the best of the author’s knowledge, this is the first report of the application of UPLCMS/MS for the determination of cocaine and benzoylecgonine in meconium.
Validation and implementation of UPLC-MS/MS methodologies capable of detecting
low levels of common drugs of abuse in meconium will assist in providing more accurate
information pertaining to the prevalence of prenatal drug exposure. The increased separation
efficiency of UPLC provides the analyst with maximal separation power necessary to resolve
endogenous sample components from target analytes. Increases in sensitivity, afforded by taller,
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narrower peaks are also achieved with UPLC separations. As a result, low levels of target
analyte, which would likely go undetected using traditional HPLC, will be detectable in the
complex meconium matrix. The introduction of tandem mass spectrometry detection into routine
meconium analysis provides obvious advantages such as enhanced selectivity relative to UV or
single mass spectrometric detection. Increases in selectivity ensure that low concentrations of
target analytes, which would normally be indistinguishable from endogenous interferences using
HLPC-UV or GC/MS, are accurately identified.
5.6

Experimental

5.6.1

Chemicals and Reagents
Cocaine, benzoylecgonine, cocaine-d3, and benzoylecgonine-d3 standards (1mg/mL in

methanol) were obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N supported
liquid-liquid extraction columns were purchased from Biotage (Charlottesville, VA). All solvents
were HPLC grade and obtained from Fisher Scientific (Pittsburgh PA).
5.6.2

Calibration Curve Matrix
Meconium specimens which had previously screened negative for cocaine using a 50

ng/g cutoff at AIT laboratories (Indianapolis, IN) were collected and spiked with both cocaine
and benzoylecgonine to give concentrations of 15 ng/mL (n=5) and 125 ng/mL (n=5). Spiked
meconium was then quantified using a calibration curve constructed in negative meconium and a
calibration curve constructed in certified drug free whole blood. Quantitative results obtained
using the meconium calibration curve showed excellent correlation (<15% CV) with those
obtained using the calibration curve made up in negative blood and as a result, all subsequent
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method validation experiments were performed using calibration curves prepared in certified
negative blood.
5.6.3

Working Standards
Calibration curves were constructed using seven calibration standards prepared in

certified drug free whole blood and all sample volumes were 1 mL. A working standard (500
ng/mL) used to prepare calibration standards, was prepared by combining 250 µL of a stock
solution (10 µg/mL) of cocaine and benzoylecgonine with 4.75 mL of deionized water. An
internal standard solution (500 ng/mL) was prepared using 1 mg/mL standards of cocaine-d3 and
benzoylecgonine-d3.
5.6.4

Calibration Curves
Calibration curves for all experiments were prepared according to Table 11.

Table 11: Preparation of cocaine and benzoylecgonine calibration curves.
Standard Concentration
Volume of Working Standard
Volume of Deionized water
250
500
500
100
200
800
50
100
900
25
50
950
10
20
980
5
10
990
Negative
0
1000

100µL of internal standard solution (500 ng/mL) was added to each sample including the blank
and all samples were then vortexed for 30 seconds.
5.6.5

Quality Control (QC) Standards
Quality control standards (QC’s) were prepared and analyzed with every batch to ensure

the accurate identification and quantitation of validation specimens. A low QC (LQC) was
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prepared at a concentration of 10 ng/mL and a high QC (HQC) at a concentration of 250 ng/mL.
Quality control standards were injected immediately following the final point of the calibration
curve and quantitation of each QC was required to be accurate within 20% of the expected
nominal value to proceed with the analysis of validation specimens.
5.6.6

Sample Preparation
Meconium samples were accurately weighed and then diluted by a factor of 3 (w/v) with

50:50 methanol/water to assist with the sonication procedure. Samples were shaken and
sonicated for 10-15 minutes. Following sonication, 1 mL of the meconium sample was added to
appropriately labeled culture tubes. Cocaine, benzoylecgonine and deuterated internal standards
were added to samples which were then block vortexed for 5 minutes. Analytes were extracted
by first adding 2 mL of cold acetonitrile while simultaneously vortexing each sample. Samples
were then centrifuged for 10 minutes at 3000 rpm. Following centrifugation, the organic layer
was transferred to a clean labeled large screw top test tube. 3 mL of 0.1 M phosphate buffer (pH
6.0) was added to each sample followed by the addition of 1 mL of concentrated ammonium
hydroxide. Samples were then vortexed by hand for 10-15 seconds followed by a 5 minute
centrifugation at 3000 rpm.
5.6.7

Solid Phase Extraction (SPE)
Analytes were selectively extracted using a solid phase extraction employing UCT clean-

screen ZSDAU020 columns with reversed phase and ion-exchange retention mechanisms.
Columns were first conditioned with sequential washes of methanol (3 mL), deionized water (3
mL) and 0.1 M phosphate buffer, pH 6.0 (1 mL). All solvents were allowed to drip through the
columns slowly under gravity and waste containers were interchanged accordingly. Following
column conditioning, samples were poured onto the columns and allowed to drip through
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unassisted for 15 minutes before any pressure was applied. Following sample loading, sequential
wash steps were performed using deionized water (1 mL), 1.0 M HCl (1 mL), and methanol (3
mL). All wash solvents were allowed to drip through the columns unassisted for 5-10 minutes
after which time any remaining solvent was assisted through the columns using a positive
pressure manifold. Following column wash steps, positive pressure was applied for 5-10 minutes
to ensure complete elution of wash solvents. Waste containers were then exchanged for small,
labeled elution test tubes and analytes were eluted with 3 mL of 78:20:2 (dichloromethane: 2propanol: ammonium hydroxide) elution solvent which was made fresh daily. Samples were
dried down under a gentle steam of nitrogen and reconstituted in 200 µL of DI water:ACN
(75:25). Samples were transferred to appropriately labeled plastic vials and injected for analysis.
5.6.8 Liquid Chromatography
Liquid chromatographic separations were performed on a Waters ACQUITYTM ultra
performance liquid chromatograph (UPLC™) (Waters Corp., Milford, MA, USA). Separations
were achieved on an ACQUITY UPLC™ HSS T3 column (2.1x 50mm) packed with 1.8µm
bridged ethyl hybrid (BEH) particles and maintained at 35°C. The mobile phase consisted of
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1%
formic acid (solvent B). Analytes elution was achieved using the following step-wise binary
elution gradient: Initial mobile phase composition was 75:25 (H2O:ACN). Initial conditions were
held constant for 0.5 mins after which the composition of solvent B was linearly increased to
50% over 1.5 mins, finally conditions were returned to their initial composition of 75:25
(H2O:ACN) over the next 0.01 mins and held for 0.49 min to equilibrate the column before the
next injection in the sequence. The total run time was 2.50 mins (Figure 17). Samples were
maintained at 7.5°C in the sample organizer and sample injection volumes were 5µL for all
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analyses. Flow rates were maintained at 0.5 mL/min for the first 0.50 mins after which they were
increased to 0.6 mL/min for the remainder of the chromatographic separation. All flow was
directed into the ESI source of the mass spectrometer.

2: MRM of 3 Channels ES+
304.14 > 150.16
9.48e5
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Figure 17: TIC from the UPLC separation of cocaine and benzoylecgonine.

5.6.9 Mass Spectrometry
Mass spectrometry conditions were as follows: capillary voltage 0.80 kV, cone voltage
20 V, extractor voltage 3.0 V, RF lens voltage 0 V. The source temperature was 120°C while the
desolvation temperature was set at 350°C. Cone gas was set at a flow of 100 L/Hr while the
desolvation gas flow was 900 L/Hr. The collision gas flow was set to 0.10 mL/min. Nitrogen
(99.995% purity) was used as the desolvation gas, and ultra-pure argon (99.999% purity) was
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used as the collision gas. Table 12 reports the mass transitions, dwell times, cone voltages, and
collision energies for each of the analytes and their deuterated internal standards.
Table 12: MS/MS parameters used for each analyte and deuterated internal standard.
Compound
Cocaine

Mass transition
304.14 > 182.10

Purpose
Quantifying ion

Cone (V)
40

Collision (V)
20

Dwell (secs)
0.01

Cocaine

304.14 > 150.16

Qualifying ion

40

20

0.01

Cocaine-d3

307.15 > 184.96

Quantifying ion

30

20

0.01

Benzoylecgonine

290.08 > 168.24

Quantifying ion

40

20

0.01

Benzoylecgonine

290.08 > 104.78

Qualifying ion

40

40

0.01

Benzoylecgonine-d3

293.11 > 170.98

Quantifying ion

40

20

0.01

Figure 18 illustrates the fragmentation pathways for cocaine and benzoylecgonine under ESI
conditions and the resulting product ions used for analyte quantitation.
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Cocaine

Benzoylecgonine

Figure 18: Fragmentation pathways for Cocaine and Benzoylecgonine during tandem mass
spectrometry experiments[219].

5.7

Results and Discussion

5.7.2

Method Validation
Preliminary equivalence studies indicated that calibration curves prepared in certified

drug-free blood were suitable for the accurate quantification of cocaine and benzoylecgonine in
the meconium matrix (Table13 & 14). The percent relative error (%RE) calculated for the 5
HQCs and 5 LQCs was less than 1.6% for cocaine and 7.2% for benzoylecgonine, indicating a
high degree of correlation between the two curves at both the high and low end of the calibration
range. Mean relative error values for low quality control specimens were 1.4%, and 3.0% for
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cocaine and benzoylecgonine, respectively. Mean relative error values for high quality control
specimens were 1.3%, and 7.0% for cocaine and benzoylecgonine, respectively.
Table 13: Cocaine equivalence studies using quantitative values obtained from calibration curves
constructed in meconium (MC) and blood (BC).
Cocaine Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
14.1
120.1
0
0.1

*MC (ng/mL)
14.3
118.6
0.2
0.2

%RE
1.40%
1.30%
N/A
N/A

*LQC and HQC concentrations represent mean values of 5 replicate analyses.
Table 14: Benzoylecgonine equivalence studies using quantitative values obtained from
calibration curves constructed in meconium (MC) and blood (BC).
Benzoylecgonine Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
15.9
134.7
0
0.1

*MC (ng/mL)
16.4
125.9
0.4
0

%RE
3.0%
7.0%
N/A
N/A

*LQC and HQC concentrations represent mean values of 5 replicate analyses.
The analytical methodology exhibited sufficient selectivity throughout studies using
blank meconium specimens and QC standards which had been spiked with various exogenous
interferences. Blank meconium specimens were analyzed to ensure that any response generated
by the matrix alone corresponded to a concentration less than the LLOQ, while spiked samples
were analyzed to assess the ability of the methodology to accurately and precisely quantitate the
analyte in the presence of possible exogenous interferences (Table 15). Three blank meconium
specimens were spiked with selectivity quality control standards (QCs) which had been
previously prepared using various analytes commonly encountered in forensic specimens. The
two remaining blank meconium specimens were spiked with opiates (codeine, morphine,
hydrocodone, hydromorphone, oxycodone, oxymorphone, and 6-monoacetylmorphine) and THC
respectively, at concentrations corresponding to HQCs. The selectivity of the analytical
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methodology in the presence of opiates and THC was investigated as these drugs are commonly
encountered in forensic specimens at appreciable concentrations.
Table 15: Exogenous compounds included in selectivity quality control standards.
Standard
Selectivity QC 1

Selectivity QC 2

Selectivity QC 3

Contents
Carbamazepine, carbamazepine epoxide, felbamate, gabapentin, lamotrigine,
levetiracetam, mephobarbital, naproxen, oxcarbazepine, phenytoin, primidone,
topiramate, valproic acid, zonisamide
Amitriptyline, bupropion, clomipramine, desipramine, doxepin, fluoxetine, imipramine,
norclomipramine, nordoxepin, norfluoxetine, norsertraline, nortriptyline, norvenlafaxine,
paroxetine, sertraline, venlafaxine
Alprazolam,
chlorpheniramine,
citalopram,
clonazepam,
cyclobenzaprine,
dextromethorphan, duloxetine, fentanyl, flunitrazepam, haloperidol, mirtazapine,
olanzapine, strychnine, zolpidem

Blank meconium specimens generated minimal detector responses corresponding to
mean analyte concentrations 0.4 ng/mL for cocaine (Table 16), and 1.5 ng/mL for
benzoylecgonine (Table 17) which were below the LLOQ of 10 ng/mL. Analysis of spiked
standards prepared at the LLOQ, indicate that the methodology is selective for the analytes of
interest, even in the presence of various exogenous interferences (Table 16 & 17).
Table 16: Cocaine selectivity studies using blank meconium from five different sources and
blank meconium specimens spiked with various exogenous interferences.
Cocaine Std

Std Conc (ng/mL)

*Measured conc
(ng/mL)

Acceptable range

Pass/Fail

Blank samples
Spiked samples

0
10

0.4
10.3

<10ng/mL
10 +/- 20%

Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
Table 17: Benzoylecgonine selectivity studies using blank meconium from five different sources
and blank meconium specimens spiked with various exogenous interferences.
Benzoylecgonine Std

Std Conc (ng/mL)

*Measured conc
(ng/mL)

Acceptable range

Pass/Fail

Blank samples
Spiked samples

0
10

1.5
11.6

<10ng/mL
10 +/- 20%

Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
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Accuracy studies performed by analyzing five replicates at three different concentrations
spanning the calibration range yielded mean values of 254.9 ng/mL, 52.7 ng/mL, and 10.5
ng/mL reflecting accuracies of 98%, 94.6%, and 95%, respectively for cocaine and 245.7 ng/mL,
50.2 ng/mL, and 10.5 ng/mL reflecting accuracies of 98.3%, 99.6%, and 95%, respectively for
benzoylecgonine (Table 18 & 19). Quantitation accuracies were greater than 94% for both
analytes over the entire calibration range.
Table 18: Cocaine accuracy studies.
Cocaine Std
High point
Midpoint
LLOQ

Std Conc
250
50
10

*Measured value
254.9
52.7
10.5

%RE
2.0%
5.4%
5.0%

*Reported concentrations are mean values of 5 replicate analyses.
Table 19: Benzoylecgonine accuracy studies.
Benzoylecgonine Std
High point
Midpoint
LLOQ

Std Conc
250
50
10

*Measured value
245.7
50.2
10.5

%RE
1.7%
0.4%
5.0%

*Reported concentrations are mean values of 5 replicate analyses.
Both intra-batch and inter-batch precision studies indicated a high degree of precision
over the three concentrations investigated with intra-batch CVs ranging from 1.6-9.2% with the
mean being 4.5% for cocaine (Table 20), while CVs for benzoylecgonine ranged from 5.3-11.8%
with a mean value of 7.4% (Table 21). Inter-batch precision produced CV values ranging from
3.9-5.0% over the three concentration ranges for cocaine and from 4.4-6.2% over the three
concentrations for benzoylecgonine.
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Table 20: Intra- and inter-batch precision studies for cocaine.
Cocaine Std
Highpoint
CV
Midpoint
CV
LLOQ
CV

*Day 1 value
254.9
2.0%
52.7
5.2%
10.5
9.2%

*Day 2 value
258.1
1.6%
48.3
4.6%
10.6
6.8%

*Day 3 value
275.9
3.5%
48.8
4.3%
10.0
6.6%

*Day 4 value
255.0
2.9%
49.6
2.4%
9.5
4.4%

4 day mean
261.0

4 day CV
3.9%

49.9

4.0%

10.2

4.9%

*Reported concentrations are mean values of 5 replicate analyses.
Table 21: Intra- and inter-batch precision studies for benzoylecgonine (BE).
BE Std
Highpoint
CV
Midpoint
CV
LLOQ
CV

*Day 1 value
245.7
6.3%
50.2
11.8%
10.5
9.5%

*Day 2 value
264.4
7.9%
49.4
5.5%
10.5
8.6%

*Day 3 value
245.5
7.1%
52.4
5.9%
10.9
7.3%

*Day 4 value
230.8
5.9%
47.0
7.2%
9.4
5.3%

4 day mean
246.6

4 day CV
5.6%

49.8

4.4%

10.3

6.2%

*Reported concentrations are mean values of 5 replicate analyses.
Analyte recovery was investigated over three concentrations which spanned the calibration range
for each analyte and was found to have a mean value of 71.7% for cocaine (Figure 19) and
10.2% for benzoylecgonine (Figure 20). Mean recoveries from triplicate analysis at the three
concentration ranges investigated ranged from 68.3-77% for cocaine and 9.3-10.7% for
benzoylecgonine representing good consistency and reproducibility even though the overall
recovery of benzoylecgonine was poor. While poor recoveries for benzoylecgonine may be
attributable to analyte loss during the solid phase extraction, further studies aimed at determining
the degree of recovery during the initial protein precipitation would prove beneficial.
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Figure 19: Cocaine recovery at three concentrations over the linear range.
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Benzoylecgonine Recovery
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Figure 20: Benzoylecgonine recovery at three concentrations over the linear range.
The limit of detection was determined to be 1 ng/mL for both cocaine and benzoylecgonine
corresponding to a concentration of 4 ng/g in the meconium specimen prior to sonication.
Unequivocal identification of analytes was not feasible at concentrations below 1 ng/mL due to
significant fluctuation and inaccuracies in calculated ion ratios. Both cocaine and
benzoylecgonine appear to be quite stable in the meconium matrix over the investigated
calibration range when stored at 4°C. Quantitation accuracies during stability studies were
greater than 84% and 93% for cocaine HQC and LQCs respectively, and greater than 95% and
99% for benzoylecgonine HQC and LQCs respectively.
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5.8

Conclusions
Development and validation of an accurate, selective, precise, and sensitive UPLC-ESI-

MS/MS method for the identification and quantification of cocaine and benzoylecgonine in
meconium was achieved. For the purpose of improved selectivity, two MRM transitions were
monitored for each analyte and quantifications was achieved using deuterated internal standards
and a six point calibration curve. Injection volumes of 5 µL allowed for the accurate
quantification of both analytes over the range 10 - 250 ng/mL, corresponding to concentrations
of 40 - 1000 ng/g in the original meconium specimens. Significant gains in sample throughput
are achieved with ultra performance liquid chromatography through rapid chromatographic
separations made possible by sub 2 µm packing materials. This increased speed of analysis
alleviates problems associated with extensive sample preparation and allows working toxicology
laboratories to increase sample throughput without sacrificing the quality of the data. To the best
of the author’s knowledge, this is the first report of a validated UPLC-ESI-MS/MS method for
the quantitative analysis of cocaine and benzoylecgonine in meconium specimens. The validated
methodology was implemented at AIT Laboratories (Indianapolis, IN) for the purpose of
confirming the presence of cocaine and benzoylecgonine in authentic meconium specimens
which had previously screened positive. From 07/01/08 – 03/06/2009 a total of 4036 meconium
specimens were screened for cocaine/benzoylecgonine. Of those samples, 303 screened positive
representing 7.5% of the total specimens. 71 of the 303 specimens were confirmed positive using
the UPLC-MS/MS method.
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Chapter 6: Detection and Quantification of Codeine, Morphine,
Hydromorphone, and 6-Monoacetylmorphine (6-MAM) in Meconium using
ISOLUTE HM-N Supported-Liquid Extraction Columns and UPLC-MS/MS
6.1

Abstract
A method for the extraction and quantification of codeine, morphine, hydromorphone,

and 6-monoacetylmoprhine (6-MAM) from meconium specimens using supported-liquid
extraction (SLE) columns and ultra performance liquid chromatography coupled to tandem mass
spectrometry (UPLC-MS/MS) is described.
Deaths resulting from heroin (diacetylmorphine) use have long been considered an
epidemic and continue to plague society due to the addictive nature and abuse potential of the
drug. While heroin remains a popular drug of abuse in today’s society, large increases in the
prescriptive medical use of several opiate analgesics over the past ten years have been
accompanied by increases in morbidity due to abuse, addiction, and diversion. Popular opiate
analgesics commonly prescribed for the treatment of pain include morphine, codeine,
hydrocodone, and hydromorphone.
Meconium specimens were sonicated to maximize homogeneity of the sample and
analytes were subsequently extracted from the matrix using ISOLUTE HM-N supported-liquid
extraction (SLE) columns. Quantitation was performed using a Waters UPLC™ chromatograph
coupled to a triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI)
source. Chromatographic separation was achieved in less than 5 minutes, data was acquired in
the MRM mode and quantitation was achieved using multi point calibration curves.
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The analytical methodology was deemed selective for the analyte of interest in the
presence of exogenous interferences. Quantitation accuracy ranged from 90 – 100% for all four
analytes over three concentrations spanning the calibration range. Intra-batch precision studies
indicated high quantitative precision with CV values ranging from 1.2 – 10.7% for all analytes.
Inter-batch precision was high over the entire calibration range with CV values ranging from 0.5
– 6.1%. Analyte recovery ranged from 52.3 – 76.3% for all four analytes representing good
extraction efficiencies. The limit of detection for all four analytes was 2.5 ng/mL, corresponding
to a concentration of 10 ng/g prior to homogenization.
By employing ISOLUTE HM-N supported-liquid extractions for the isolation of analytes
in meconium, sample preparation time is greatly reduced without sacrificing analyte recovery.
Ultra performance liquid chromatography allowed for the rapid chromatographic separation of
all four analytes in less than 5 minutes and tandem mass spectrometric detection ensured
increased sensitivity and selectivity relative to traditional techniques such as HPLC-UV and
GC/MS. Development of analytical techniques requiring minimal sample preparation for the
determination of opiates in meconium specimens will aid in the identification of infants
prenatally exposed to drugs such as heroin, morphine, codeine, hydrocodone, and
hydromorphone.
6.2

Mechanism of Opiate Action
Members of the opiate family mimic the effects of endogenous analgesics termed

‘endogenous opioid peptides,’ which include β-endorphin, leu-enkephalin, met-enkephalin,
dynorhpins, and the neoendorphins[220]. Such peptides are released by the body to regulate pain
and it is this action which is mimicked by members of the opiate family which bind to specific
receptors in the spinal cord and prevent the release of excitatory neurotransmitters[220]. In
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combination to directly blocking the release of excitatory neurotransmitter in the spinal cord,
opiates also act to inhibit the release of neurotransmitters in certain nerve fibers which are
responsible for relaying pain signals to the spinal cord. The combination of central and
peripheral inhibition results in a powerful analgesic effect common to all members of the drug
class[220].
The identification of specific receptors at which opiates bind was not reported until 1976
when Martin and coworkers performed a detailed analysis of the neurophysiological and
behavioral properties of several opiate compounds looking specifically for cross tolerance[221].
Studies suggested the presence of three types of opioid receptors which were subsequently
named after the drugs used in the studies. The µ (mu) receptor was named after morphine, while
the κ (kappa) receptor was named after ketocyclazocine and the σ (sigma) receptor after Nallylnormetazocine. The σ receptor is no longer considered an opiate receptor. In 1977,
Kosterlitz and coworkers identified the δ (delta) opiate receptor when they noticed that action of
enkephalins on the vas deferens was relatively insensitive to naloxone[222].
The existence of such receptors has always been theorized due mainly to the
stereoselectivity of the opiates, the existence of antagonists and the differences in potencies
throughout the opiate family. As already mentioned, opiates act by binding to one or multiple of
the opiate receptors thereby preventing the transmission of second messenger signals associated
with pain. Although the actual biochemical mechanism associated with this process is not fully
understood, it is thought to involve changes in the coupling of a G-protein to the regulatory
enzyme adenylate cyclase which in turn inhibits the actions of adenylate cyclase. Inhibition of
the adenylate cyclase enzyme facilitates the opening of potassium (K+) ion channels and the
simultaneous closing of calcium (Ca++) channels which results in the hyperpolarization of
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neurons and the overall regulation of pain[223]. Most of the commonly prescribed opiates are
full agonists at the mu receptor and many members of the opiate family act on all three receptors
(Table 22).
Table 22: Receptor activity for selected opiates and synthetic derivatives.
Opiate

Overall relationship

µ (mu) receptor
action

δ (delta) receptor
action

κ (kappa) receptor
action

Morphine

full agonist

strong agonist

weak agonist

weak agonist

Codeine

full agonist

weak agonist

weak agonist

no activity

Methadone

full agonist

strong agonist

weak agonist

weak agonist

Fentanyl

full agonist

strong agonist

weak agonist

no activity

Buprenorphine

partial agonist

partial agonist

no activity

antagonist

Pentazocine

partial agonist

antagonist

weak agonist

moderate agonist

Naloxone

antagonist

antagonist

antagonist

antagonist

Agonists for any of the three opiate receptors will possess some degree of analgesic inducing
properties however additional side effects will vary somewhat depending on the individual
receptor. Mu-specific agonists will cause powerful analgesia along with the euphoria responsible
for the widespread abuse of opiates. The mu receptor is also responsible for many of the
unwanted effects of opiates such as respiratory depression which is considered to be the main
side effect of opiates associated with most overdoses. Drug induced respiratory depression
occurs when the brain is unaware of accumulating levels of CO2 and subsequently
understimulates the lung musculature[224]. The brain is unaware of such accumulation due to
desensitization of the medulla which is responsible for determining the need to breathe deeper,
faster, and more rhythmically in times of CO2 accumulation[224]. In addition to inducing
respiratory depression, agonists at the mu receptor also produces miosis, reduction in motility of
the GI system, and physiological dependence[220]. Agonists at the kappa receptor will induce

138

spinal analgesia, dysphoria, and sedation while opiate agonists at the delta receptor will mediate
analgesia, additional respiratory depression, slight euphoria and dependence[220].
6.3

Introduction to Commonly Abused Opiates
The opiates are a large family of drugs which are structurally and pharmacologically

related to morphine. Morphine is the central member of the opiate family and is obtained from
raw opium, which is the dried sap of the seed capsule in the opium poppy (Papaver somniferum).
Raw opium is initially purified to refined opium which is a sticky gum exudate containing many
alkaloids including morphine (~10%), codeine (~0.5%) and thebaine (~0.4%) which are
subsequently extracted and prepared for medicinal purposes[220, 225]. Members of the opiate
family include several semi-synthetic compounds such as codeine, oxycodone, dihydrocodeine,
hydrocodone, and hydromorphone, which are derived from the morphine molecule through
chemical modification[220].
Several synthetic opiates, known more commonly as opioids, such as fentanyl,
methadone, meperidine, propoxyphene and buprenorphine are also commonly prescribed for
their analgesic properties. Although these compounds appear structurally unique relative to the
morphine molecule, their three dimensional interaction with opioid receptors is very similar.
Although the exact mechanism by which opiates act on the central nervous system (CNS) is still
largely speculative, their pharmacological effect has been documented and sought after for over
two hundred years[226].
The interaction of opiates with specific receptors in the CNS is responsible for their
central effects such as analgesia, drowsiness, mental dullness, changes in mood, and
euphoria[220, 225, 227]. The pharmacological activity of opiates mimics that of endogenous
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opioid peptides which are produced naturally in the body and interact with receptors throughout
the nervous system and GI tract to alter the body’s response to painful stimuli[227]. Because of
their ability to modulate pain and reduce suffering, opiates are an extremely important and
widely prescribed class of drug throughout many fields of medicine. The ability of opiates and
certain illicit derivatives (eg. heroin) to produce feelings of euphoria, also means that they are
one of the most widely abused drug classes in today’s society.
In 1999, the federally sponsored Drug Abuse Warning Network (DAWN) program
indicated that heroin toxicity accounted for almost half (42%) of all narcotic-related deaths and
41.3% of all reported drug-related deaths[204]. In 2006, a National Vital Statistics Report
published by the US Department of Health and Human Services indicated that heroin related
deaths were continuing to increase and that a total of 2,101 deaths were attributed to heroin
overdose in 2002, representing a 17% increase from the previous year[228, 229]. As opiate
related deaths continue to increase throughout the world, heroin is still considered the most
prevalent opiate of interest in post mortem toxicology due to its widespread availability and
ability to induce life threatening respiratory depression[230]. Following administration, heroin is
rapidly converted via deacetylation to 6-monoacetylmorphine (6-MAM) and then to morphine
(Figure 21)[204].
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Figure 21: Metabolism of heroin.

The conversion of heroin to 6-monoacetlymorphine is complete within 10-15 minutes
while the total conversion of heroin to morphine is completed within a few hours [204]. Due to
its rapid biochemical transformation following administration, heroin has a similar excretion
profile to morphine, although small amounts of 6-MAM are found in the urine of most heroin
users[220]. The presence of 6-MAM in the urine distinguishes heroin use from morphine use and
although the presence of trace levels of codeine are also consistent with heroin use (due to the
presence of codeine in the heroin as an impurity), only the presence of 6-MAM can
unequivocally identify the source of morphine as heroin. 6-MAM has also been shown to cross
the placental membrane and accumulate in the meconium of infants exposed to heroin prenatally,
and similar to urine, its identification in meconium provides definitive proof of maternal heroin
use[92]. The detection of 6-MAM in the meconium of newborn infants is vital to distinguish
morphine use from heroin use.
Morphine is administered to pregnant women for several reasons such as the induction of
spinal anesthesia[231], for the treatment of acute pancreatitis[232], and to provide improved
labor and postcesarean analgesia[233] and while most sources of morphine will be administered
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only hours prior to birth and will likely not present in the meconium of the newborn, the
presence of 6-MAM will distinguish heroin use from any morphine use, licit or otherwise.
Morphine (MS Contin, Kadian, Avinza) is one of the most widely prescribed opiates for
the treatment of chronic pain due to its highly potent analgesic effects. Morphine is likely the
most effective opiate for the treatment of severe pain and while its analgesic effects are well
utilized in the field of pain management, its potent agonist activity at the mu receptor also
induces euphoric effects which are sought after by addicts worldwide.
Joranson and coworkers investigated trends in the medical use of morphine for the
treatment of severe pain over a six year period. In 1990, approximately 2.2 million grams of
morphine were prescribed to patients suffering from severe pain. Over the next six years, this
number increased by 59% and by 1996, 3.5 million grams of morphine were being actively
prescribed to patients across north America[234]. Although the authors conclude that the
increasing use of medical morphine did not appear to contribute to the increasing health
consequences of opiate analgesic abuse, a separate study published in the Journal of Addictive
Diseases reports that the rate of morphine prescription (number of morphine prescriptions per
10,000 patient encounters) increased 2.64 fold over the time period 1995-2004, while the rate of
emergency department (ED) mentions for morphine simultaneously increased 1.16 fold[235].
Since 1995, there has been an overall 86% increase in morphine use across the United
States[235]. Morphine is largely metabolized by glucuronidation at the 3- and 6-positions to
form morphine-3-glucuronide and morphine-6-glucuronide respectively, the latter of which has a
similar pharmacological activity to morphine (Figure 22).
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Figure 22: Biotransformation and conjugation of morphine.

Both free and conjugated forms of morphine have been shown to cross the placental barrier and
accumulate in the meconium of prenatally exposed newborns[92]. Recent studies also suggest
that morphine undergoes a minor metabolic transformation to hydromorphone in the cases of
high dose, steady state patients (Figure 22)[236, 237]. Hydromorphone is considered a secondary
metabolite of morphine that will not necessarily be detectable in the case of an acute overdose
but may be present in the urine of patients taking large doses over significant periods of time at
concentrations corresponding to 2-5% of the morphine. Hydromorphone has also been shown to
cross the placental barrier and accumulate in the meconium of infants prenatally exposed to the
drug or one of its metabolic precursors such as hydrocodone and morphine[92].
Hydrocodone (Vicodin, Lortab, Lorcet) is a popular, short acting, opiate analgesic
prescribed for the treatment of mild pain and often formulated with non-opiate analgesics such as
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acetaminophen or salicylates. Such formulations provide increased analgesia via drug synergy
and also to deter patients from overdosing by formulating the opiate with NSAIDS which have
unpleasant side effects when taken in high doses.
Wisniewski et al. investigated the relationship between the prescribing trends for
hydrocodone products and the aggregate indicators of non-medical abuse such drug induced and
drug-related emergency department (ED) visits, over an eight year time period[235]. Studies
indicated that the number of prescriptions written per 10,000 patients increased 2.03 fold over
the eight year period while the number of hydrocodone-related ED visits increased 1.60
fold[235]. The rate of hydrocodone use has consistently increased since 1999 and in 2005, more
prescriptions were written for hydrocodone/acetaminophen combination products than any other
medication including drugs such as amoxicillin and atorvastatin[238].
Hydrocodone is metabolized in man by O- and N-demethylation and reduction of the 6keto group[239]. Hydrocodone, like many drugs is metabolized by a large family of enzymes
know as the cytochrome P450 (or CYP450) enzymes. The 2D6 isozyme of the CYP450 family,
known as CYP2D6 is responsible for the O-demethylation of hydrocodone to hydromorphone,
which is also a potent opiate analgesic prescribed for the treatment of pain (Figure 23).
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Figure 23: Metabolism of hydrocodone to hydromorphone.

Rapid metabolizers have been shown to produce and excrete significantly more of a dose as
hydromorphone than poor metabolizers[239].
Hydromorphone (Dilaudid) is a strong opiate analgesic prescribed for the treatment of
chronic pain. Hydromorphone is also the active metabolite of hydrocodone which undergoes Odemethylation by CYP2D6 to form the active metabolite. Joranson and coworkers reported a
19% increase in the medical use of hydromorphone from 1900 to 1996 at which time 141,325
grams of the drug were being prescribed across the united states[234]. Hydromorphone is a
potent opiate which has been responsible for fatalities at concentrations as low as 51 ng/mL and
a particular review of hydromorphone related deaths in Ontario from 1985 to 2003 revealed that
deaths attributed to hydromorphone toxicity involved concentrations ranging from 77 to 2684
ng/mL[240]. Hydromorphone abuse is increasing in today’s society and its detection in
meconium is of additional importance as it will also assist in identifying maternal hydrocodone
use.
Prenatal exposure to opiates has been associated with the following symptoms in infants:
colic pains, agitation, irritability, high pitched cries, and long term withdrawal symptoms known
as prenatal opiate withdrawal[241, 242].
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Table 23 provides the chemical structures of morphine, codeine, hydromorphone, and 6monacetylmorphine along with certain physicochemical properties such as molecular weights,
and pKa’s.
Table 23: Chemical structures, molecular weights, molecular formulas, and pKa's of morphine,
codeine, hydromorphone, and 6-monoacetylmorphine.
Morphine
Codeine
Chemical structure

Chemical structure

Molecular weight

285.34 g/mol

Molecular weight

299.36 g/mol

Molecular formula

C17H19NO3

Molecular formula

C18H21NO3

pKa

7.87

pKa

8.28

Hydromorphone

6-MAM

Chemical structure

Chemical structure

Molecular weight

285.34 g/mol

Molecular weight

327.37 g/mol

Molecular formula

C17H19NO3

Molecular formula

C19H21NO4

pKa

8.08

pKa

146

8.19

6.4

History of Opiate Detection in Meconium
The detection of opiates in meconium has been the focus of far fewer research efforts

than that of cocaine. The detection of opiates in meconium is becoming increasingly important as
prescription opiates such as morphine, codeine, and hydrocodone are being abused as a result of
their widespread availability on the street and cheap cost. Analytical methodologies capable of
detecting opiates in meconium have been largely based on GC/MS technologies due to the
selectivity afforded by MS.
Moriya and co-workers successfully detected the presence of morphine in the stool of a
41 day old infant at a concentration of 1340 ng/g following derivatization with trifluoroacetic
anhydride and GC/MS analysis[85]. In an effort to increase the selectivity and sensitivity of
meconium analysis which had been largely performed using radioimmunoassays, ElSohly et al
employed GC/MS for the determination of several drug classes, including opiates, in
meconium[243]. Pichini and co-workers employed an ESI-LC/MS assay operating in SIM mode
for the simultaneous determination of opiates and cocaine in meconium. Analytes were extracted
using an initial liquid extraction into methanol or ammonium hydrogen carbonate buffer
followed by a solid phase extraction for subsequent sample clean-up. Method validation included
a linear dynamic range of 0.005 – 1.00µg/g[217].
Coles and co-workers reported the first tandem mass spectrometry method for the
determination of codeine, morphine, hydrocodone, hydromorphone, oxycodone, and 6acetylmorphine in meconium following liquid chromatographic separation. A decreased sample
preparation time was achieved by eliminating the glucuronide hydrolysis step and employing a
solid phase extraction in which the elution occurred directly into autosampler vials. LC-MS/MS
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provided enhanced selectivity for the detection of the six opiates with a decreased interference
rate of 3.9% compared to 13.6% for a previously established GC/MS method[92].
To the best of the author’s knowledge, this is first report of the simultaneous detection of
codeine, morphine, hydromorphone and 6-monoacetylmorphine in meconium using UPLCMS/MS. The implementation of UPLC methodologies into routine meconium analysis will
increase the speed and efficiency of chromatographic separations allowing for more rapid
separation of various opiate derivatives without the need for complex mobile phases. Combining
the chromatographic advantages of UPLC with the increased selectivity of tandem mass
spectrometry will result in more rapid, accurate, and sensitive identifications of various opiate
derivatives in human meconium.
6.5

Experimental

6.5.1

Chemicals and reagents
Codeine, morphine, hydromorphone, 6-monoacetylmorhine, codeine-d3, morphine-d3,

hydromorphone-d3, and 6-monoacetylmorphine-d6 standards (1mg/mL in methanol) were
obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N supported liquid-liquid
extraction columns were purchased from Biotage (Charlottesville, VA). All solvents were HPLC
grade and obtained from Fisher Scientific (Pittsburgh PA).
6.5.2

Calibration Curve Matrix
Meconium specimens which had previously screened negative for opiates using a 50 ng/g

cutoff at AIT laboratories (Indianapolis, IN) were collected and spiked with codeine, morphine,
hydromorphone, and 6-monoacetylmorphine to give concentrations of 10 ng/mL (n=5) and 500
ng/mL (n=5). Spiked meconium was then quantified using a calibration curve constructed in
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negative meconium and a calibration curve constructed in certified drug free whole blood.
Quantitative results obtained using the meconium calibration curve showed excellent correlation
(<15% CV) with those obtained using the calibration curve made up in negative blood and as a
result, all subsequent method validation experiments were performed using calibration curves
prepared in certified negative blood.
6.5.3

Working Standards
Calibration curves were constructed using eight calibration standards prepared in certified

drug free whole blood and all sample volumes were 1 mL. Two working standards were used to
construct the calibration standards, working standard 1 (500 ng/mL) was prepared by combining
150µL of an amphetamine and methamphetamine stock solution (10µg/mL) with 2850µL of
negative blood. Working standard 2 (50 ng/mL) was prepared by combining 300µL of working
standard 1 with 2700µL of negative blood. An internal standard solution (500 ng/mL) was
prepared using 1 mg/mL standards of codeine-d3, morphine-d3, hydromorphone-d3, and 6monoacetylmorphine-d6.
6.5.4

Calibration Curves
Calibration curves for all experiments were prepared according to Table 24.

Table 24: Preparation of codeine, morphine, hydromorphone, and 6-monacetylmorphine
calibration curves.
Standard Concentration (ng/mL)
500
250
100
50
25
10
5
Negative

Volume of Working Standard (µL)
1000 (Std 1)
500 (Std 1)
200 (Std 1)
1000 (Std 2)
500 (Std 2)
200 (Std 2)
100 (Std 2)
0
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Volume of Negative Blood (µL)
0
500
800
0
500
800
900
1000

100µL of internal standard solution (500 ng/mL) was added to each sample including the blank
and all samples were then vortexed for 30 seconds.
6.5.5

Quality Control (QC) Standards
Quality control standards (QC’s) were prepared and analyzed with every batch to ensure

the accurate identification and quantitation of validation specimens. A low QC (LQC) was
prepared at a concentration of 10 ng/mL and a high QC (HQC) at a concentration of 500 ng/mL.
Quality control standards were injected immediately following the final point of the calibration
curve and quantitation of each QC was required to be accurate within 20% of the expected
nominal value to proceed with the analysis of validation specimens.
6.5.6

Sample Preparation
Meconium samples were accurately weighed and then diluted by a factor of 3 (w/v) with

50:50 methanol/water to assist with the sonication procedure. Samples were shaken and
sonicated for 10-15 minutes. Following sonication, 1 mL of the meconium samples was added to
appropriately labeled culture tubes. Codeine, morphine, hydromorphone, and 6monoacetylmorphine standards and deuterated internal standards were added to samples which
were then block vortexed for 5 minutes. Samples were centrifuged for 5 minutes at 3500 rpm
after which the supernatants were transferred to appropriately labeled culture tubes (12x75).
Samples were then diluted with 2mL of deionized water and vortexed for 10-15 seconds.
Samples were loaded into 5mL ISOLUTE HM-N supported liquid extraction columns and left to
sit for 10 minutes. Analytes were initially eluted with 5 mL of ethyl acetate and after a 3 minute
waiting period a second elution step was performed with 3 mL of ethyl acetate. Samples were
dried down under a gentle stream of nitrogen and reconstituted in 200 µL of DI water. Samples
were transferred to UPLC vials and injected.
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6.5.7 Liquid Chromatography
Liquid chromatographic separations were performed on a Waters ACQUITYTM ultra
performance liquid chromatograph (UPLC™) (Waters Corp., Milford, MA, USA). Separations
were achieved on an ACQUITY UPLC™ HSS T3 column (2.1x 50mm) packed with 1.8µm
bridged ethyl hybrid (BEH) particles and maintained at 35°C. The mobile phase consisted of
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1%
formic acid (solvent B). Analyte elution was achieved using the following step-wise binary
elution gradient: Initial mobile phase composition was 97:3 (H2O:ACN). The composition of
solvent B was increased to 20% over the first 2.50 mins and then rapidly increased to 99% over
the next 0.05 mins where it was held constant for 0.45 mins, finally conditions were returned to
their initial composition of 97:3 (H2O:ACN) over the final 0.01 mins of the chromatographic
run. The total run time was 3.01 minutes (Figure 24). Samples were maintained at 7.5°C in the
sample organizer and sample injection volumes were 5µL for all analyses. Flow rates remained
constant at 0.6 mL/min and all flow was directed into the ESI source of the mass spectrometer.
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Figure 24: TIC from the UPLC separation of morphine, hydromorphone, codeine, and 6monoacetylmorphine (6-MAM).
6.5.8

Mass Spectrometry
Mass spectral conditions were as follows: capillary voltage 0.40 kV, cone voltage 48 V,

extractor voltage 3.1 V, RF lens voltage 0.1 V. The source temperature was 150°C while the
desolvation temperature was set at 450°C. Cone gas was set at a flow of 50 L/Hr while the
desolvation gas flow was 900 L/Hr. The collision gas flow was set to 0.18 mL/min. Nitrogen
(99.995% purity) was used as the desolvation gas, and ultra-pure argon (99.999% purity) was
used as the collision gas. Table 25 reports the mass transitions, dwell times, cone voltages, and
collision energies for each of the analytes and their deuterated internal standards.
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Table 25: MS/MS parameters used for each analyte and their deuterated internal standards.
Compound
Codeine
Codeine
Codeine-d3
Morphine
Morphine
Morphine-d3
Hydromorphone
Hydromorphone
Hydromorphone-d3
6-monoacetlymorphine
6-monoacetlymorphine
6-monoacetlymorphine-d6

Mass
300.01 > 164.90
300.01 > 215.00
303.03 > 215.00
285.97 > 164.90
285.97 > 152.50
288.89 > 200.90
285.98 > 184.90
285.98 > 156.80
288.97 > 184.90
328.01 > 164.90
328.01 > 210.90
334.10 > 164.90

Purpose
Quantifying ion
Qualifying ion
Quantifying ion
Quantifying ion
Qualifying ion
Quantifying ion
Quantifying ion
Qualifying ion
Quantifying ion
Quantifying ion
Qualifying ion
Quantifying ion
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Cone (V)
45
45
50
50
50
50
55
55
50
55
55
55

Collision (V)
40
22
26
36
46
26
28
40
30
36
26
36

Dwell (secs)
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02

Figure 25 illustrates the fragmentation pathways for codeine, morphine, hydromorphone, and 6monoacetylmorphine under ESI conditions and the resulting product ions used for analyte
detection.

Morphine
m/z 286

Codeine
m/z 300

Hydromorphone
m/z 286

[C13H9]+
m/z 165

[C13H9]+
m/z 165

[C12H9O2]+
m/z 185

6-mam
m/z 328

[C13H9]+
m/z 165

Figure 25: Fragmentation pathways for morphine, codeine, hydromorphone, and 6monoacetylmorphine during tandem mass spectrometry experiments[244].
6.6

Results and Discussion

6.6.1

Method Validation
Initial equivalence studies indicated that calibration curves prepared in certified drug-free

blood were appropriate for the quantitation of codeine, morphine, hydromorphone, and 6monoacetylmorphine quality control standards prepared in negative meconium. Accurate
quantification of QCs and a high degree of correlation between the calibration curves prepared in
blood and those prepared in meconium indicate that curves prepared in drug-free blood will
enable accurate quantitations of analytes in authentic meconium specimens (Table 26-29).
Relative errors were calculated for all QC standards following quantitation with curves
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constructed in blood and those constructed in meconium. Relative errors did not exceed 9% for
LQC (10 ng/mL) standards while the relative error associated with quantitating HQC (500
ng/mL) standards did not exceed 2.5% indicating a high degree of correlation for all four
analytes. Calibration curves constructed in certified drug-free blood were employed for the
remainder of validation experiments.
Table 26: Codeine equivalence studies using quantitative values obtained from calibration curves
constructed in meconium (MC) and blood (BC).
Codeine Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
10.6
506.8
0.1
0.1

*MC (ng/mL)
9.8
507.2
0
0

%RE
8.2%
0.1%
N/A
N/A

*Reported concentrations are mean values of 5 replicate analyses.
Table 27: Morphine equivalence studies using quantitative values obtained from calibration
curves constructed in meconium (MC) and blood (BC).
Morphine Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
9.0
504.7
0
0

*MC (ng/mL)
9.2
517.2
0
0

%RE
2.2%
2.4%
N/A
N/A

*Reported concentrations are mean values of 5 replicate analyses.
Table 28: Hydromorphone equivalence studies using quantitative values obtained from
calibration curves constructed in meconium (MC) and blood (BC).
Hydromorphone Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
9.5
492.9
0
0

*MC (ng/mL)
9.3
490.1
0
0

*Reported concentrations are mean values of 5 replicate analyses.
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%RE
2.2%
0.6%
N/A
N/A

Table 29: 6-monoacetylmorphine (6-MAM) equivalence studies using quantitative values
obtained from calibration curves constructed in meconium (MC) and blood (BC).
6-monoacetylmorphine Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
9.8
491.0
0
0

*MC (ng/mL)
9.1
482.4
0
0

%RE
7.7%
1.8%
N/A
N/A

*Reported concentrations are mean values of 5 replicate analyses.
The analytical methodology was deemed selective following the analysis of blank
meconium specimens from five different sources and the accurate quantitation of five standards
prepared at the LLOQ which had been spiked with various xenobiotics commonly encountered
in forensic toxicology (Table 30).
Table 30: Exogenous compounds included in selectivity quality control standards.
Standard
Selectivity QC 2
Selectivity QC 3

Contents
Amitriptyline, bupropion, clomipramine, desipramine, doxepin, fluoxetine, imipramine,
norclomipramine, nordoxepin, norfluoxetine, norsertraline, nortriptyline, norvenlafaxine,
paroxetine, sertraline, venlafaxine
Alprazolam, chlorpheniramine, citalopram, clonazepam, cyclobenzaprine, dextromethorphan,
duloxetine, fentanyl, flunitrazepam, haloperidol, mirtazapine, olanzapine, strychnine, zolpidem

Selectivity QC 4

Chlordiazepoxide, chlorpromazine, clozapine, diazepam, lorazepam, midazolam, norclozapine,
nordiazepam, oxazepam, PMA, quetiapine, temazepam

Selectivity QC 5

Amphetamine, benzoylecgonine, cocaethylene, cocaine, EDDP, ephedrine, MDMA,
methadone, methamphetamine, norpropoxyphene, nortramadol, PCP, propoxyphene, tramadol

Selectivity QC 6

Alfentanil, diphenhydramine, doxylamine, meperidine, normeperidine,
promethazine, propranolol, trazodone, trimipramine, verapamil

orphenadrine,

Blank meconium matrices failed to generate a response for any of the four analytes investigated
indicating that the method is sufficiently selective to eliminate the possibility of matrix
interferences generating false positives (Table 31-34). Accurate quantitation of QC standards
prepared at the LLOQ which had been spiked with various exogenous interferences commonly
encountered in forensic specimens indicated that the methodology is selective for the analytes of
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interest (Table 31-34). Quantitation accuracies ranged from 94% to 100% for codeine, 91% to
96% for morphine, 94% to 97% for hydromorphone, and 92% to 99% for 6monoacetylmorphine. Quantitation accuracy at the LLOQ indicates a high degree of selectivity
in the presence of exogenous interferences.
Table 31: Codeine selectivity studies using blank meconium from five different sources and
blank meconium specimens spiked with various exogenous interferences.
Codeine Std

Std Conc

Blank samples
Spiked samples

0
10

*Measured
Conc
0
10.0

Acceptable range

Pass/Fail

<10ng/mL
10+/- 20%

Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
Table 32: Morphine selectivity studies using blank meconium from five different sources and
blank meconium specimens spiked with various exogenous interferences.
Morphine Std

Std Conc

Blank samples
Spiked samples

0
10

*Measured
Conc
0
9.3

Acceptable range

Pass/Fail

<10ng/mL
10+/- 20%

Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
Table 33: Hydromorphone selectivity studies using blank meconium from five different sources
and blank meconium specimens spiked with various exogenous interferences.
Hydromorphone Std

Std Conc

Blank samples
Spiked samples

0
10

*Measured
Conc
0
9.6

Acceptable range

Pass/Fail

<10ng/mL
10+/- 20%

Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
Table 34: 6-monoacetylmorphine selectivity studies using blank meconium from five different
sources and blank meconium specimens spiked with various exogenous interferences.
6-monoacetylmorphine Std
Blank samples
Spiked samples

Std Conc
0
10

Measured Conc
0
10.1

Acceptable range
<10ng/mL
10+/- 20%

Pass/Fail
Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
Accuracy of the methodology was investigated by analyzing five replicates over three
concentrations spanning the calibration range. Accuracy was investigated at concentrations of
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500, 50, and 10 ng/mL for all analytes. Mean values of 487.1 ng/mL, 50.2 ng/mL, and 9.7 ng/mL
reflecting accuracies of 97.4%, 99.6%, and 97% were obtained for codeine (Table 35), while
analysis of morphine standards yielded mean values of 478.6 ng/mL, 46.5 ng/mL, and 9.9 ng/mL
corresponding to accuracies of 95.7%, 93%, and 99% (Table 36). High accuracies were also
observed through the analysis of hydromorphone standards which produced mean values of
493.9 ng/mL, 49.8 ng/mL, and 9.8 ng/mL corresponding to accuracies of 98.8%, 99.6%, and
98% (Table 37). Analysis of 6-monoacetlymorphine QC standards prepared at concentrations of
500, 50, and 10 ng/mL yielded mean values of 515.7 ng/mL, 52.0 ng/mL, and 9.8 ng/mL
corresponding to accuracies of 96.9%, 96%, and 98% (Table 38). Quantitation accuracy over the
calibration range was greater than 93% for all four analytes.
Table 35: Codeine accuracy over three concentrations spanning the calibration range.
Codeine Std
High point
Midpoint
LLOQ

Std Conc
500
50
10

*Measured value
487.1
50.2

9.7
*Reported concentrations are mean values of 5 replicate analyses.

%RE
2.6%
0.4%
3.0%

Table 36: Morphine accuracy over three concentrations spanning the calibration range.
Morphine Std
High point
Midpoint
LLOQ

Std Conc
500
50
10

*Measured value
478.6
46.5
9.9

%RE
4.3%
7.0%
1.0%

*Reported concentrations are mean values of 5 replicate analyses.
Table 37: Hydromorphone accuracy over three concentrations spanning the calibration range.
Hydromorphone Std
High point
Midpoint
LLOQ

Std Conc
500
50
10

*Measured value
493.9
49.8
9.8

*Reported concentrations are mean values of 5 replicate analyses.
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%RE
1.2%
0.4%
2.0%

Table 38: 6-monoacetylmorphine accuracy over three concentrations spanning the calibration
range.
6-monoacetylmorphine Std
High point
Midpoint
LLOQ

Std Conc
500
50
10

*Measured value
515.7
52.0
9.8

%RE
3.1%
4.0%
2.0%

*Reported concentrations are mean values of 5 replicate analyses.
Intra- and inter-batch precision was investigated during method validation. Five
replicates prepared at three different concentrations spanning the calibration range were analyzed
and mean values were calculated for each concentration to determine the precision associated
with the methodology. Quality control standards were prepared in negative meconium at
concentrations of 10, 50, and 500 ng/mL for each analyte. Both intra- and inter-batch precision
studies indicated a high degree of method precision over the investigated concentration range
with intra-batch CVs ranging from 1.4-9.5% with a mean value of 2.9% for codeine (Table 39),
while intra-batch morphine studies produced CVs ranging from 1.2-10.7% with a mean value of
3.1% (Table 40). Analysis of hydromorphone QCs produced intra-batch CVs ranging from 1.47.6% with a mean value of 3.3% (Table 41), while 6-monoacetylmorphine standards yielded
CVs ranging from 1.3-10% with a mean value of 3.3% (Table 42). Method precision was high
over the entire calibration range including the LLOQ where individual CVs did not exceed
10.7% (Tables 39-42). Inter-batch precision calculations were performed to assess method
precision over a four day period. CVs were calculated based on four-day mean values for QCs at
concentrations of 500, 50, and 5 ng/mL and produced values of 3.3%, 4.5, and 4.7% respectively
for codeine, 3.1%, 4.0%, and 4.7% for morphine, 3.1%, 2.3%, and 6.1% for hydromorphone, and
1.4%, 0.5%, and 5.2% for 6-monoacetlymorphine (Tables 39-42).
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Table 39: Intra- and inter-batch precision for codeine.
Codeine Std

*Day 1 value

*Day 2 value

*Day 3 value

*Day 4 value

4 day mean

4 day CV

Highpoint
CV
Midpoint
CV
LLOQ
CV

487.1
1.4%
50.2
1.6%
9.7
4.9%

505.8
1.9%
53.3
2.6%
10.5
2.3%

507.6
1.7%
50.0
1.5%
9.6
2.6%

527.8
1.8%
54.7
2.9%
10.5
9.5%

507.1

3.3%

52.0

4.5%

10.1

4.7%

4 day mean
484.7

4 day CV
3.1%

46.6

4.0%

9.3

4.7%

*Reported concentrations are mean values of 5 replicate analyses.
Table 40: Intra- and inter-batch precision for morphine.
Morphine Std
Highpoint
CV
Midpoint
CV
LLOQ
CV

*Day 1 value
478.6
1.4%
46.5
2.7%
9.9
1.2%

*Day 2 value
499.9
1.8%
45.5
2.6%
9.2
2.6%

*Day 3 value
466.3
1.5%
45.0
3.0%
9.1
1.6%

*Day 4 value
494.0
2.7%
49.2
5.5%
8.9
10.7%

*Reported concentrations are mean values of 5 replicate analyses.
Table 41: Intra- and inter-batch precision for hydromorphone.
Hydromorphone
Std

Highpoint
CV
Midpoint
CV
LLOQ
CV

*Day 1 value

*Day 2 value

*Day 3 value

*Day 4 value

4 day mean

4 day CV

493.9
2.5%
49.8
2.0%
9.8
2.6%

499.3
2.7%
48.6
1.4%
8.9
3.8%

508.2
4.4%
47.7
3.4%
9.2
3.4%

529.2
2.7%
50.2
2.7%
10.2
7.6%

507.7

3.1%

49.1

2.3%

9.5

6.1%

*Reported concentrations are mean values of 5 replicate analyses.
Table 42: Intra- and inter-batch precision for 6-monoacetylmorphine (6-MAM).
6-MAM Std

*Day 1 value

*Day 2 value

*Day 3 value

*Day 4 value

4 day mean

4 day CV

Highpoint
CV
Midpoint
CV
LLOQ
CV

515.7
1.3%
52.0
2.2%
9.8
1.9%

525.9
3.0%
52.3
3.0%
10.6
2.4%

528.0
2.2%
52.2
4.1%
10.5
2.6%

534.0
2.9%
52.6
3.6%
9.6
10.0%

525.9

1.4%

52.3

0.5%

10.1

5.2%

*Reported concentrations are mean values of 5 replicate analyses.
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Analyte recovery was investigated over three concentrations by comparing the detector
response of analyte at three different concentrations which had been added to, and extracted
from, the meconium matrix. Analyte recovery was investigated by comparing peak areas of
extracted samples at concentrations of 10, 50, and 500 ng/mL with unextracted samples which
represented 100% recovery. Mean analyte recoveries over the three concentrations investigated
were 64.3%, 52.3%, 55.9%, and 76.3% for codeine, morphine, hydromorphone, and 6monacetylmorphine respectively. Mean recoveries from triplicate analysis at the three
concentrations investigated ranged from 61-69% for codeine (Figure 26), 47-61% for morphine
(Figure 27), 48-64% for hydromorphone (Figure 28), and 68-84% for 6-monoacetylmorphine
(Figure 29).

Codeine Recovery
100
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50
40
30
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0
High point (500 ng/mL)

Mid point (50 ng/mL)

Figure 26: Codeine extraction recovery.
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Morphine Recovery
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Figure 27: Morphine extraction recovery.

Hydromorphone Recovery
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Figure 28: Hydromorphone extraction recovery.
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6-monoacetylmorphine Recovery
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Low point (10 ng/mL)

Figure 29: 6-MAM extraction recovery.

The limit of detection was 2.5 ng/mL for all four analytes corresponding to a concentration of 10
ng/g in the original meconium specimen. Limits of detection were calculated based on
acceptance criteria for retention times and ion ratios. At concentrations below 2.5 ng/mL
unequivocal identification was not possible due to inaccurate ion ratios. Stability studies
indicated that all four analytes were stable in the meconium matrix when stored long-term at
4°C. High and low QC standards corresponding to the calibration range were subject to a 72 hour
freeze-thaw cycle and analyzed following thawing on the third day. Quantitation accuracies
during stability studies were greater than 97%, and 94% for codeine LQCs and HQCs
respectively, greater than 98%, and 92% for morphine low and high QCs, greater than 98%, and
99% for hydromorphone low and high QCs and greater than 96%, and 99% for 6monoacetylmorphine low and high QCs respectively. Accurate quantitations during stability
studies indicate that storage temperature and conditions are suitable for authentic meconium
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specimens and any accurate quantitation of the four analytes following thawing should be
feasible.
6.7

Conclusions
Development, optimization and validation of a UPLC-ESI-MS/MS method allowed for

the accurate, selective, precise, and sensitive determination of morphine, codeine,
hydromorphone, and 6-monoacetylmorphine following supported liquid extraction from
meconium specimens. Extraction of all four analytes from the meconium matrix using ISOLUTE
HM-N supported liquid extraction columns significantly reduced sample preparation time while
the rapid separations afforded by UPLC significantly reduced analysis time, allowing for
increased sample throughput. The increased separation efficiency afforded by UPLC, combined
with the inherent selectivity and sensitivity of tandem mass spectrometric detection is well suited
to low level, multi-analyte determination in complex biological matrices such as meconium.
Rapid UPLC separations combined with certain automated features of the Waters TQD
instrument, significantly reduces method development and validation time, making the
instrumental combination well suited to high throughput toxicology laboratories. Two MRM
transitions were monitored for each analyte and quantifications were made using deuterated
internal standards and seven point calibration curves. Detection limits for all four analytes was
2.5 ng/mL in the homogenized extract, and injection volumes of 5 µL allowed for the linear
quantification of analytes up to 500 ng/mL. To the author’s knowledge, this is the first validated
UPLC-MS/MS methodology for the quantification of morphine, codeine, hydromorphone, and 6monoacetylmorphine in meconium specimens.
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Chapter 7: Simultaneous Quantification of Amphetamine and
Methamphetamine in Meconium Using ISOLUTE® HM-N Supported Liquid
Extraction Columns and UPLC-MS/MS
7.1

Abstract
A procedure for the rapid extraction and quantification of amphetamine and

methamphetamine from meconium using ISOLUTE HM-N supported liquid extraction columns
and ultra performance liquid chromatography coupled with tandem mass spectrometry (UPLCMS/MS) is described. Due to the matrix complexity of meconium samples, extraction and
sample preparation prior to instrumental analysis can prove difficult and time consuming. The
present study introduces a novel sample preparation technique for the simultaneous
quantification of amphetamine and methamphetamine in meconium using UPLC-MS/MS.
Ultra performance liquid chromatography (UPLC) is an emerging analytical technique
which draws upon the principles of chromatography to run separations at higher flow rates for
increased speed, while simultaneously achieving superior resolution and sensitivity.
Extraction of both analytes was achieved using ISOLUTE HM-N supported liquid
extraction columns containing a modified form of diatomaceous earth. Subsequent separation
and quantification using ultra UPLC-MS/MS was achieved in less than 3 minutes. Limits of
detection for amphetamine and methamphetamine were 4 ng/g and 1000 pg/g respectively. The
lower limit of quantitation (LLOQ) was 20 ng/g. The methodology exhibited high intra run
precision with CV values ranging from 1-9% for amphetamine and 1-6% for methamphetamine.
Inter run precision experiments produced CV values ranging from 3-7% for amphetamine and 16% for methamphetamine.
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The reported methodology proved suitable for the accurate quantification of
amphetamine and methamphetamine in meconium samples and greatly reduced sample
preparation time normally required for traditional solid phase extraction. Development and
validation of such analytical methodologies will prove beneficial for the identification of prenatal
substance abuse which.
7.2

Introduction
Due to the increasing abuse and synthesis of amphetamine like stimulants, there is a

desire among analytical chemists for sensitive methodologies capable of detecting low levels of
these drugs in meconium. Such methodologies would aid in further understanding the effects of
fetal exposure on newborns. Clefting, cardiac anomalies, and fetal growth reduction deficits have
all been seen in infants exposed to amphetamines during pregnancy [245]. Animal studies
involving prenatal exposure to amphetamines have allowed for the same observations and
methamphetamine has been shown to cross the placenta within thirty seconds of intraperitoneal
injection [246]. Methamphetamine is the most widely abused amphetamine and animal studies
observed increased maternal and offspring mortality, retinal eye defects, cleft palate, rib
malformations, decreased rate of physical growth, and delayed motor development associated
with prenatal methamphetamine exposure [247-250]. Although peak concentrations are lower on
the fetal side, slower elimination of the amphetamines means that the fetus is subject to
prolonged exposure which can significantly impact neonatal health and development [246].
In the first large scale investigation into the prevalence of methamphetamine use during
pregnancy in areas of the United States where methamphetamine is a notable concern, it was
found that 5.2 % of the 1632 subject mothers used methamphetamine at some point during their
pregnancy [251]. The authors concluded that the methamphetamine exposed group was 3.5 times
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more likely to be small for gestational age than the unexposed group [252]. Prenatal exposure to
amphetamines has also been associated with behavioral problems, cranial abnormalities,
increased incidence of premature delivery, placental abruption, increased rates of fetal distress,
biliary atresia, and decreased growth parameters (weight, head circumference, length)[253, 254].
Table 43 provides the chemical structures of methamphetamine and amphetamine along with
certain physicochemical properties such as molecular weights, and pka’s.
Table 43: Chemical structures, molecular weights, molecular formulas and pKa's of
amphetamine and methamphetamine.
Amphetamine
Methamphetamine
Chemical structure

Chemical structure

Molecular weight

135.21 g/mol

Molecular weight

149.23 g/mol

Molecular formula

C9H13N

Molecular formula

C10H15N

pKa

7.3

9.80

pKa

10.1

Mechanism of Action
The amphetamines are similar to cocaine in their ability to modify the actions and levels

of catecholamines. Amphetamines acts to stimulate the sympathomimetic nervous system both
centrally and peripherally. This again is achieved through increasing levels of dopamine and
norepinephrine, however, the mechanism by which the amphetamines achieve this differs
slightly from other stimulants such as cocaine. Amphetamines are chemically similar to
dopamine and norepinephrine allowing them to enter the presynaptic terminal assisted by protein
molecules that would normally transport dopamine and norepinephrine back into the nerve
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terminal from the synaptic cleft. Once in the presynaptic terminal, amphetamines acts to release
dopamine and norepinephrine from vesicles resulting in increased levels of free catecholamines
in the nerve ending. Amphetamines also inhibit monoamine oxidase (MAO), an enzyme
responsible for the deactivation of free catecholamines in the presynaptic terminal. As a result,
excess levels of dopamine and norepinephrine are transported out of the presynaptic terminal and
into the synapse where they produce feelings of pleasure and euphoria.
7.4

Effect of Prenatal Exposure
Clefting, cardiac anomalies, fetal growth reduction deficits have all been seen in infants

exposed to amphetamines during pregnancy, increased maternal and offspring mortality, retinal
eye defects, cleft palate, rib malformations, decreased rate of physical growth, and delayed motor
development have all been associated with prenatal exposure to amphetamines. Although peak
concentrations are lower on the fetal side, slower elimination of the amphetamines means that
the fetus is subject to prolonged exposure which can significantly impact neonatal health and
development [245-250].
7.5

History of Amphetamine Analysis in Meconium (Literature Review)
Meconium has become the specimen of choice for the detection of prenatal exposure to

several drugs of abuse [255, 256]. There are several reasons for this, including the relatively
simple and non-invasive procedure used to collect meconium samples, making it more successful
than urine collection [70]. Meconium analysis also extends the window of drug detection to
approximately the last 20 weeks of gestation as well as extending the window for specimen
collection, as it is not fully evacuated until 125 hours post-natally [213, 257, 258].
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Due to the complexity of the meconium matrix, analysis can prove difficult as sample
preparation may require additional laborious steps to efficiently extract the desired analytes from
the non-homogenous sample [259]. Ostrea et al. [260] employed a two stage extraction
procedure for the detection of illicit drugs and other xenobiotics in newborn infants. Such
procedures involve an initial liquid extraction from the meconium after which the organic layer
is evaporated and reconstituted in phosphate buffer in preparation for solid-phase extraction.
Conventional SPE columns require multi-step conditioning and subsequent aspiration before the
sample can be introduced onto the column. Most SPE extraction procedures involve 2-3
sequential washes before analytes are eluted with a suitable solvent made fresh daily. The
combination of a two stage extraction involving a multi wash SPE procedure with the need to
prepare elution solvents daily can prove very laborious in high throughput laboratories.
ElSohly et al [243] achieved limits of detection of 50 ng/g for amphetamine and
methamphetamine employing a multi-step liquid extraction procedure and GC/MS. Additional
sample cleanup was achieved by incorporating a back extraction for the purpose of eliminating
neutral molecules present in the matrix. Researchers at the National Institute on Drug Abuse
(NIDA) recently developed the first reported tandem mass spectrometry method for the detection
of 10 amphetamine-, methamphetamine- and 3,4-methylenedioxymethamphetamine-related
(MDMA) analytes in human meconium. Specimens were homogenized and subject to solid
phase extraction prior to chromatographic separation and mass spectrometric detection. The
authors employed a triple quadrupole mass spectrometer equipped with an APCI source.
Selective determination of the 10 analytes was achieved by monitoring two specific MRM
transitions. The enhanced sensitivity of LC-MS/MS analysis relative to more traditional GC/MS
analysis allowed for lower limits of quantitation in the range of 1.25 to 40 ng/ng while upper
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limits of quantitation were set at 10,000 ng/g. Successful detection of phydroxymethamphetamine, norephedrine and 4-hydroxy-3-methoxymethamphetamine in the
meconium of a methamphetamine-exposed neonate was reported for the first time[93]. While
such methodologies have allowed for the selective determination of amphetamines in meconium,
sample preparation remains a time costly and limiting factor in the analysis of meconium.
Laborious solid phase extractions following homogenization and initial liquid-liquid extractions
can prove very time inefficient and greatly affect the turnaround time of high throughput
toxicology laboratories.
The aim of the present study was to develop a time and cost effective methodology for
the preparation of meconium samples which would allow for the rapid and simultaneous
quantification of amphetamine and methamphetamine in meconium. In this report, we describe
the first application of supported liquid extraction columns for the preparation of meconium
specimens prior to analysis and quantification by UPLC-MS/MS. ISOLUTE HM-N supported
liquid extraction columns require no column conditioning and once the sample is introduced onto
the column, elution is achieved with two washes of ethyl acetate. This is the first report of the
use of UPLC-MS/MS for the determination of amphetamine and methamphetamine in
meconium.
7.6

Experimental

7.6.1

Chemicals and reagents
Amphetamine, methamphetamine, amphetamine-d6, and methamphetamine-d9 standards

(1mg/mL in methanol) were obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N
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supported liquid-liquid extraction columns were purchased from Biotage (Charlottesville, VA).
All solvents were HPLC grade and obtained from Fisher Scientific (Pittsburgh PA).
7.6.2

Calibration Curve Matrix
Meconium specimens which had previously screened negative for amphetamines using a

50 ng/g cutoff at AIT laboratories (Indianapolis, IN) were collected and spiked with both
amphetamine and methamphetamine to give concentrations of 10 ng/mL (n=5) and 500 ng/mL
(n=5). Spiked meconium was then quantified using a calibration curve constructed in negative
meconium and a calibration curve constructed in certified drug free whole blood. Quantitative
results obtained using the meconium calibration curve showed excellent correlation (<15% CV)
with those obtained using the calibration curve made up in negative blood and as a result, all
subsequent method validation experiments were performed using calibration curves prepared in
certified negative blood.
7.6.3

Working Standards
Calibration curves were constructed using eight calibration standards prepared in certified

drug free whole blood and all sample volumes were 1 mL. Two working standards were used to
construct the calibration standards, working standard 1 (500 ng/mL) was prepared by combining
150µL of an amphetamine and methamphetamine stock solution (10µg/mL) with 2850µL of
negative blood. Working standard 2 (50 ng/mL) was prepared by combining 300µL of working
standard 1 with 2700µL of negative blood. An internal standard solution (500 ng/mL) was
prepared using 1 mg/mL standards of amphetamine-d6 and methamphetamine-d9.
7.6.4

Calibration Curves
Calibration curves for all experiments were prepared according to Table 44.
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Table 44: Preparation of amphetamine and methamphetamine calibration curves.
Standard Concentration (ng/mL)
500
250
100
50
25
10
5
Negative

Volume of Working Standard (µL)
1000 (Std 1)
500 (Std 1)
200 (Std 1)
1000 (Std 2)
500 (Std 2)
200 (Std 2)
100 (Std 2)
0

Volume of Negative Blood (µL)
0
500
800
0
500
800
900
1000

100µL of internal standard solution (500 ng/mL) was added to each sample including the blank
and all samples were then vortexed for 30 seconds.
7.6.5

Quality Control (QC) Standards
Quality control standards (QC’s) were prepared and analyzed with every batch to ensure

the accurate identification and quantitation of validation specimens. A low QC (LQC) was
prepared at a concentration of 5.0 ng/mL and a high QC (HQC) at a concentration of 500 ng/mL.
Quality control standards were injected immediately following the final point of the calibration
curve and quantitation of each QC was required to be accurate within 20% of the expected
nominal value to proceed with the analysis of validation specimens.
7.6.6

Sample Preparation
Meconium samples were accurately weighed and then diluted by a factor of 3 (w/v) with

50:50 methanol/water to assist with the sonication procedure. Samples were shaken and
sonicated for 10-15 minutes. Following sonication, 1 mL of the meconium samples was added to
appropriately labeled culture tubes. Amphetamine and methamphetamine standards and
deuterated internal standards were added to samples which were then block vortexed for 5
minutes. Samples were centrifuged for 5 minutes at 3500 rpm after which the supernatants were
transferred to appropriately labeled culture tubes (12x75). Sample recovery was optimized by
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adding 500 µL of 2.0M NaOH to ensure that the analyte was present in its basic state. Samples
were then diluted with 2mL of deionized water and vortexed for 10-15 seconds. Samples were
loaded into 5mL ISOLUTE HM-N supported liquid extraction columns and left to sit for 10
minutes. Analytes were initially eluted with 5 mL of ethyl acetate and after a 3 minute waiting
period a second elution step was performed with 3 mL of ethyl acetate. 200 µL of 1% HCl was
added to all eluates to ensure formation of the hydrochloride salts to reduce the possibility of
analyte loss during evaporation steps. Samples were dried down under a gentle stream of
nitrogen and reconstituted in 200 µL of DI water. Samples were transferred to UPLC vials and
injected.
7.6.7 Liquid Chromatography
Liquid chromatographic separations were performed on a Waters ACQUITYTM ultra
performance liquid chromatograph (UPLC™) (Waters Corp., Milford, MA, USA). Separations
were achieved on an ACQUITY UPLC™ phenyl column (2.1x 50mm) packed with 1.7µm
bridged ethyl hybrid (BEH) particles and maintained at 35°C. The mobile phase consisted of
deionized water containing 0.1% formic acid (solvent A), and acetonitrile containing 0.1%
formic acid (solvent B). Analyte elution was achieved using the following step-wise binary
elution gradient: Initial mobile phase composition was 99:1 (H2O:ACN). The composition of
solvent B was increased to 2% over the first 0.10 mins after which time it was linearly increased
to 10% over 2.9 mins followed by an increase to 100% over 0.50 mins. Conditions were returned
to their initial composition of 99:1 (H2O:ACN) over 0.50 mins and held for 1 min to equilibrate
the column before the next injection. The total run time was 5 mins. Samples were maintained at
10°C in the sample organizer and sample injection volumes were 1µL for all analyses. Flow rates
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remained constant at 0.5 mL/min and all flow was directed into the ESI source of the mass
spectrometer.
7.6.8 Mass Spectrometry
Mass spectrometry conditions were as follows: capillary voltage 0.60 kV, cone voltage
22 V, extractor voltage 3.1 V, RF lens voltage 0.1 V. The source temperature was 150°C while
the desolvation temperature was set at 350°C. Cone gas was set at a flow of 50 L/Hr while the
desolvation gas flow was 900 L/Hr. The collision gas flow was set to 0.18 mL/min. Nitrogen
(99.995% purity) was used as the desolvation gas, and ultra-pure argon (99.999% purity) was
used as the collision gas. Table 45 reports the mass transitions, dwell times, cone voltages, and
collision energies for each of the analytes and their deuterated internal standards.
Table 45: MS/MS parameters used for each analyte and deuterated internal standard.
Compound
Amphetamine
Amphetamine
Amphetamine-d6
Methamphetamine
Methamphetamine
Methamphetamine-d9

Mass transition
135.97 > 90.90
135.97 > 119.0
141.94 > 93.00
149.97 > 90.90
149.97 > 119.0
159.03 > 92.90

Purpose
Quantifying ion
Qualifying ion
Quantifying ion
Quantifying ion
Qualifying ion
Quantifying ion

Cone (V)
20
20
20
25
25
25

Collision (V)
14
10
16
16
12
18

Dwell (secs)
0.02
0.02
0.02
0.02
0.02
0.02

Figure 30 illustrates the fragmentation pathways for amphetamine and methamphetamine under
ESI conditions and the resulting product ions for analyte detection in MRM experiments.
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Amphetamine

Methamphetamine

Figure 30: Fragmentation pathways for amphetamine and methamphetamine during tandem mass
spectrometry experiments[261].
7.7

Results and Discussion
During direct infusion experiments, the most abundant product ion for both amphetamine

and methamphetamine was identified as the m/z 90.90 ion (Figure 30). Subsequently, the mass
transition from 135.97>90.90 was monitored as the quantifying trace for amphetamine and the
mass transition from 149.97>90.90 was monitored as the quantifying trace for
methamphetamine. In order to monitor these mass transitions, MS1 was set to pass masses of
135.97 and 149.97 along with the parent masses of the deuterated internal standards. Following
collision induced dissociation of the protonated molecular ions into their characteristic product
ions, MS2 was set to transmit only product ions with m/z 90.90. To eliminate the potential
effects of cross-talk between the identical fragment ions of amphetamine and methamphetamine,
attempts were made at developing a chromatographic run capable of baseline resolving the two
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analytes. Due to their structural similarities, amphetamine and methamphetamine exhibit almost
identical physicochemical properties. Initial UPLC experiments indicated that the baseline
resolution of the two compounds could only be achieved with a non-traditional step-wise
gradient.
7.7.1

Chromatographic Separation of Amphetamine and Methamphetamine
Preliminary chromatographic experiments aimed to chromatographically resolve

amphetamine and methamphetamine to eliminate the possibility of ion ‘cross talk’ which can
complicate the quantitation process. The initial elution gradient profile was as follows: 0 – 0.10
min, 25% B; 0.10 – 3.0 min, 25 – 100% B; 3.0 – 3.5 min, return to initial conditions; 3.5 – 5.0
min, equilibration of the column. The chromatographic separation under these conditions
exhibited poor resolution (Figure 31).
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Amp/Mamp

Figure 31: TIC of UPLC separation #1. Elution gradient failed to resolve amphetamine (Amp)
and methamphetamine (Mamp).

In order to achieve baseline resolution of amphetamine from methamphetamine, a second
gradient profile was evaluated. The elution gradient profile was as follows: 0 – 0.10 min, 15% B;
0.10 – 3.0 min, 15 – 100% B; 3.0 – 3.5 min, return to initial conditions; 3.5 – 5.0 min,
equilibration of the column. The chromatographic separation of amphetamine and
methamphetamine improved under these conditions however significant co-elution meant that
quantitation could still prove inaccurate as a result of ion ‘cross talk’ (Figure 32).
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Mamp
Amp

Figure 32: TIC of UPLC separation #2. Elution gradient resulted in the co-elution of
amphetamine (Amp) and methamphetamine (Mamp).

Chromatographic resolution was improved using the second elution gradient profile in which the
initial aqueous component was increased. In order to investigate the effect of increasing the
aqueous component further, a third gradient profile was evaluated. The elution gradient profile
was as follows: 0 – 0.10 min, 5 – 10% B; 0.10 – 3.0 min, 10 – 100% B; 3.0 – 3.5 min, return to
initial conditions; 3.5 – 5.0 min, equilibration of the column. Chromatographic resolution was
not significantly improved using an increased aqueous component (Figure 33).
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Mamp
Amp

Figure 33: TIC of UPLC separation #3. Elution gradient was unable to resolve amphetamine
(Amp) and methamphetamine (Mamp).

As an increase in the initial aqueous component of the gradient profile did not significantly
improve the chromatographic resolution, the effect of sustaining a slightly higher aqueous
component in the early stage of the separation was investigated. The elution gradient profile was
as follows: 0 – 0.10 min, 1% B; 0.10 – 3.0 min, 1 – 100% B; 3.0 – 3.5 min, return to initial
conditions; 3.5 – 5.0 min, equilibration of the column. The higher aqueous composition again
shifted the retention times of both analytes but did not significantly improve the chromatographic
separation (Figure 34).
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Mamp
Amp

Figure 34: TIC of UPLC separation #4. Elution gradient was unable to resolve amphetamine
(Amp) and methamphetamine (Mamp).

In order to evaluate the separation power of a largely aqueous mobile phase, the elution gradient
profile was modified to sustain a largely aqueous composition not only during the early stages of
the separation but also throughout and beyond analyte elution. The elution gradient profile was
as follows: 0 – 0.10 min, 1 – 5% B; 0.10 – 3.0 min, 5 – 10% B; 3.0 – 3.5 min, 10 – 90% B; 3.50
– 4.50 min, return to initial conditions; 4.5 – 5.5 min, equilibration of the column. While
chromatographic resolution of amphetamine and methamphetamine was achieved using the
highly aqueous mobile phase, significant peak broadening, especially in the case of
methamphetamine, meant that quantitation was unreliable and often inaccurate (Figure 35).
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Amp

Mamp

Figure 35: TIC of UPLC separation #5. Elution gradient resulted in significant peak broadening.

In order to minimize peak broadening while still achieving baseline resolution, the following
elution gradient profile was evaluated: 0 – 0.10 min, 1 – 2% B; 0.10 – 3.0 min, 2 – 10% B; 3.0 –
3.5 min, 10 – 100% B; 3.50 – 4.0 min, return to initial conditions; 4.0 – 5.0 min, equilibration of
the column. The elution gradient maintained a higher aqueous component during the initial stage
of the separation and increased the organic component during the ramp between 3.0 and 3.5
minutes. Band broadening was significantly reduced without significantly altering retention
times (Figure 36). Both analytes eluted in less than three minutes and the total run time was five
minutes (Figure 36). This elution gradient profile was employed for the remainder of validation
experiments.
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Mamp

Amp

Figure 36: TIC of UPLC separation #6. Elution gradient allowed for the baseline resolution of
amphetamine (Amp) and methamphetamine (Mamp).

7.7.2

Method Validation
Equivalence studies were performed to investigate the accuracy of employing calibration

curves constructed in certified drug-free blood for the purpose of quantifying analytes in the
meconium matrix. Five LQC and five HQC standards were prepared and quantified using a
calibration curve constructed in negative whole blood, and a calibration curve constructed in
meconium which had previously screened negative for the analytes of interest. The relative error
of the two quantitative values was calculated for each QC and used to determine the level of
agreement between the two calibration curves. Relative error did not exceed 2% indicating a
high degree of correlation between calibration curves constructed in blood and calibration curves
constructed in meconium for the purpose of quantifying amphetamine and methamphetamine in
the meconium matrix (Table 46 and 47). Calibration curves constructed in negative blood appear
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to generate accurate quantitations when applied to the meconium matrix which is encouraging.
Calibration curves constructed in certified drug-free blood were deemed suitable for the
quantitation of amphetamine and methamphetamine in the meconium matrix and were
subsequently employed for the remainder of validation experiments.
Table 46: Amphetamine equivalence studies using quantitative values obtained from calibration
curves constructed in meconium (MC) and blood (BC).
Amphetamine Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
10.0
513.4
0
0

*MC (ng/mL)
10.1
506.7
0
0

%RE
1.0%
1.3%
N/A
N/A

*Reported concentrations are mean values of 5 replicate analyses.
Table 47: Methamphetamine equivalence studies using quantitative values obtained from
calibration curves constructed in meconium (MC) and blood (BC).
Methampheatmine Std
LQC
HQC
NEG(B)
NEG(M)

*BC (ng/mL)
9.8
538.7
0
0

*MC (ng/mL)
9.4
503.3
0
0

%RE
4.3%
7.0%
N/A
N/A

*Reported concentrations are mean values of 5 replicate analyses.
The analytical methodology was deemed selective following the analysis of five
meconium blanks and five QC standards prepared at the LLOQ which had been spiked with
various exogenous interferences commonly encountered in forensic specimens (Table 48). Blank
meconium specimens were analyzed to ensure minimal analyte response was generated from any
endogenous matrix components. Analysis of five LLOQ specimens which had been spiked with
potential interfering species was performed to ensure selectivity at the low end of the calibration
range and to eliminate the possibility of false positives generated from exogenous interferences.
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Table 48: Exogenous compounds included in selectivity quality control standards.
Standard
Selectivity QC 1

Contents
Carbamazepine, carbamazepine epoxide, felbamate, gabapentin, lamotrigine,
levetiracetam, mephobarbital, naproxen, oxcarbazepine, phenytoin, primidone, topiramate,
valproic acid, zonisamide

Selectivity QC 2

Amitriptyline, bupropion, clomipramine, desipramine, doxepin, fluoxetine, imipramine,
norclomipramine, nordoxepin, norfluoxetine, norsertraline, nortriptyline, norvenlafaxine,
paroxetine, sertraline, venlafaxine

Selectivity QC 3

Alprazolam,
chlorpheniramine,
citalopram,
clonazepam,
cyclobenzaprine,
dextromethorphan, duloxetine, fentanyl, flunitrazepam, haloperidol, mirtazapine,
olanzapine, strychnine, zolpidem

Analysis of blank meconium specimens indicated that endogenous matrix components
are capable of generating only minimal detector responses which correspond to concentrations
well below the LLOQ. Analyte responses during the analysis of blank samples did not exceed
0.2 ng/mL for either analyte (Tables 49 and 50). Results indicate that false positives arising from
endogenous matrix interferences are unlikely. Analysis of QC standards prepared at the LLOQ,
which had been spiked with various exogenous interferences, indicated that accurate and
selective identification of amphetamine and methamphetamine was possible even in the presence
of various other xenobiotics. Quantitation accuracies of spike QC standards ranged from 96% to
100% for amphetamine and 94% to 98% for methamphetamine (Table 49 & 50). Accurate
quantitations at the LLOQ for both analytes were possible due to the high selectivity of the
tandem mass spectrometric methodology. Selectivity studies indicate that false positives due to
matrix interferences or potentially interfering exogenous species are not likely.
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Table 49: Amphetamine selectivity studies using blank meconium from five different sources
and blank meconium specimens spiked with various exogenous interferences.
Amphetamine Std
Blank samples
Spiked samples

Std Conc
(ng/mL)
0
5

*Measured Conc (ng/mL)

Acceptable range

Pass/Fail

0.1
5.0

<5ng/mL
5+/- 20%

Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
Table 50: Methamphetamine selectivity studies using blank meconium from five different
sources and blank meconium specimens spiked with various exogenous interferences.
Methamphetamine Std
Blank samples
Spiked samples

Std Conc
0
5

*Measured Conc (ng/mL)
0.2
5.2

Acceptable range
<5ng/mL
5+/- 20%

Pass/Fail
Pass
Pass

*Reported concentrations are mean values of 5 replicate analyses.
The accuracy of the analytical method was investigated by analyzing five replicate QC
standards over three different concentrations spanning the calibration range. Accuracy was
assessed by calculating the closeness of the mean test results to the known standard
concentration. Mean values were determined using five replicates prepared at concentrations of
500, 50, and 5 ng/mL. Mean values of 491.1 ng/mL, 50.8 ng/mL, and 4.8 ng/mL were obtained
from replicate analysis of amphetamine standards at concentrations of 500, 50, and 5 ng/mL
respectively, representing accuracies of 98.2%, 98.4%, and 96% (Table 51). Replicate analysis of
methamphetamine QCs prepared at concentrations of 500, 50, and 5 ng/mL produced mean test
values of 530.9 ng/mL, 53.2 ng/mL, and 4.7 ng/mL respectively, representing accuracies of
93.8%, 93.6%, and 94% (Table 52).
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Table 51: Amphetamine accuracy studies.
Amphetamine Std
High point
Midpoint
LLOQ

Std Conc (ng/mL)
500
50
5

*Measured value (ng/mL)
491.1
50.8
4.8

%RE
1.8%
1.6%
4.0%

*Reported concentrations are mean values of 5 replicate analyses.
Table 52: Methamphetamine accuracy studies.
Methamphetamine Std
High point
Midpoint
LLOQ

Std Conc (ng/mL)
500
50
5

*Measured value (ng/mL)
530.9
53.2
4.7

%RE
6.2%
6.4%
6.0%

*Reported concentrations are mean values of 5 replicate analyses.
Precision of the analytical methodology was investigated by analyzing five replicate QC
standards at concentrations of 500, 50, and 5 ng/mL over four consecutive days. Both intra- and
inter-batch studies indicated high method precision (CVs <8.5%). Intra-batch precision studies
yielded CVs ranging from 1.4%-8.5% for amphetamine and 0.7%-5.4% for methamphetamine
indicating high intra-batch precision over the entire calibration range. (Table 53 & 54). Interbatch precision studies were also promising with four-day CVs of 3.9%, 2.0%, and 6.2% for
amphetamine QCs prepared at concentrations of 500, 50, and 5 ng/mL, while analysis of
methamphetamine standards over the four day time period produced CVs of 1.9%, 3.7%, and
5.3% for the 500, 50, and 5 ng/mL QCs respectively (Table 53 & 54).
Table 53: Intra- and inter-batch precision studies for amphetamine.
Amphetamine
Highpoint
CV
Midpoint
CV
LLOQ
CV

*Day 1 value
491.1
1.6%
50.8
1.8%
4.8
5.6%

*Day 2 value
494.7
3.2%
49.8
1.9%
4.6
8.5%

*Day 3 value
530.1
2.7%
51.3
1.4%
5.1
4.5%

*Day 4 value
523.8
1.4%
48.9
5.3%
5.3
2.6%

*Reported concentrations are mean values of 5 replicate analyses.

186

4 day mean
509.9

4 day CV
3.9%

50.2

2.0%

5.0

6.2%

Table 54: Intra- and inter-batch precision studies for methamphetamine.
Mamp

Highpoint

*Day 1 value
530.9

*Day 2 value
507.7

*Day 3 value
519.9

*Day 4 value
524.9

CV

1.6%

1.6%

0.7%

3.2%

Midpoint

53.2

49.7

52.3

49.3

CV

0.9%

1.6%

2.7%

4.3%

LLOQ

4.7

4.6

4.9

5.2

CV

3.8%

5.4%

2.7%

2.9%

4 day mean
520.9

4 day CV
1.9%

51.1

3.7%

4.9

5.3%

*Reported concentrations are mean values of 5 replicate analyses.
Recovery of amphetamine and methamphetamine from the meconium matrix using the
HM-N supported-liquid extraction technique was investigated to determine the efficiency of the
extraction. Extraction efficiency was assessed by comparing the detector response for
unextracted standards prepared at concentrations of 500, 50, and 5 ng/mL with the detector
response for extracted standards prepared at the same concentrations. Standards were prepared in
triplicate and peak area responses for unextracted standards represented 100% recovery. Peak
area responses for extracted standards were then used to calculate recovery. Mean analyte
recoveries over the three concentrations investigated were 52% for amphetamine and 52.7% for
methamphetamine (Figure 37 & 38). Mean analyte recoveries for triplicate standards at each of
the three concentrations ranged from 49-57% for amphetamine and 47-58% for
methamphetamine. Analyte recovery was extremely consistent and precise and recoveries of
greater than 50% ensure acceptable method sensitivity.
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Figure 37: Amphetamine recovery.
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Figure 38: Methamphetamine recovery.
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Low point (5 ng/mL)

The limit of detection was 1.0 ng/mL for amphetamine and 0.250 ng/mL for methamphetamine
corresponding to concentrations of 4.0 ng/g and 1 ng/g in the meconium specimen prior to
sonication. Limits of detection were calculated based on acceptance criteria for retention times
and ion ratios. At concentrations below 1 ng/mL for amphetamine and 0.250 ng/mL for
methamphetamine, unequivocal identification was not possible due to inaccurate ion ratios.
Stability studies indicated that amphetamine and methamphetamine are both stable in the
meconium matrix when stored long-term at 4°C. Stability studies were performed by preparing
High and low QC standards which were subsequently subject to a 72 hour freeze-thaw cycle and
analyzed following thawing on the third day. Quantitation accuracies during stability studies
were greater than 98% and 99% for amphetamine LQCs and HQCs respectively, and greater than
98%, and 99% for methamphetamine low and high QCs respectively. High accuracy and
precision during stability studies indicated that current storage temperature and conditions are
appropriate for the accurate analysis of authentic meconium specimens.
7.8

Conclusions
Meconium is a complex biological matrix that can indicate prenatal exposure to drugs of

abuse. Unfortunately, meconium specimens require extensive sample pre-treatment before they
are suitable for instrumental analysis. Extensive sample preparation can prove detrimental to
sample turnaround time in high throughput toxicology laboratories. ISOLUTE HM-N supported
liquid-liquid extraction columns provide an attractive sample pre-treatment technique for the
extraction of amphetamine and methamphetamine from meconium specimens. ISOLUTE HM-N
columns are designed to deal with difficult matrices such as sonicated meconium specimens
which can sometimes cause traditional SPE columns to plug due to sample turbidity. Rapid and
selective extraction of both analytes was possible with the columns and subsequent separation
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and quantitation was achieved in less than 5.0 min using UPLC-MS/MS. Two MRM transitions
were monitored for each analyte and quantifications were made using deuterated internal
standards and seven point calibration curves. Limits of detection were 1 ng/mL and 250 pg/mL
for amphetamine and methamphetamine, respectively. Injection volumes of 1 µL allowed for the
linear quantitation of analytes over the range 5 ng/mL – 500 ng/mL. To the author’s knowledge,
this is the first validated UPLC-ESI-MS/MS methodology for the quantitation of amphetamine
and methamphetamine in meconium specimens. The proposed methodology could greatly reduce
the sample preparation time for meconium testing which is becoming an extremely important
tool for the identification of prenatal exposure to drugs of abuse. The validated methodology was
implemented at AIT Laboratories (Indianapolis, IN) for the purpose of confirming the presence
of amphetamine and methamphetamine in authentic meconium specimens which had previously
screened positive. From 07/01/08 – 03/06/2009 a total of 4036 meconium specimens were
screened for amphetamine/methamphetamine. Of those samples, 138 screened positive
representing 3.4% of the total specimens. 37 of the 138 specimens were confirmed positive using
the UPLC-MS/MS method.
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Chapter 8: Investigations into the Application of Desorption Electrospray
Ionization (DESI) for the Rapid Screening of Meconium Specimens
8.1

Abstract
The current study investigates the suitability of desorption electrospray ionization (DESI)

for the purpose of screening human meconium samples for several cocaine, amphetamine, and
opiate derivatives. DESI offers the advantage of ambient sampling meaning that specimens can
be directly analyzed following limited sample preparation. Due to the complex nature of the
human meconium matrix, significant sample preparation is often required before specimens can
be screened using traditional immunoassay techniques. Traditional immunoassay techniques
such as ELISA, EMIT, and RIA are designed for qualitatively detecting analytes in common
biological matrices such as serum and urine. Direct application of such techniques to the analysis
of more complex matrices, such as meconium, can result in inaccurate results and a high rate of
false-positives. The suitability of the DESI-MS/MS method for screening meconium specimens
was investigated by analyzing 21 authentic specimens that had previously screened positive for
either cocaine or amphetamines using an immunoassay screen. Direct comparison of the
immunoassay screening results with those obtained using the DESI-MS/MS method indicates
that the mass spectral method greatly enhances selectivity and decreases the rate of false
positives. Investigations into the suitability of DESI-MS/MS for screening meconium specimens
aimed to reduce both the degree of sample preparation and also the number of false-positive
results commonly observed with immunoassay techniques.
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8.2

Introduction

8.2.1

Desorption Electrospray Ionization (DESI)
Desorption electrospray ionization is achieved by directing a fine spray of electrically

charged droplets at an ambient object of interest. When the fine spray of droplets hits the surface
of interest, desolvated ions created from small organic molecules as well as large biomolecules
are released. Analytes initially leave the surface of interest entrained within small, progeny
droplets which subsequently evaporate to produce analyte ions. Desorbed ions are subsequently
vacuumed through air into a conventional mass spectrometer (Figure 39)[262].

Figure 39: Schematic representation of desorption electrospray ionization (Adapted from Takats
2004).
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DESI was first described in 2004 by Cooks et al who employed the technique for the
ionization of peptides and proteins from metal, polymer, and mineral surfaces[263]. The
distinguishing feature of DESI is that is allows for the collection of mass spectral data under
ambient conditions. Approximately two decades prior to the introduction of DESI by Cooks and
co-workers, two new ionization methods were introduced almost simultaneously and have since
had an enormous impact on the utilization of mass spectrometry in biology and the life
sciences[264]. One of these methods, employed primarily for the analysis of solids, is a
desorption ionization (DI) technique known as matrix assisted laser desorption ionization
(MALDI)[265]. The second technique, applicable to the analysis of solutions is electrospray
ionization (ESI)[266]. Although ionization techniques based upon matrix-assisted laser
desorption and electrospray ionization have origins dating back some thirty years, the
recognition of their potential for the analysis of large biomolecules has only been realized
recently[267]. Both MALDI and ESI are soft ionization techniques meaning that ions produced
using either method will possess low internal energies and thus undergo little
fragmentation[138]. Both methods exhibit very high ionization efficiencies and allow for very
precise Mr measurements. DESI combines experimental features of both ESI (see section 2.7.6)
and MALDI (see section 8.2.2) and a thorough understanding of both techniques is required to
fully recognize the potential applications of DESI in the fields of biology, chemistry, forensics,
and toxicology.
8.2.2 Matrix Assisted Laser Desorption Ionization (MALDI)
Matrix assisted laser desorption ionization (MALDI) was first described in 1985 by Karas
et al. who employed the technique for the ionization of organic molecules while simultaneously
studying the influence of the wavelength on laser desorption[268]. Since its introduction some
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twenty years ago, MALDI, along with ESI has become the heart of virtually all proteomic
experiments due to its ability to provide the key tools essential for the analysis of proteins[138].
Although the exact mechanism of ionization and desorption during MALDI experiments remains
debatable, it is widely accepted that the transfer of energy to an organic matrix causes rapid
thermal heating of molecules and eventually leads to desorption of both matrix and analyte ions
into the gas phase (Figure 40)[138].

Laser beam

Matrix ion

To mass
analyzer

Proton transmission
Analyte Ion
Analyte/Matrix mixture

Figure 40: Schematic representation of MALDI ionization region (Adapted from
www.magnet.fsu.edu/.../ionization_maldi.html).

While theories regarding the mechanistic pathway of MALDI remain largely divergent,
significant convergence in one area has resulted in the widely accepted theory that MALDI
ionization occurs via a two step process, involving initial matrix (primary) ionization followed
by analyte (secondary) excitation and ionization.
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MALDI is achieved by co-crystallizing a sample with a thousand-fold excess (minimum)
of an organic matrix on a metal target. A pulsed laser is then focused onto the surface of the
matrix-analyte solid solution[269]. The organic matrix is chosen based on its ability to absorb
energy at the wavelength corresponding to the laser being employed[270]. Frequency coupling
between the incoming laser and the matrix chromaphore causes rapid vibrational excitation
leading to localized disintegration of the solid solution. Laser ablative induced disintegration of
the solid solution surface results in the ejection of ‘clusters’ composed of analyte molecules
surrounded by matrix (primary) ions[271]. Following evaporation of matrix molecules, free gasphase analyte molecules occupy the ablation plume where they undergo ionization through
proton transfer reactions with the photo-excited matrix molecules[271]. It is these analyte
(secondary) ions which are then extracted and separated in the mass spectrometer based on their
mass to charge ratios[272].
Considerable time and effort has been expended into the further development and
application of MALDI, however, minimal progress has been made in the understanding of its
mechanistic principles. Without a thorough mechanistic understanding of the processes behind
MALDI analysts may be unequipped to handle the difficulties often associated with absolute
sensitivity, variable response factors, range of applicability and reproducibility[273]. This lack of
mechanistic understanding is evident in the literature by the predominately empirical approach
toward MALDI research and utilization. While the empirical approach to MALDI continues to
dominate in fields such as proteomics and biomolecular analysis, others have concentrated
research efforts on further understanding experimental variables. One study aims to
quantitatively predict or interpret observed mass spectra as a function of experimental variables
such as, matrix choice, analyte physical and chemical properties, concentrations, preparation
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method, laser characteristics, local environment and ion extraction method, by drawing on the
mechanistic principles behind the technique[273]. Studies exploring mechanistic theory and
evaluating proposed models of MALDI will aid in its practical applications and provide a better
understanding of factors capable of affecting relative and absolute signal intensities[273].
MALDI has quickly found notoriety as an analytical tool for the characterization of
peptides and proteins. Coupled to the appropriate mass analyzer, MALDI allows for the accurate
mass analysis of low-picomole amounts of biomolecules with molecular weights exceeding 100
kDa. MALDI offers the inherent advantage of generating low charge state ions from samples
containing appreciable levels of commonly encountered buffers and salts which can significantly
affect ionization efficiencies when employing alternative techniques. The use of a pulsed laser
during MALDI experiments results in the production of packets of ions rather than a continuous
beam as in the case of ESI[138].
The mass spectra of ions generated by MALDI are typically measured using a time-offlight mass spectrometer. This is primarily due to the fact that time-of-flight mass analyzers are
immediately compatible with the pulsed generation of high-energy ions and provide a
theoretically unlimited mass range[270]. Each pulse of laser radiation generates packets of ions
in a relatively short (≈5cm) source region. An electrical potential contained in the source region
then accelerates the ions to a fixed kinetic energy before allowing them to traverse the field-free
drift region of the TOF mass spectrometer. Ions ultimately arrive at the detector following a drift
time that is dependent on their mass. The drift time or TOF of each packet of MALDI generated
ions is measured by an internal clock which is triggered by the laser pulse, making time-of-flight
mass analysis perfectly suited to the pulsed ionization process utilized in MALDI [269, 270,
274].
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8.2.3 History and Background of Meconium Screening
Screening techniques employed for the purpose of identifying drugs of abuse in
meconium have largely utilized immunoassay analysis. The large majority of meconium studies
published in the scientific literature have utilized either radioimmunoassay or enzyme
immunoassay techniques. Immunoassays are based on an interaction between a drug (antigen)
and specific antibody. When the drug of interest is recognized by the antibody, the subsequent
interaction produces an antigen-antibody complex which is then separated from the remainder of
the reaction mixture. The endpoint of the reaction, whether it be radioactivity in the case of
radioimmunoassays or enzymatic activity in the case of enzyme immunoassays, is then measured
and provides an indication of the quantity of drug present[39].
Radioimmunoassays (RIA) are performed by first generating a known quantity of
radiolabeled antigen. This is normally achieved using radioactive isotopes of iodine attached to
tyrosine. The radioactive labeled antigen then competes with the wild antigen (the drug of
interest) for a limited number of binding sites in an antibody[39]. As the concentration of drug in
the sample increases, the amount of bound radioactive antigen decreases due to fewer available
binding sites in the antibody. The concentration of the drug can be estimated using a doseresponse curve generated by analyzing standards of known concentrations[39]. RIA has been
widely employed for the detection of drugs of abuse in meconium and the vast majority of
methods published prior to 1990 relied heavily in this technique[243]. The main drawback
associated with RIA is the hazard and cost of preparing, handling, and disposing of the
radioactive labeled antigen. RIA still finds widespread use in clinical laboratories, however, the
majority of studies involving the detection of drugs of abuse in meconium published in the last
fifteen years have utilized enzyme immunoassay.
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Enzyme linked immunosorbent assay (ELISA) is the most commonly employed enzyme
immunoassay for various reasons including its inherent sensitivity, ability to handle multiple
samples, and safe reagents. ELISA operates on the same principles as RIA in that the drug of
interest competes with an enzyme labeled antigen for a limited number of binding sites in the
antibody. Antigen labels are non-radioactive and are linked to an enzyme while the antibody is
immobilized into a solid support[39]. The enzyme used to label the antigen is chosen based on its
ability to produce a colored product from a colorless substrate. This color reaction between the
enzyme and the substrate is the endpoint of the assay and can be used to estimate the
concentration of drug in the sample. Due to the competitive binding nature of the assay, the
concentration of the drug is inversely proportional to the concentration of the enzyme labeled
antigen that is bound to the antibody[39].
Enzyme multiplied immunoassay technique (EMIT) also finds widespread use as a
screening tool for drugs of abuse in biological specimens. EMIT is similar to ELISA in that the
antigen is again linked to an enzyme however it is the activity of this enzyme that indicates the
presence or absence of a drug class. The enzyme used to label the antigen is inactivated upon
binding with the antibody meaning that enzymatic activity will be higher in the presence of the
drug due to competitive binding mechanisms. The total amount of drug present in the sample is
directly proportional to the enzymatic activity which is measured as the product of a reaction.
Enzymatic activity is the endpoint of the assay and indicates the total amount of drug in the
sample[39].
Unlike the National Institute on Drug Abuse protocol regulating urine testing, meconium
analysis is not government regulated and many of the testing techniques have been directly
adapted from pre-existing urine assays with the assumption that specific analysis procedures
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have no significant impact on results[275]. Due to the complex nature of the meconium matrix
and the lack of research detailing its composition, the presence of endogenous compounds
capable of generating false positives must be considered. False positive results arise when
endogenous or exogenous components of the sample are erroneously recognized as the drug of
interest by the testing technique. Recognition of the interfering compound as the drug of interest
generates a positive result in the true absence of the drug. Specimens that screen positive should
be subject to subsequent confirmation testing utilizing mass spectrometry where feasible.
The superior selectivity of mass spectrometry provides the analyst with structural
information for the drug of interest, eliminating the possibility of false positives. Incorrect
recognition of interferences as the drug of interest may be due to similarities in chemical
structure or simply to the lack of selectivity afforded by most immunoassay techniques.
Situations in which the drug of interest is present but not detected by the technique are referred
to as false negative results and must also be considered when adapting pre-existing testing
techniques to the analysis of complex matrices such as meconium. False negative results must
also be considered when adapting a pre-existing extraction technique to a new matrix. Many of
the extraction techniques employed for the confirmation testing of drugs in meconium have been
directly adapted from pre-existing blood assays. Inappropriate or inefficient extraction of drugs
from meconium can result in a negative confirmation result through analyte loss.
Although many studies involving the detection of drugs of abuse in meconium by way of
immunoassay techniques appeared in the literature in the late 1980s and early 1990s, it was not
until 1995 that the issue of false-positive and false-negative rates was addressed by Moore et al.
from the US Drug Testing Laboratories in Chicago. Moore and coworkers investigated the rates
of both false-negative confirmation results arising from inefficient extraction of drugs, and false199

positive results arising from screen-only testing[275]. Experiments were aimed at determining
whether differences exist between published screening procedures and to determine whether
reporting screen-only data is reliable and acceptable. The authors compared three published
procedures for the determination of abused drugs in meconium to determine the false-negative
rates associated with various screening methods. Following this, additional experiments were
performed with the aim of calculating the rate of false-positives by determining the actual
number of immunoassay screen-positive samples which were subsequently confirmed negative
by GC-MS. False-positive rates were investigated to assess the accuracy of screen-only results
which are often the only results generated by hospital laboratories. The use of screen-only results
for decision making is unethical and in the case of meconium analysis, can have devastating
consequences not only for mothers, but also for children and other family members [275].
Although all negative specimens were correctly screened negative, results indicated that the three
screening techniques differed substantially in their ability to detect the drugs of abuse in predetermined positive samples. Only 19.6% of the positive samples were identified using one
method while the remaining two methods had success rates of 54.5%, and 100%. Results
indicate that considerable time and effort is required during method development and
optimization to minimize the potential for false-negative screen results. Experiments aimed at
determining the rate of false-positives illustrated the importance of confirmation testing as only
53.3% of samples which screened positive were subsequently confirmed positive, indicating a
false-positive rate of 46.7%[275]. The greatest discrepancies between screen and confirmation
data occurred with the amphetamine drug class in which only 25.7% of positive screens were
confirmed positive by GC-MS. Of the 228 specimens that screened positive for cocaine
metabolites, only 59.2% were confirmed positive. The opiate drug class had a similar false-
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positive rate with 56.7% of positive screens confirming positive[275]. To some degree, high
false-positive results can be attributed to the presence of various over the counter (OTC) and
prescription medications which contain cross-reacting substances, however, confirmation testing
to distinguish these compounds from drugs of abuse is essential to make ethical and accurate
decisions[275].
The suitability of immunoassay screening kits for the detection of drugs of abuse in
meconium was also investigated by ElSohly and coworkers in 1999[243]. The authors aimed to
develop and validate methods for meconium sample preparation prior to screening and
confirmation testing while simultaneously evaluating the suitability of two different
immunoassays for the purpose of screening for various drugs of abuse in meconium[243].
Experiments involved subjecting ninety five meconium specimens to the screening procedures
and confirming any presumptive positives using GC-MS to determine the rate of false-positives.
False-negative rates were also investigated by subjecting seventy meconium specimens for each
drug class to confirmation analysis regardless of screening results. While immunoassay
technologies did not generate any false-negative results, rates of false-positives were again
alarming and ranged from 15% for opiates, to 100% for amphetamines[243]. The authors
highlight the importance of carrying out GC-MS confirmation of positive screens prior to
reporting results due to the high rate of false-positives.
Rates of false-positive results in authentic meconium specimens were also monitored at
AIT Laboratories (Indianapolis, IN) for the cocaine and amphetamine drug classes. Following
the implementation of UPLC-MS/MS methodologies for meconium confirmation analysis (see
chapters 5 & 7), the rate of false-positives was monitored over an eight month period
(07/01/2008 – 03/01/2009). All specimens were screened using ELISA and the false-positive rate
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was determined by calculating the percentage of positive screens that were subsequently
confirmed negative. During the eight month time period a total of 4036 meconium specimens
were screened for amphetamines and cocaine. Of the 303 samples that screened positive for
cocaine/benzoylecgonine, 71 were confirmed positive representing a false-positive rate of 76%.
Of the 138 samples that screened positive for amphetamines, only 37 were confirmed positive
representing a false-positive rate of 73%.
Based on results from the reported studies investigating the suitability of immunoassays
for the purpose of screening meconium, it is evident that reporting screen-only results is both
unethical and inaccurate due to the high rate of false-positive results. False-positive results not
only complicate decision making processes for health care professionals, they also result in
additional costs for the toxicology laboratory through unnecessary confirmation analysis. While
the confirmation analysis is of extreme importance in the case of false-positives, such testing
requires expensive reagents for suitable sample preparation and additional expenses associated
with labor. Confirmation analysis is an expensive procedure for laboratories utilizing state of the
art technologies such as LC/MS/MS for the purpose of providing enhanced sensitivity.
Traditional confirmation techniques such as GC-MS require substantial sample preparation such
as liquid-liquid or solid phase extraction of the drug from the meconium matrix, purification of
the extract, and derivatization of the analyte, all of which require expensive chemical reagents. In
addition to the cost of reagents, sample extraction and preparation prior to instrumental analysis
can be very labor intensive consuming both time and labor costs for the toxicology laboratory.
False-positive results associated with immunoassays are inevitable due to the inferior
selectivity associated with the technique and the complexity of the biological samples being
analyzed. Laboratories employing confirmation testing for the purpose of unequivocally
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identifying the drug of interest recognize the potential for false-positives, however, the ability of
immunoassays to screen out a large majority of negative samples in a cost effective manner
somewhat offsets this disadvantage. High throughput production laboratories view immunoassay
screening kits as a cheap, quick, reliable and effective way to screen biological samples for drugs
of abuse, however, the potential for high rates of false-positive results means that laboratories
must carefully monitor the time and cost associated with performing such assays. From a
production standpoint, there is little value in dedicating resources to performing immunoassay
screening tests that generate a large number of false-positive results requirin expensive
confirmation testing.
While it is widely accepted that screen testing will never possess the selectivity of
confirmation analysis, laboratories must continue to monitor the effectiveness of screening
techniques with respect to their intended purpose. An immunoassay screen test generating a
100% false-positive rate is obviously not serving its purpose as an effective way to screen
samples, and careful monitoring of the costs associated with avoidable confirmations relative to
the effectiveness of the screen will allow the laboratory to assess the overall value of the
technique.
Sample preparation prior to immunoassay analysis can be laborious depending on the
specific screening technique, the analyte of interest and the biological matrix in which it exists.
ElSohly et al. proposed a procedure for the preparation of meconium extracts for immunoassay
analysis[243]. The authors investigated several procedures for the extraction of drugs from the
meconium matrix prior to immunoassay analysis. Many of these methods were deemed to be
inefficient, inconsistent, impractical, or generally problematic and therefore useless for
meconium extractions[243]. Reduced sensitivity, maximal background signals leading to invalid
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results, low recoveries, and colored extracts unsuitable for analysis were some of the problems
encountered throughout investigations into multiple sample preparation techniques. The final
extraction method was developed based on the observations from previous trials and is outlined
in Figure 41.
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Figure 41: Proposed procedure for the preparation of meconium extracts for immunoassay
analysis (Adapted from ElSohly et al., 1999).

The procedure proposed by ElSohly and coworkers for the preparation of meconium extracts for
immunoassay analysis is laborious and a represents a significant sample work up. The
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performance of an immunoassay test requiring such extensive sample preparation should be
monitored closely to ensure that unnecessary confirmations as a results of false-positives are
minimal. The value of an immunoassay screening test which requires significant sample
preparation and generates a large number of false-positives is arguably negligible, and
investigations into alternate screening techniques more suited to the analysis at hand may prove
beneficial for laboratories experiencing this problem.
Commercially available immunoassay screening kits are designed for the detection of
drugs in blood and/or urine and care must be taken when adapting such methodologies to
alternate matrices. Alternate toxicology samples such as amniotic fluid, tissue, fly larvae, and
meconium are complex biological matrices rich in interfering species of both endogenous and
exogenous origin. The suitability of immunoassay based testing for such specimens must be
carefully evaluated as the potential for false-positive results will be much higher in the complex
matrix. More alarming than the possibility of false-positive results which generate additional
costs for the toxicology laboratory is the possibility of false-negative results.
False-negative results arise when screening kits are unable to detect a drug of interest,
and can arise due to matrix complexity or sensitivity issues. False-negative results are a major
concern for toxicology laboratories as testing is normally discontinued following a negative
screen. In the case of a false-positive, subsequent confirmation testing utilizing mass
spectrometry will indicate the true absence of the drug, however, in the case of a false-negative,
there is no confirmation test. Following a negative screen, specimens are simply reported
negative and discarded following a standard storage period. As a result, laboratories must ensure
that screening techniques employed for the purpose of identifying drugs of abuse are suitable for
the analysis at hand. While false-positive results generate additional costs for the laboratory
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through unnecessary confirmation testing, false-negatives mean that drug use goes undetected. In
the case of meconium specimens, false-negative results mean that maternal drug use goes
undetected and the drug-exposed child is denied the treatment and care that is normally provided
following authoritative intervention in such cases.
Due to the increasing utilization of alternate toxicological specimens for the
determination of drugs of abuse, the use of alternate screening techniques more suited to such
complex biological matrices must be investigated. Immunoassay based technologies are likely to
generate higher rates of false-positives when used for the analysis of more complex species due
to the lack of selectivity associated with the technique. As the number of endogenous interfering
species in the matrix increases, the accuracy of the immunoassay is likely to decrease as the
inferior selectivity of the technique will be exploited to a greater extent than with traditional
blood or urine based specimens. The use of mass spectrometry for screening purposes would
alleviate many of the problems associated with immunoassay based techniques by affording
inherent selectivity and eliminating the possibility of false-positive results.
8.2.4 Mass Spectrometry as a Screening Tool
Investigations into the use of mass spectrometry as a screening tool for drugs of abuse in
biological specimens date back to the late 1970s. Thompson described one of the earliest GC-MS
methodologies developed as a screening tool for the detection of anticonvulsant drugs in
urine[276]. Sample preparation involved evaporating a small aliquot of urine (50-200 µL), and
permethylating the residue with methylsulfinylmethide carbanion and methyl iodide. Product
mixtures were resolved using GC allowing the authors to identify drug metabolites, mono-, di-,
and trisaccharides, and organic acids, including fatty acids and glucuronides based on mass
spectral data.
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Wilson and coworkers described a GC-MS methodology employing chemical ionization
mass fragmentography for the purposes of simultaneously identifying seven secondary and
tertiary tricyclic antidepressants in plasma[277]. Sample preparation involved a one step liquidliquid extraction into hexane which was subsequently injected onto the chromatograph. The
authors present the methodology as a suitable technique for monitoring therapeutic
concentrations and for screening plasma samples in suspected overdose cases where the drug of
abuse has not been identified.
In 1980, Dugal et al detailed the methodological aspects of a computerized system for the
gas chromatographic screening and primary identification of several CNS stimulants and
narcotic analgesics in human urine[278]. Sample preparation involved a relatively simple liquidliquid extraction followed by sample derivatization. Analytes were screened using selective
nitrogen detection. The authors conclude that the methodology is suitable for the purposes of
screening several drugs and their respective metabolites in a short amount of time.
Broad based screening methodologies utilizing gas chromatography coupled to one of
several detection systems continued to appear in the literature in the years following this early
work. The vast majority of methodologies employed mass spectrometry for the purpose of
unequivocally identifying analytes based on EI fragmentation patterns and library matching.
While GC-MS methodologies offer fast analysis times and mass spectrometric detection for the
screening of acidic, basic, and neutral compounds, and sample preparation can prove laborious
and reduce the overall effectiveness of the screening technique.
Due to the nature of the column packing in gas chromatographs, samples must be
introduced onto the column in an organic solvent of minimal polarity. Many methodologies
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described in the literature satisfied this requirement by buffering the sample matrix with a base
and extracting basic analytes into organic solvents suitable for direct injection. In addition, many
compounds are too polar and/or do not possess sufficient volatility for direct GC-MS analysis.
To alleviate such problems, many compounds must be chemically derivatized prior to GC-MS
analysis. Sample derivatization is performed to decrease the polarity and/or increase the
volatility of an analyte which does not naturally lend itself to analysis by GC-MS. The
incompatibility of GC-MS with aqueous solvents combined with the need for chemical
derivatization complicates sample preparation and means that significant sample
preparation/clean up is required to simply screen the specimen. While sample preparation for
broad based GC-MS screening can be laborious due to the nature of the chromatographic system,
the advantage of obtaining mass spectral screening data often offsets this disadvantage. As a
result, many laboratories employ GC-MS for the purpose of screening for general unknowns.
Figure 42 describes a typical sample preparation procedure for a broad based GC-MS screen.
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Figure 42: Extraction flow chart for a broad based GC-MS screen.
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Investigations into the use of LC-MS and LC-MS/MS for the purpose of general unknown
screening began to appear in the scientific literature in the early 1980s. One of the earliest reports
described the use of a triple quadrupole mass spectrometer for the rapid screening and
confirmation of up to fifty analytes in a single sample of equine blood, serum, and urine in less
than two minutes[279]. The enhanced sensitivity afforded by the tandem mass spectrometer
enabled the authors to achieve detection limits in the ng/mL to µg/mL range for most analytes.
The authors conclude that the use of LC-MS/MS technology for the purpose of screening
provides a fast, sensitive technique for the accurate determination of selected drugs and
metabolites in blood urine and serum.
Chromatographic resolution is not always necessary when employing mass spectrometry
for the purpose of screening, provided the instrument possesses the capability to operate in SIM,
SRM, or MRM mode. As a result, technologies such as GC/MS and LC/MS/MS have the
capability to simultaneously screen for large numbers of drugs without the need for baseline
resolution by monitoring selected ion transitions. Monitoring the presence or absence of
compounds based on an ion trace rather than retention time means that rapid chromatographic
separations are possible as extracted ion traces provide accurate qualitative data even in cases of
chromatographic co-elution. Mass spectrometers coupled to liquid chromatographs offer
additional advantages over GC/MS technologies as aqueous extracts of biological samples can be
analyzed directly due to the column chemistry of the separation and the sophisticated nature of
the LC/MS interface.
The ability of LC/MS and LC/MS/MS technologies to simultaneously screen for large
numbers of drugs following minimal sample preparation and rapid LC separation was the driving
force for the large number of methodologies appearing in the literature in the following years.
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The majority of methods described rapid, broad based screens for drugs of abuse in biological
samples. In 1987, Straub and coworkers described the use of tandem mass spectrometric
techniques for the purpose of rapid structural elucidation and metabolite quantification in
complex sample matrices[280]. The authors report the ability of tandem mass spectrometers to
serve as separation devices as well as tools for structural elucidation. Studies employed
desorption ionization techniques and primary metabolites along with drug conjugates were
identified using an appropriate combination of neutral loss and precursor ion scans[280]. Jones
and colleagues from the facility of advanced instrumentation employed tandem mass
spectrometry for the purpose of screening mercapturates in urine following ionization in the
negative ion mode[281]. The authors employed neutral loss scanning to screen urine samples for
the presence of mercapturates in the low nanogram per milliliter range. Identifications were
made based on the simple daughter ion spectra of the deprotonated molecular ions. In the same
year, Brzezinka and colleagues also employed the neutral loss scanning mode of a tandem mass
spectrometer for the purpose of screening serum samples for the presence of barbiturates[282].
Subsequent confirmation testing and quantification was performed using MRM and limits of
detection were reported to be better than one microgram per milliliter for most analytes.
Weinmann and Svoboda employed solid phase extraction followed by flow injection
analysis (FIA) with ionspray-ionization and tandem mass spectrometry for the simultaneous and
quantitative screening of illicit drugs in serum and urine[283]. Experiments were performed on
an API 3000 triple quadrupole instrument and MS/MS analysis was performed by sequentially
isolating the precursor ions of the analytes and their deuterated standards with subsequent
fragmentation and monitoring of one fragment ion for each substance[283]. The authors
conclude that the increased speed, sensitivity, selectivity, and accuracy afforded by the tandem
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mass spectrometer offers many advantages over traditional screening methodologies for the
simultaneous determination of different drugs and metabolites in biological samples. Nordgren
and co-authors evaluated the usefulness of LC-MS/MS for the purpose of screening urine
samples for the designer amphetamines MDA, and MDMA[284]. Qualitative identifications
were based on the detection of selected positive ions following APCI and studies were performed
to assess the accuracy of the technique compared to immunochemical methodologies. Studies
involved the analysis of 1000 clinical patient samples of which the LC-MS/MS methodology
was able to identify four times as many positive samples as the immunochemical technique. The
authors conclude that LC-MS/MS offers an attractive alternative to immunochemical techniques
for drugs of abuse screening[284].
In 2004, Eichhorst and colleagues published one of the earliest studies aimed at directly
comparing LC-MS/MS with more traditional screening techniques such as GC-MS and ELISA
for the purpose of detecting methylphenidate in urine samples[285]. The use of LC-MS/MS for
screening urine samples was investigated in the hope of replacing less reliable, more expensive,
and time consuming screening techniques such as GC/MS with a combined one-step screening
and confirmation LC-MS/MS method. Implementation of the rapid LC-MS/MS method enabled
the authors to achieve enhanced sensitivity, selectivity and reliability while simultaneously
reducing the cost per sample.
In 2005, Mueller and co-workers described a broad based multi-target screening (MTS)
procedure for the detection of over 300 forensically relevant drugs in blood and urine using a
hybrid triple-quadrupole linear ion trap mass spectrometer (QTrap)[197]. This was one of the
earliest studies employing the various scanning capabilities of a tandem mass spectrometer for
the purpose of screening such a large number of drugs in a single LC-MS/MS run. A multiple
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reaction monitoring (MRM) scan and an enhanced product ion (EPI) scan were performed in an
information-dependant acquisition (IDA) experiment. The MRM survey scan contained 298
transitions for the 301 selected substances and three deuterated internal standards. In order to
perform the EPI scan, Q3 was used as a linear ion trap to scan product ions. Drug identification
was carried out by a library search with a newly developed MS/MS library based on EPI
spectra[197]. Authors conclude that the developed methodology is useful for the rapid detection
or exclusion of over 300 drugs in a blood, plasma, or serum extract. Limitations to the
methodology include the cycle time required to perform both MRM and EPI experiments and
multiple collision energies and the limited number of data points obtained across
chromatographic peaks with 5ms dwell times.
Nordgren and coworkers also employed a triple quadrupole mass spectrometer to
simultaneously screen for 23 analytes in urine samples by monitoring the presence or absence of
a single ion transition in the multiple reaction monitoring mode[286]. In a study of 3000 human
urine samples, the methodology correctly identified the presence of at least one substance 65%
of the time. Authors conclude that while the LC-MS/MS methodology offers a sensitive, robust
alternative to more traditional screening techniques, future studies should consider incorporating
additional ion transitions into the criteria for a positive result to decrease the number of false
positive results obtained when monitoring only a single transition. Allen and coworkers
investigated the usefulness of LC-MS/MS for the purpose of screening oral fluid samples for
opiates, cocaine, methadone, and benzodiazepines and directly compared the method with the
pre-existing ELISA method[287]. Individual analytes were again identified using multiple
reaction monitoring and analysis of 72 patient samples indicated that the LC-MS/MS method
compares favorably with the more traditional immunoassay based techniques. The authors
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conclude that the tandem mass spectrometric method offers a more flexible, selective and
sensitive alternative for screening oral fluid samples than ELISA due to the large number of
individual drugs and metabolites that can be detected from a single sample injection.
In the years to follow, several reports appeared in the literature describing the use of
tandem mass spectrometers; mainly triple quadrupoles and quadrupole – ion trap hybrids
(QTrap), for the purpose of screening large numbers of drugs and metabolites in biological
specimens[168, 170, 183, 288-291]. Several research groups investigated the applications of
exact mass measurements for the purposes of forensic drug screening [292-294]. Studies
involved the use of time-of-flight (TOF) mass spectrometry coupled with either LC or UPLC for
the purpose of measuring exact mass. While the exact mass measuring capabilities of TOF mass
spectrometry have long been utilized in new drug discovery and ADME studies, several early
reports describing the use of TOF for forensic drug screening indicate the widespread
applicability of the technique for general unknown screening. Time of flight mass spectrometry
provides high resolution exact mass measurements while minimizing both sample preparation
time and cost of analysis when compared to GC/MS or ELISA technologies. Development of
analyte libraries based on exact mass and retention time provides the analyst with a powerful
technique for the purpose of general unknown screening. Screening techniques based on triple
quadrupole technologies such as TQDs or QTraps only possess the capability to screen for
analytes which exist in a predetermined MRM library. This is due to the fact that MRM studies
must first be performed on standard materials to identify characteristic fragmentation patterns
suitable for analyte identification. Once the information has been experimentally determined,
parameters can be incorporated into the pre-existing MS/MS method to screen for the new
analyte. Addition of new analytes to pre-existing TQD or QTrap methodologies directly affects
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sensitivity as dwell times must be minimized to obtain sufficient data points across
chromatographic peaks. While screening technologies based on TOF mass spectrometry may
also utilize analyte library searches for the purpose of analyte identification, additional analytes
which do not exist in the library may be identified based on exact mass. While analyte
identifications based on LC-TOF or UPLC-TOF are generally made based on a combination of
retention time and exact mass, qualitative data based solely on exact mass can be extracted postrun from data which has already been analyzed.
Over the past twenty years, the potential applications of mass spectrometry as a screening
tool have been investigated by many research groups. While the vast majority of methods have
utilized triple quadrupole technologies or hybrid tandem mass spectrometers, recent studies has
paved inroads into the use of alternate mass spectrometric methods requiring minimal sample
preparation and little, if any, chromatographic separation. Mass spectrometric techniques
requiring minimal sample preparation and no chromatographic separation will undoubtedly be
the subject of rigorous future research efforts as the potential to reduce analysis time and
increase the number of samples screened per unit time offers many advantages for high
throughput toxicology laboratories.
8.2.5 Principles of Desorption Electrospray Ionization (DESI)
Desorption electrospray ionization allows ambient sampling for mass spectrometric
analysis by using an electrospray of aqueous droplets which act to desorb analytes from a surface
of interest. Analyte leaves the surface of interest entrained in small, progeny droplets (solvated)
which subsequently evaporate resulting in analyte ion production. Desorbed gas-phase ions are
then transferred to a mass spectrometer through an atmospheric pressure ion-transfer tube[263].
DESI is a multistep process which is initiated by producing primary charged droplets through an
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electrospray source. Primary droplets are then projected toward the surface of interest where they
collide and produce smaller droplets through collision-induced breakup. Secondary charged
droplets, which are produced during this interaction, are then transported, along with ablated
materials and free ions, through an atmospheric pressure interface and into a mass spectrometer
(Figure 39)[295].
DESI eliminates the need to introduce the sample into a region of vacuum or an
inaccessible region closely coupled to a vacuum system meaning that the sample can be moved
continuously or reoriented in space while collecting mass spectral data[263]. As previously
mentioned, DESI experiments combine features of ESI with those of desorption ionization
methods such as MALDI. An electrospray emitter, similar to those employed in traditional ESI
experiments, is used to generate gas phase solvent ions, ionic clusters, and charged microdroplets
which are directed as the surface of the sample. Several kilovolts of electrical charge are applied
to the spray solution and pneumatic nebulization is used to assist with solvent desolvation.
Electrosprayed microdroplets of the aqueous spray solution, normally containing additives which
ensure maximal analyte ionization, act as projectiles and subsequently generate gas-phase ions
when directed at the surface of interest through electrostatic and pneumatically assisted
desorption mechanisms[263, 264]. The interaction of the spray with the surface of interest results
in the ionization of analytes present on the sample exterior.
Analyte ions are then transported from ambient pressure conditions into a standard
atmospheric pressure interface mass spectrometer[295]. The interrogating solution often consists
of a water-alcohol mixture but may be modified with reagents such as acids or bases to enhance
analyte ionization[295]. This spray solution is then electrohydrodynamically nebulized and
directed at the surface of interest[295]. Unlike electrospray ionization (ESI) where the sample is
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dissolved in the spray solvent, analytes to be analyzed using DESI are present in solid materials
or liquids which have been deposited onto suitable surfaces allowing for direct analysis without
the need for extensive sample preparation[295].
The DESI spray solvent is an extremely important variable which can significantly affect
the intensity and stability of analyte signal. Spray solvent composition requires careful
consideration during method development as analytes must be somewhat soluble in the spray and
its composition must be such that adequate droplet desorption can occur[296, 297]. Manicke and
coworkers investigated the effect of spray solvent composition on signal intensity and stability
by directing various sprays at a sample surface and monitoring the resultant ion current for the
molecular ion. The authors directly compared five spray solvents comprised of different
proportions of water and methanol[298]. The authors discovered that signal decay occurred more
slowly with time as the proportion of water in the spray solvent increased. The increased rate of
signal decay when using higher proportions of organic solvent can be attributed to the higher
solubility of the analyte in the spray. In the presence of increased methanol content, more analyte
is likely to be soluble in the spray leading to more efficient desorption from the surface and
maximum ion signal. Increased sample solubility in the methanol rich solvent leads to maximum
signal intensity at early time points with subsequent large decreases in signal due to depleted
analyte concentrations at the exterior of the sample[298]. Maximum signal intensities were not
significantly different for spray solvents consisting of 100% methanol, 75% methanol, and 50%
methanol suggesting that additional factor others than analyte solubility are responsible for
maximal desorption from the sample surface. This is in fact the case as increases in the organic
component of the spray causes changes in solvent properties which work to negate the effect of
increased analyte solubility. An example of these phenomena is the effect which increasing
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organic solvent has on spot size which represents the area of analyte that is sampled. As the
concentration of methanol increases, the spot size and therefore the area of analyte sampled
decreases due to the lower surface tension of the liquid. Experiments also indicate that when the
amount of water in the spray solvent exceeds 50% there is a significant decrease in the maximum
signal intensity. This is consistent with the theory that the analyte will be less soluble in the
aqueous spray, however, poor droplet desorption due to unfavorable viscosity may also
contribute to decreased signal intensity[298]. The authors conclude that a 1:1 methanol/water
(vol/vol) solution typically provided the best combination of signal intensity and stability for the
analytes of interest[298].
The exact composition of the solvent spray can be varied significantly depending on the
analytical application of the experiment. Spray solvents consisting of high water content are
often employed for MSn experiments which require more stable, longer lasting signal to
complete mass spectral data acquisition. Similarly, high contents of methanol may be
incorporated into the spray solvent for DESI experiments requiring high spatial resolution, such
as molecular imaging. Spray solvents with higher fractions of methanol are more suited to such
analyses as the high organic content reduces the spot size and provides greater spatial
resolution[298]. Physical characteristics of the spray have also been investigated using phase
Doppler anemometry (PDA) and experiments indicate that droplet sizes average 2-4 µm, and at a
distance of 2 mm from the spray source, velocities range between 100-200 ms-1[295, 297].
Venter and coworkers employed PDA for the purpose of determining the size and
velocities of droplets involved in DESI experiments to further understand the likely ionization
mechanisms behind the technique[295]. In contrast to desorption techniques which involve the
production and acceleration of particles in the vacuum region of a mass spectrometer, such
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massive cluster bombardment (MCI), droplet impact/secondary ion mass spectrometry (EDI),
and secondary ion mass spectrometry (SIMS), DESI occurs at atmospheric pressure. Ionization
mechanisms are therefore likely to be very different to vacuum techniques as fast moving
droplets will be slowed by aerodynamic drag forces due to their interaction with surrounding gas
molecules[295]. It is for this same reason that DESI if finding an increasing number of
applications in the forensic and clinical toxicology laboratory.
Samples analyzed by DESI are done so in the open environment of the laboratory which
enables easy access during analysis for manipulation or higher throughput. Samples are also
analyzed directly with little to no sample preparation, further alleviating problems associated
with sample preparation for traditional instrumental analysis. While investigating the physical
properties of droplets generated in DESI experiments, Venter and coworkers note that the kinetic
energies per impacting water molecule are quite low and indicate that sputtering through
momentum transfer during collisions or ionization via alternate electronic processes is
unlikely[295]. The authors evaluate the validity of several proposed ionization mechanisms
including droplet pick-up, chemical sputtering, evaporation followed by gas-phase ionization,
and shockwave ionization by measuring the size and velocities of both inbound electrosprayed
droplets and droplets leaving the sample exterior. Experimental evidence acquired throughout the
study indicates that the droplet pick-up model may be the major process leading to the ionization
of analytes during DESI experiments. The droplet pick-up model is believed to take place during
the brief contact time that exists when impinging droplets collide with the sample surfaces and
analytes are extracted into the departing droplet or droplet fragments. Following the salvation of
condensed phase analytes by impinging droplets, typical electrospray ionization processes are
thought to occur[295].
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The DESI ion source is comprised of two main parts, the sprayer assembly and the
surface assembly which are both mounted on the base of the ion source (Figure 43).
Center of MS orifice
Sprayer tip

Figure 43: Schematic representation of the DESI ion source illustrating geometric parameters α
(incident angle), β (collection angle), d1 (tip-to-surface distance), and d2 (MS inlet-to-surface
distance) (Adapted from Takats et al. 2005).

The sprayer is mounted to, and controlled from, a vertical rotating stage which is mounted onto a
three dimensional linear moving stage. Linear motion is used to modify the sprayer-to-MS or
sprayer-to-surface distance and to compensate for the different angles at which the sprayer is
used[264].
Parameters associated with the geometry of the ion source, the solvent spray, and the
sample surface, all affect the analytical performance of DESI and each require consideration and
optimization during method development. Of greatest importance are the geometric parameters
(α, β, d1, d2; Fig 45), gas and liquid flow rates, voltages, solvent composition, deposition solvent,
and surface composition, temperature, and potential[264]. The geometric parameters, α, and d1
have a direct effect on the efficiency of the ionization process, while parameters, β and d2 have
important effects of the collection efficiency, and therefore the sensitivity of the method. Cooks
and coworkers indicate that the optimal settings for β and d2 are generally 5-10° and 0-2 mm,
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respectively[264]. Generally, low d1 values are preferred and are normally combined with large α
values, although a dramatic increase in chemical noise is observed when α exceed 80°[264].
The design of DESI instruments is complicated by the challenge of providing efficient
ion transfer from the ion source to the fore vacuum region of the mass spectrometer without
modifying the pumping capacity of the vacuum system[264]. Metal capillaries are most widely
employed for the transfer of ions to the mass spectrometer as capillaries containing insulators can
experience significant charge buildup on the inner surface resulting in poor ion transmission.
While metal capillaries do not experience this same phenomenon, extensive neutralization of
analyte ions can occur which leads to poor transmission efficiencies.
Spectral characteristics of DESI are very similar to those of ESI in that spectra feature
multiply charged ions, adducts, complexes, and abundant protonated molecular ions. Strong
similarities between the two techniques are attributed to the similarities in the latter stages of ion
formation. The drop pick-up ionization mechanism thought to occur in DESI experiments
assumes that following analyte solvation by impinging droplets, analyte is incorporated into
droplets and ionization occurs via traditional ESI mechanisms involving analyte-containing
charged droplets[264].
8.3

Experimental

8.3.1

Chemicals and Reagents
All drug standards and deuterated internal standards (1mg/mL in methanol) were

obtained from Cerilliant (Round Rock, TX). ISOLUTE® HM-N supported liquid-liquid
extraction columns were purchased from Biotage (Charlottesville, VA). All solvents were HPLC
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grade and obtained from Fisher Scientific (Pittsburgh PA). All DESI experiments were
performed using Omni Slides™ from Prosolia (Indianapolis, IN).
8.3.2

Electrospray Solvent Preparation
The spray solvent used for all experiments was an acetonitrile/water (80:20) mixture

containing 0.1% (v/v) formic acid.
8.3.3 DESI Source and Mass Spectrometry Conditions
All experiments were performed on the Thermo TSQ Quantum Discovery MAX triple
quadrupole mass spectrometer equipped with the Omni Spray® ion source (Prosolia, Inc.,
Indianapolis, IN). Omni Spray® ion source operating parameters were as follows: Nitrogen was
used as the nebulizing gas and was applied to the spray head at a regulated pressure of 125 psi.
The solvent was sprayed under the influence of 5 kV at a flow rate of 5 µL/min. The gas jet was
composed of electrosprayed aqueous microdroplets, and free gas-phase ions were directed onto
the surface at an incident angle of 55° to the normal. The vertical distance from the end of the
solvent capillary to the top of the disposable surface was 2 mm. The inlet of the mass
spectrometer was maintained at a temperature of 300°C. Total analysis time for each sample was
approximately 13 seconds with a surface scan rate of 200 µm/s.
8.3.4

Sample Preparation
All samples were spotted directly onto Omni Slides™ using a 2µL Eppendorf pipette.

Samples were left to dry under ambient conditions and analyzed directly using the DESI source.
8.3.5

DESI Analysis of Standards
Preliminary DESI experiments involved the analysis of amphetamine, methamphetamine,

cocaine, benzoylecgonine, morphine, codeine, and hydromorphone standards (1mg/mL in
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methanol) for the purpose of developing and optimizing mass spectrometric conditions. The
DESI-MS/MS instrument used for all experiments is analogous to the triple quadrupole
instrument described previously except that the electrospray ionization source is replaced by the
DESI source which allows for ambient sampling. Precursor ions for MRM experiments are first
generated by the DESI source before entering the vacuum region of the triple quadrupole mass
spectrometer where they undergo collision induced dissociation in Q2 while Q1 and Q3 are used
as mass filters. In order to develop and optimize the MS/MS method, drug standards (1mg/mL in
methanol) were spotted onto Omni Slides™ and analyzed directly. These preliminary studies are
analogous to infusion experiments using the ESI-MS/MS in which the collision gas is turned off
to allow the precursor ions generated by the DESI source to reach the detector and produce a
recordable signal. Precursor ions for all seven analytes were protonated molecular ions generated
by the soft DESI technique (Table 55).
Following identification of the molecular ion signal, an auto tune was completed for each
analyte which involved adjusting collision energies to maximize the signal for the product ions
generated in the collision cell. The mass transition from the protonated molecular ion [M+H]+ to
the most abundant product ion was designated the qualifying ion transition and was used for all
positive identifications (Table 55). Following auto tuning of each analyte, the optimized
parameters were used to construct the MS/MS method which was then used to acquire data in the
MRM mode. Table 55 reports the mass transitions, collision energies and tube lens voltages for
each of the seven analytes.
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Table 55: Optimized MS/MS parameter employed for all DESI experiments.
Analyte
Parent mass (m/z) Product ion (m/z) Collision energy (V) Tube lens (V)
Amphetamine

136

91

26

82

Methamphetamine

150

91

22

81

Cocaine

304

182

30

128

Benzoylecgonine

290

168

79

118

Codeine

300

165

30

128

Morphine

286

152

20

124

Hydromorphone

286

185

24

134

Figure 44 shows the mass spectral responses for all seven analytes which were spotted in
consecutive channels of the Omni Slide™.
RT: 0.00 - 1.68 SM: 3G
RT: 0.18
AA: 1192767
100

Amphetamine
RT: 0.48
AA: 24407

50
0
100
50

RT: 0.09
AA: 19944
RT: 0.20
AA: 291026

RT: 0.40
AA: 880377

Relative Abundance

Methamphetamine

0

RT: 1.35
AA: 157797 RT: 1.53
AA: 37470

RT: 0.91
AA: 105728

RT: 1.01
RT: 1.16
RT: 1.34
AA: 65086 AA: 195553 AA: 344194
RT: 0.90
AA: 17385562

RT: 0.20
AA: 28973

RT: 0.39
AA: 66107

NL: 2.45E6
TIC F: + c NSI SRM ms2
290.000 [163.000-173.000]
MS ICIS 062308-standards 1

RT: 1.21
RT: 1.35
AA: 14894 AA: 104058
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Figure 44: Mass spectral responses for all seven analytes using DESI-MS/MS.
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In order to determine the suitability of the DESI-MS/MS method for the analysis of authentic
meconium specimens, several spiked samples were prepared and analyzed.
8.3.6

Direct Analysis of Spiked Meconium Specimens
Several meconium specimens which had undergone no sample preparation other than the

initial homogenization step were spiked with appropriate analytes and analyzed directly using the
DESI-MS/MS method. Experiments aimed to investigate the suitability of the DESI-MS/MS
method for the direct analysis of meconium specimens having undergone minimal sample
preparation.
8.3.7

Sample Preparation
Meconium specimens which had previously screened negative at AIT Laboratories

(Indianapolis, IN) were spiked with varying amounts of analyte to give concentrations
corresponding to the top point of calibration curves used in previous ESI-MS/MS experiments
(Table 56). Concentrations were chosen arbitrarily for the purpose of evaluating the sensitivity of
the DESI-MS/MS methodology. Prior to spiking, sample preparation of the meconium
specimens was limited to the initial homogenization process required for immunoassay
screening. Analytes of interest were then spiked directly into the homogenate at appropriate
concentrations (Table 56).
Table 56: Analyte concentrations chosen for initial DESI-MS/MS experiments.
Sample
Analytes
Concentration (ng/mL)
1
morphine, codeine, hydromorphone
500
2
amphetamine, methamphetamine
500
3
cocaine, benzoylecgonine
250
4
blank
n/a
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Negative meconium specimens (1 mL) were spiked with appropriate volumes of analyte,
vortexed and spotted directly onto Omni Slides™. Samples were left to dry under ambient
conditions and analyzed directly.
8.3.8 Preliminary Results
Extremely poor analyte signals were observed for all analytes prepared in the blank
meconium matrix and analyzed directly (Figure 45).
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Figure 45: Analyte signals following direct analysis of spiked meconium samples.

Preliminary experiments were aimed at evaluating the usefulness of DESI-MS/MS for the
purpose of screening meconium specimens which had undergone little to no sample pre226

treatment. While the use of mass spectrometry for screening offers several advantages over
traditional techniques, sample pre-treatment must be kept minimal in order for the technique to
prove both time and cost effective. Poor signal intensities (Figure 45) indicated that significant
matrix effects were likely suppressing mass spectral signal and that further sample clean up
would be required to achieve the desired screening sensitivity. In order to evaluate the matrix
effect on signal intensity, DESI spectra of neat drug standards were directly compared to samples
prepared in blank meconium (Figures 46-48) at the same concentration. Experiments were
performed by directly spotting neat drug standards on the first four channels of the Omni Slide™
and the meconium matrix containing the same concentration of analyte on the last four channels.
By comparing analyte signal intensities from the neat drug standards relative to the spiked
meconium specimens, the degree of signal suppression due to matrix effects was more apparent.
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Figure 46: Effect of meconium matrix on morphine, hydromorphone, and codeine signal. Mass
spectral signals for neat drug standards prepared at 500 ng/mL can be seen in channels 1-4 while
analyte signals for spiked meconium standards containing 500 ng/mL of each analyte can be seen
in channels 5-8.
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Figure 47: Effect of meconium matrix on amphetamine and methamphetamine signal. Mass
spectral signals for neat drug standards prepared at 200 ng/mL can be seen in channels 1-4 while
analyte signals for spiked meconium standards containing 200 ng/mL of each analyte can be seen
in channels 5-8.
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Figure 48: Effect of meconium matrix on cocaine and benzoylecgonine signal. Mass spectral
signals for neat drug standards prepared at 200 ng/mL can be seen in channels 1-4 while analyte
signals for spiked meconium standards containing 200 ng/mL of each analyte can be seen in
channels 5-8.

Figures 46-48 clearly illustrate the effect of the complex meconium matrix on the analyte
signal. While signal intensities were reasonable for all analytes sampled as dilute drug standards,
signals all but diminished when analytes were sampled at the same concentrations in the
meconium matrix. The negative effect of the meconium matrix on analyte signal intensity meant
that additional sample preparation/cleanup was required to achieve the desired screening
sensitivity. Multiple sample preparation techniques were investigated in the hope that mass
spectral responses for all analytes could be significantly enhanced without the need for extensive
sample preparation.
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8.3.9

Meconium Sample Preparation Method #1
Meconium specimens employed for all DESI-MS/MS experiments were accurately

weighed and diluted by a factor of 3 (w/v) with 50:50 methanol/water to assist with the
sonication procedure required for immunoassay screening. In an attempt to clean up the sample
and increase sensitivity by eliminating some of the matrix effects, the following sample
preparation procedure was applied to blank meconium specimens that had been spiked with
appropriate analytes:
1. Combine 1 mL of the meconium homogenate with 2 mL of cold acetonitrile
2. Vortex sample for 45 seconds
3. Centrifuge sample for 2 minutes at 3000 rpm
4. Transfer 500 µL of the organic layer to clean test tube and evaporate to dryness
5. Reconstitute in 50µL of ACN and spot 2µL directly onto Omni Slide™ for analysis
Following sample preparation, reconstituted samples were directly spotted onto the surface of the
Omni Slide™. Resulting analyte signals for the amphetamines and cocaine derivatives can be
seen in Figures 49 and 50.
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Figure 49: DESI-MS/MS signal for the amphetamines following limited sample preparation
according to sample preparation method #1.
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Cocaine

Benzoylecgonine

Figure 50: DESI-MS/MS signal for cocaine and benzoylecgonine following limited sample
preparation.

Signal intensities for both amphetamine and methamphetamine were only marginally enhanced
following the additional sample cleanup (Figure 49). The combination of precipitating out many
of the endogenous proteins and concentrating the sample by drying down appears to have
eliminated some of the matrix components responsible for signal suppression and slightly
increased sensitivity. While the additional sample cleanup appears to slightly increase the mass
spectral response for both analytes, the signal to noise (S/N) ratio is still very low making
identification of the sample spots very difficult (Figure 49). The added step of concentrating the
analyte has obvious advantages with regard to sensitivity, however, the process of drying down
and reconstituting can be time consuming and laborious and must be kept minimal, if not
completely eliminated, during screening procedures. Introducing such steps into screening
procedures greatly reduces the efficiency of the screen by increasing time and labor costs
233

associated with sample preparation. Screening techniques should provide accurate, qualitative
information without the need for extensive sample preparation.
Although signal intensities for benzoylecgonine remained very poor (Figure 50), the
additional sample clean up appears to have significantly enhanced the DESI-MS/MS response
for cocaine. While sensitivity has long been recognized as a downfall associated with ambient
pressure ionization techniques, preliminary data reveals yet another complicating factor which
needs to be addressed when developing and optimizing experimental protocols for DESI. Figures
49 and 50 clearly illustrate the potential for sample redistribution leading to a continuous analyte
response over the entire surface of the Omni Slide™. If sample spots remained confined to the
sample wells on the surface of the Omni Slide™ a distinct number of analyte responses
corresponding to the number of spotted samples would be observed. The continuous analyte
response seen in Figure 50 indicates that the meconium matrix may be susceptible to
redistribution on the surface of the Omni Slide™ leading to indistinguishable sample spectra.
During initial experiments involving the Omni Slides™, it was repeatedly noted that
samples prepared in the meconium matrix did not adhere very well to the surface of the slide.
This observation provides a likely explanation for the sample redistribution seen in Figure 50.
When meconium based samples are spotted onto the Omni Slide™, they redistribute outside the
boundaries of the sample channel. In addition to this phenomenon, spray solvents tend to
dissolve on the surface on Omni Slides™ causing further sample redistribution which can lead to
cross contamination from one sample channel to the next.
Poor signal intensities were again observed for codeine, morphine, and hydromorphone
even following additional sample cleanup. This factor, combined with the significant signal
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enhancements noticed for amphetamine, methamphetamine, and cocaine following identical
sample cleanup, suggest that the poor sensitivities associated with several morphine derivatives
may be due to limitations of the ionization process itself rather than matrix components causing
suppression.
Interestingly, sample redistribution leading to indistinguishable analyte responses did not
appear to be in issue during the analysis of drugs standards prepared in methanol (Figure 44).
This observation suggests that a more efficient sample preparation capable of removing
additional matrix components may reduce the extent of sample redistribution on the hydrophobic
surface of the Omni Slide™ which can lead to contamination in surrounding sample channels.
Various techniques for reducing the degree of sample redistribution require investigation,
however, significant enhancements in sensitivity need first be achieved before the DESI-MS/MS
methodology can be considered useful for any practical screening applications. Meconium
sample preparation method #2 was developed for the purpose of increasing sensitivity and
possibly reducing the degree of sample redistribution.
8.3.10 Meconium Sample Preparation Method #2
Preliminary experiments indicate that the removal of complex matrix components
causing signal suppression will not only increase sensitivity for all analytes but may also
decrease sample redistribution on the hydrophobic surface of the Omni Slide™ which can lead to
sample redistribution and indistinguishable analyte responses. In order to evaluate the use of an
additional filtration step for sample cleanup, sample preparation method #2 was investigated. In
addition to the protein crash employing cold acetonitrile it was hoped that by filtering the organic
phase through 0.1µm Durapore PVDF filter units, additional sample cleanup would be achieved
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leading to greater signal intensities and less sample redistribution. Samples were prepared as
follows:
1. Combine 1 mL of the meconium homogenate with 2 mL of cold acetonitrile
2. Vortex sample for 45 seconds
3. Centrifuge sample for 2 minutes at 3000 rpm
4. Filter organic layer through Durapore PVDF 0.1µm filter units
5. Spot 2 µL directly onto Omni Slide™ for analysis
Four sample spots of meconium matrix prepared according to meconium sample preparation
method #2 were analyzed directly adjacent to neat drug standards (positive control) prepared at
appropriate concentrations. Positive quality control (QC) specimens had been prepared by
diluting neat drug standards (1 mg/mL in methanol) to appropriate screening concentrations.
Experiment were designed to evaluate the usefulness of analyzing positive controls prior to
scanning authentic patient samples for the purpose of identifying true positive samples through
direct comparison of analyte responses. Samples were spotted onto the Omni Slides™ according
to Figure 51.

Figure 51: Previously prepared positive quality control (QC) samples were spotted in the first
two sample channels to assist with identifying positive authentic samples spotted in channels 3-6.
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Figure 52 illustrates the analyte responses for a cocaine/benzoylecgonine quality control
standard prepared at 50 ng/mL spotted in channels 1-2 and analyte responses for a blank
meconium specimen spiked with cocaine and benzoylecgonine at a concentration of 250 ng/mL
and spotted in sample channels 3-6. All positive quality control standards were prepared from
neat drug standards (1 mg/mL in methanol) through serial dilutions.
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Figure 52: Sample channels 1-2 represent analyte responses for a cocaine and benzoylecgonine
quality control (QC) standard (50 ng/mL) while sample channels 3-6 were spotted with spiked
meconium samples (250 ng/mL).

Cocaine and benzoylecgonine signals appear to have been significantly enhanced using the
additional filtration step described in sample preparation method #2. The filtration removal of
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endogenous compounds in the meconium matrix has greatly enhanced the benzoylecgonine
signal which was undetectable using sample preparation method #1. While the non-linear
response between the quality control standard (50 ng/mL) and the spiked meconium (250 ng/mL)
indicates that there is still some degree of signal suppression, the additional filtration step
appears to have reduced this effect and enhanced overall sensitivity. The additional preparation
step has also appears to have reduced the degree of sample redistribution. This is evident by the
distinct analyte responses corresponding to individual sample spots on the surface of the Omni
Slide™.
Figure 53 shows the mass spectral response of a cocaine/benzoylecgonine positive
control prepared at 50 ng/mL and spotted in channels 1-3 and analyte responses for a blank
meconium specimen spotted in channels 4-6.
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Figure 53: Mass spectral responses for a cocaine/benzoylecgonine positive control (50 ng/mL) in
channels 1-3 and analyte responses for a blank meconium specimen spotted in channels 4-6.

Blank meconium specimens spotted in channels 4-6 were negative for cocaine and
benzoylecgonine when scanned using the 2 MRM transition MS/MS method.
Figure 54 shows the mass spectral response of an amphetamine/methamphetamine
positive control sample prepared at a concentration of 50 ng/mL and spotted in channels 1-2 and
analyte responses for a meconium specimen spiked with amphetamine and methamphetamine at
a concentration of 500 ng/mL and spotted in channels 3-6.
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Figure 54: Mass spectral response of an amphetamine/methamphetamine positive control sample
(50 ng/mL) spotted in channels 1-2 and analyte responses for a meconium specimen spiked with
amphetamine and methamphetamine (500 ng/mL) in channels 3-6.

Meconium sample preparation method #2 also enhanced the mass spectral response for
amphetamine and methamphetamine in the meconium matrix (Figure 54). While both analytes
were detected in the meconium matrix using the initial sample preparation method, sensitivities
were poor and appear to have been greatly enhanced with the additional filtration step. The S/N
ratio has been increased using sample preparation method #2 and the amphetamine signals are
now more clearly distinguished from background noise. Distinct analyte signals for amphetamine
and methamphetamine are also seen in Figure 54 indicating that sample redistribution has been
minimized/eliminated using the new preparation method. Although analyte signals are
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significantly enhanced following the additional filtration step, direct comparison of the signals
from the 50 ng/mL quality control and the 500 ng/mL spiked sample indicate that matrix effects
still exist.
Figure 55 shows the mass spectral signals for an amphetamine/methamphetamine
positive control (50 ng/mL) spotted in sample channels 1-2 and analyte responses for a blank
meconium specimen prepared according to sample preparation method #2 and spotted in
channels 3-6.
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Figure 55: Mass spectral response of an amphetamine/methamphetamine positive control sample
(50 ng/mL) spotted in channels 1-2 and analyte responses for a blank meconium specimen
spotted in channels 3-6.
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Blank meconium specimens spotted in sample channels 3-6 did not generate any
appreciable analyte response for either amphetamine or methamphetamine (Figure 55).
Figure 56 shows the mass spectral response for an opiate positive control specimen (500
ng/mL) spotted in sample channels 1-2 and analyte responses for a blank meconium specimen
spiked with morphine, codeine, and hydromorphone at a concentration of 500 ng/mL.
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Figure 56: Mass spectral response of an opiate positive control sample (500ng/mL) spotted in
channels 1-2 and analyte responses for a meconium specimen spiked with opiates (500 ng/mL)
and spotted in channels 3-6.

Extremely poor analyte signals were again observed for all opiate analytes in both the spiked
meconium specimen and the positive quality control specimen. Poor analyte signals observed for
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the 500 ng/mL neat drug standard supported earlier hypotheses that chemical properties of the
opiates combined with DESI mechanisms may be responsible for the low analyte signals as
opposed to matrix effects. While evidence of matrix suppression does exist, the inferior
sensitivity of the opiates relative to the amphetamine and cocaine derivatives suggests that the
morphine derivatives may not readily lend themselves to DESI, leading to inefficient ion
formation. Efficient extraction and desorption of the analyte from the surface of interest is vital
for any DESI experiment. Without efficient extraction and desorption from the surface, analyte
ionization will be limited leading to decreased sensitivities. Studies indicate that efficient
recovery of opiate derivatives from the meconium matrix may not be feasible using DESI.
Although signal intensities were consistently poor for all opiate derivatives, significant
signal enhancement for the amphetamine and cocaine derivatives indicated that the sample
filtration step reduced signal suppression and increased overall sensitivity. In order to evaluate
the increased sensitivity afforded by filtering the organic phase, meconium specimens were
prepared with and without the filtration step and analyzed side by side. Positive quality control
specimens prepared through serial dilutions of neat drug standards were again analyzed prior to
authentic specimens to assist with positive identifications. All positive quality control specimens
were spotted in sample channel 2 while channels 1 and 3 were left empty. Meconium samples
prepared using sample preparation method #1 were spotted in sample channels 4-6 and
meconium samples prepared using the additional filtration step described in sample preparation
method #2 were spotted in sample channels 7-9. Figure 57 shows the mass spectral responses of
amphetamine and methamphetamine standards (a-b) as well as benzoylecgonine and cocaine
standards (c-d) which were spotted in channel 2. Channels 4-6 were spotted with meconium
which had been spiked with amphetamine and methamphetamine and prepared according to
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sample preparation method #1. Channels 7-9 were spotted with meconium which had been
spiked with amphetamine and methamphetamine and prepared according to sample preparation
method #2. The MS/MS method consisted of four MRM transitions, one for each of the analytes.
Side by side analyses were performed to determine the extent to which the additional filtration
step increases overall sensitivity.
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Figure 57: Mass spectral responses of amphetamine and methamphetamine standards (a-b) as
well as benzoylecgonine and cocaine standards (c-d) spotted in channel 2. Mass spectral
responses in channels 4-6 represent meconium samples which had been spiked with
amphetamine and methamphetamine (500 ng/mL) and prepared according to sample preparation
method #1. Mass spectral responses in channels 7-9 represent meconium specimens which had
been spiked with amphetamine and methamphetamine (500 ng/mL) and prepared according to
sample preparation method #2.
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Both the amphetamine and cocaine positive quality control specimens were prepared at a
concentration of 25 ng/mL. Rows a-b in Figure 57 show the mass spectral responses for the
positive quality control specimen (sample channel 2) and a meconium specimen spiked with
amphetamine and methamphetamine at a concentration of 500 ng/mL (channels 4-9). Samples
spotted in channels 7-9 had undergone additional filtration to remove matrix components
responsible for signal suppression. Only a small increase in signal intensity is seen for the
filtered samples indicating that the time expended performing the filtration step may not provide
significant increases in sensitivity to warrant its inclusion in the method.
In an attempt to further enhance sensitivity, the mass spectrometry method was separated
into two separate methods each containing 2 MRM transitions. By separating the mass spectral
method into two components, each consisting of 2 MRM transitions, it was hoped that dwell
time, and therefore sensitivity, could be maximized. The MS/MS method was divided into two
separate methods, one containing the MRM transitions for amphetamine and methamphetamine,
the other containing MRM transitions for cocaine and benzoylecgonine. Meconium specimens
which had been spiked with amphetamine and methamphetamine were first analyzed using the
combined MS/MS method (Figure 57) and then using the specific
amphetamine/methamphetamine method (Figure 58). Specimens which had been spiked with
cocaine and benzoylecgonine were first analyzed using the combined MS/MS method (Figure
59) and then using the specific cocaine/BE method (Figure 60). It was hoped that by reducing the
number of MRM transitions within each mass spectral method, improvements in sensitivity
would be observed. Any gains in sensitivity would obviously come at the cost of analysis time,
as samples would require analysis by two specific mass spectral methods as opposed to one
combined method containing all four MRM transitions.
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Figure 58: Mass spectral responses for amphetamine and methamphetamine with the
amphetamine/methamphetamine specific MS/MS method containing 2 MRM transitions. Sample
channel 2 contains a positive quality control specimen prepared at 25 ng/mL. Sample channels 46 contain meconium matrix spiked with amphetamine and methamphetamine (500 ng/mL) and
prepared according to sample preparation method #1. Sample channels 7-9 contain meconium
matrix spiked with amphetamine and methamphetamine (500 ng/mL) and prepared according to
sample preparation method #2.

Figure 59 shows the mass spectral responses for amphetamine and methamphetamine in both the
positive quality control specimen and the spiked meconium matrix. Mass spectral responses were
obtained using the amphetamine specific MS/MS method containing one MRM transition for
each analyte. Small improvements in signal intensities were observed for amphetamine and
methamphetamine when scanning with the 2 MRM transition method.

246

R T: 0 .0 0 - 3 .0 0

S M : 7G

1 2 3 4 5RMT:A6:057.40 6888 39

100

N L : 8 .5 2 E 3
TIC F : + c N S I S R M
m s 2 1 3 6 .0 0 0
[9 0 .9 5 0 -9 1 .0 5 0 ] M S
0 9 2 2 0 8 m e rc o nium
ne g s p l 2 a

a) Amp

0 .5 7

80
0 .4 2

60
40
20

0 .1 4

Relative Abundance

0 .4 6

100

0 .9 6

0 .7 2

0 .3 4

0

1 .1 5

1 .4 4

1 .5 1

1 .6 5
1 .7 1

1 .9 8 2 .1 0 2 .1 9

2 .3 9

2 .6 9 2 .7 3

2 .9 0

R T: 0 .5 7
M A : 62253

N L : 6 .9 3 E 3
TIC F : + c N S I S R M
m s 2 1 5 0 .0 0 0
[9 0 .9 5 0 -9 1 .0 5 0 ] M S
0 9 2 2 0 8 m e rc o nium
ne g s p l 2 a

b) Mamp

80
60

2 .9 0

40
0 .1 4

20

0 .6 4

0 .3 3

0

0 .7 1

1 .0 1

1 .2 6

1 .3 9

1 .6 4
1 .7 9

2 .1 1

2 .4 1

2 .1 9

2 .6 1

2 .7 7
N L : 1 .5 6 E 4
TIC F : + c N S I S R M
m s 2 2 9 0 .0 0 0
[1 6 7 .9 5 0 -1 6 8 .0 5 0 ]
M S 092208
m e rc o nium ne g s p l 2 a

R T: 0 .4 3
M A : 30924

100

c) BE

80
60

R T: 1 .1 9
A A : 8984

40
20

0 .5 5
0 .0 9

0

0 .3 2

0 .7 2

0 .7 9

R T: 1 .5 2
M A : 4854
1 .4 5

1 .0 7

R T: 2 .3 9
M A : 15307
R T: 1 .8 0
M A : 2314

R T: 2 .1 1
A A : 780

2 .6 6

R T: 2 .3 7
M A : 67746

100
80

R T: 2 .7 3
M A : 7947
2 .7 9
R T: 2 .7 3
A A : 78834

R T: 0 .5 8
M A : 87422

60
40

0 .4 4

20
0 .0 9

0
0 .0

0 .1 8
0 .2

0 .7 2
0 .4

0 .6

R T: 1 .1 9
R T: 1 .0 2 M A : 2 4 2 5 8
AA : 719

0 .8

1 .0

1 .2

R T: 1 .4 5
A A : 23936

R T: 1 .7 3
M A : 4173

1 .4
1 .6
Tim e (m in)

1 .8

R T: 2 .1 2
M A : 17516
2 .4 8

2 .0 4

2 .1 5

2 .0

2 .2

2 .4

N L : 3 .8 1 E 4
TIC F : + c N S I S R M
m s 2 3 0 4 .0 0 0
[1 8 1 .9 5 0 -1 8 2 .0 5 0 ]
M S 092208
m e rc o nium ne g s p l 2 a

d) Cocaine

2 .7 8
2 .6 5
2 .6

2 .9 0
2 .8

3 .0

Figure 59: Mass spectral responses of amphetamine and methamphetamine standards (a-b) as
well as benzoylecgonine and cocaine standards (c-d) spotted in channel 2. Mass spectral
responses in channels 4-6 represent meconium samples which had been spiked with cocaine and
benzoylecgonine (250 ng/mL) and prepared according to sample preparation method #1. Mass
spectral responses in channels 7-9 represent meconium specimens which had been spiked with
cocaine and benzoylecgonine (250 ng/mL) and prepared according to sample preparation method
#2.

While mass spectral responses for cocaine and benzoylecgonine in the meconium matrix
(sample channels 4-9) were relatively low in intensity, significant signal enhancement was
observed for specimens which had been filtered through Durapore PVDF 0.1µm filter units
(sample channels 7-9). Figure 59 indicates that filtration of the acetonitrile layer following
protein precipitation may aid in the removal of endogenous compounds responsible for the
suppression of cocaine and benzoylecgonine signals. Filtration of the organic layer did not
appear to enhance the amphetamine/methamphetamine signal to the same degree, however, small
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increases in the cocaine/BE signals were more easily observed due to the complete absence of
signal in unfiltered samples.
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Figure 60: Mass spectral responses of benzoylecgonine and cocaine standards (a-b) spotted in
channel 2. Mass spectral responses in channels 4-6 represent unfiltered meconium samples
which had been spiked with cocaine and benzoylecgonine and analyzed using the cocaine/BE
specific MS/MS method consisting of one MRM transition for each analyte. Mass spectral
responses in sample channels 7-9 represent filtered meconium specimens analyzed by the same
method.

The increased mass spectral responses observed in Figure 60 for cocaine and
benzoylecgonine indicate that better sensitivities may be afforded by the 2 MRM transition
method. Further studies into the extent of this signal enhancement are required to evaluate the
suitability of employing multiple mass spectral methods when scanning authentic samples. While
reducing the number of transitions in a mass spectral method allows for longer dwell times and
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greater sensitivity, separating a comprehensive MS/MS method into multiple methods containing
fewer MRM transitions can be both time and cost ineffective. If a specimen is to be screened for
the presence of amphetamines and cocaine, analysis time will be minimized using a mass
spectral method that simultaneously screens for both drug classes. Separating this comprehensive
method into two separate MS/MS methods would allow for slightly greater sensitivities, but
would also mean that samples would need to be analyzed twice, once for each method. This
would have obvious drawbacks in high throughput toxicology laboratories as analysis time
would be essentially doubled. The advantage of scanning each sample spot twice would be the
increase in sensitivity afforded by the MS/MS method comprising fewer MRM transitions.
Detailed experiments aimed at evaluating the disadvantages of increased analysis time
versus the advantages of increases sensitivities must be performed before conclusions can be
drawn. The analysis of dilute drug standards prior to authentic patient samples appears to
significantly aid in the identification of true positives. Due to the complex nature of the
meconium specimens, low level background signal is often observed when analyzing blank
specimens. Differentiating between background signal attributable to endogenous matrix
components and true positive samples can be difficult without the use of a positive quality
control specimen to act as a reference. By analyzing positive quality control specimens prepared
at appropriate concentrations prior to authentic patient samples, it is hoped that low level
background signal will be easily distinguished from authentic analyte responses.
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8.4

Qualitative Determination of Amphetamine, Methamphetamine, Cocaine, and

Benzoylecgonine in Authentic Meconium Specimens using DESI-MS/MS.
In order to evaluate the usefulness of DESI-MS/MS for screening authentic meconium
specimens for drugs of abuse, direct comparative studies were performed with existing
immunoassay techniques. While preliminary experiments involving spiked meconium specimens
are satisfactory for ‘proof of concept’ studies, no insight into the overall applicability of the
method can be gained until it is applied to authentic samples.
8.4.1

Experimental Design
Authentic meconium specimens (n=21) which had previously screened positive at AIT

Laboratories (Indianapolis, IN) for amphetamine and/or cocaine were selected for the studies
aimed at directly comparing the screening accuracy of DESI-MS/MS to the pre-existing
immunoassay technique. Immunoassay screening results are shown in Table 57. All specimens
chosen for this study were leftover from routine analysis performed at AIT Laboratories.
Samples were selected based solely on initial screening results and were given arbitrary
identification numbers to ensure that all samples were blinded and could not be connected to
individuals at any point during the investigation.
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Table 57: Immunoassay screening results for experimental specimens.
Specimen #
Amphetamine screen (ELISA)
Cocaine/BE screen (ELISA)
1

Positive

Negative

2

Positive

Negative

3

Negative

Positive

4

Negative

Positive

5

Positive

Negative

6

Negative

Positive

7

Positive

Negative

8

Negative

Positive

9

Negative

Positive

10

Negative

Positive

11

Negative

Positive

12

Positive

Negative

13

Negative

Positive

14

Positive

Negative

15

Negative

Positive

16

Positive

Negative

17

Negative

Positive

18

Positive

Negative

19

Positive

Positive

20

Positive

Positive

21

Negative

Positive

Ten specimens screened positive for amphetamines using the immunoassay screening
technique while thirteen of the meconium specimens screened positive for
cocaine/benzoylecgonine (Table 57). All specimens (n=21) were then screened using the DESIMS/MS methodology.
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8.4.2

Sample Preparation for DESI-MS/MS Screening Experiments
Sample preparation for DESI-MS/MS screening was as follows:
1. Combine 1 mL of the meconium homogenate with 2 mL of cold acetonitrile
2. Vortex sample for 45 seconds
3. Centrifuge sample for 2 minutes at 3000 rpm
4. Filter organic layer through Durapore PVDF 0.1µm filter units
5. Transfer and spot 1.5 µL of the acetonitrile phase directly onto the Omni Slide™

By eliminating the dry down and reconstitution steps, sample preparation was significantly
reduced. Following sample preparation, samples were spotted onto the Omni Slides™ according
to the Figure 61.

Figure 61: Positive quality control specimens were spotted in channel 2 and analyzed first to aid
with positive identifications. Authentic meconium specimens were then spotted in every second
sample channel to reduce the possibility of sample redistribution.
8.4.3

Preparation of Positive Quality Control Specimens
Positive quality control specimens were again employed for the purpose of aiding in

positive identifications. In order to more accurately compare analyte signals from positive
quality control specimens to authentic patient specimens, all positive controls were prepared in
blank meconium and subjected to the same sample preparation as authentic specimens.
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Preparation of the amphetamine positive control involved spiking the blank meconium matrix
with amphetamine and methamphetamine at concentrations of 25 ng/mL. Similarly, the cocaine
positive control was prepared by spiking the blank meconium matrix with cocaine and
benzoylecgonine at a concentration of 25 ng/mL. By subjecting the positive controls to the same
sample preparation as authentic specimens, resulting analyte signals of positive controls will
more accurately reflect drug concentrations in patient samples. While unextracted drug standards
used in previous experiments were suitable for differentiating an analyte response from
background noise, extracted positive QC standards prepared in the meconium matrix will
provide more accurate indications as to the presence or absence of a drug in the matrix.
8.4.4 DESI-MS/MS Parameters
All DESI source and mass spectrometric parameters were identical to those described in
sections 8.3.1 – 8.3.3. Optimized MS/MS parameters for amphetamine, methamphetamine,
cocaine, and benzoylecgonine can be found in Table 55. Analysis time was approximately 15
seconds per sample.
8.4.5 DESI-MS/MS Screening Results
DESI-MS/MS screening results for all specimens are shown in Table 58.
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Table 58: DESI-MS/MS screening results for authentic meconium specimens (n=21) screened
for amphetamines and cocaine.
Specimen #
Amphetamine screen (DESI)
Cocaine screen (DESI)
1

Positive

Negative

2

Negative

Negative

3

Negative

Negative

4

Negative

Positive

5

Positive

Negative

6

Negative

Positive

7

Negative

Negative

8

Negative

Negative

9

Negative

Negative

10

Negative

Negative

11

Negative

Positive

12

Negative

Negative

13

Negative

Negative

14

Positive

Negative

15

Negative

Negative

16

Negative

Negative

17

Negative

Negative

18

Negative

Negative

19

Negative

Negative

20

Negative

Negative

21

Negative

Positive

Fewer positive results were observed with the DESI-MS/MS screening method. Three
specimens screened positive for amphetamines while only four specimens screened positive for
cocaine/benzoylecgonine (Table 58). Specimens which screened positive using the DESIMS/MS method also screened positive on the immunoassay. In order to determine the accuracy
of each screening method, all specimens were subject to confirmation analysis using UPLCMS/MS methods described in chapters 5 & 7. Confirming the presence or absence of each
analyte using UPLC-MS/MS allowed for a more critical evaluation of each screening method
with respect to accuracy, selectivity, and sensitivity. Tables 59 and 60 contrast the screening
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results the immunoassay based screen and the DESI-MS/MS screen with confirmed results,
respectively.
Table 59: Immunoassay (ELISA) screening results for 21 authentic meconium specimens.
Positive screen
Positive
Rate of false
Rate of false
(ELISA)
confirmation
positives
negatives
Amphetamines
Cocaine

10
13

1
4

90%
69%

0%
0%

Table 60: DESI-MS/MS screening results for 21 authentic meconium specimens.
Positive screen
Positive
Rate of false
Rate of false
(DESI)
confirmation
positives
negatives
Amphetamines
3
1
67%
0%
Cocaine
4
4
0%
0%

All specimens were first screened for amphetamines and cocaine using immunoassay and
DESI-MS/MS and then subject to confirmation analysis using UPLC-MS/MS to validate the
reliability of each screening technique. Of the 21 meconium specimens making up the
experimental sample set, only 5 were confirmed positive for either amphetamines or cocaine.
Four specimens were confirmed positive for cocaine and/or benzoylecgonine while only one
specimen was confirmed positive for amphetamine (Tables 59 and 60). The 5 positive samples
screened positive using both the immunoassay technique and the DESI-MS/MS technique,
indicating that neither method is susceptible to generating false negatives. While both methods
successfully identified all true positives, the DESI-MS/MS method appeared to offer far greater
selectivity than the immunoassay based screen. Of the 10 specimens that screened positive for
amphetamines using immunoassay, only 1 specimen was confirmed positive representing a 90%
false positive rate. Of the 13 specimens that screened positive by immunoassay for cocaine, only
four were confirmed positive representing a 69% false positive rate. When screened using DESI255

MS/MS the false positive rates for amphetamines and cocaine were drastically reduced to 67%
and 0%, respectively. The enhanced selectivity afforded by the mass spectrometry based screen
significantly reduced the number of positive screens. Only 3 of the 21 specimens screened
positive for amphetamines using the DESI-MS/MS method compared to 10 positives seen with
the immunoassay based screen (Table 59 and 60). Similarly, only 4 of the 21 specimens screened
positive for cocaine using the DESI-MS/MS method compared to 13 positive seen with the
immunoassay technique (Table 59 and 60). Of the 3 samples that screened positive for
amphetamines using DESI-MS/MS, one was confirmed positive. All four specimens that
screened positive for cocaine using DESI-MS/MS were confirmed positive. Sensitivity of the
DESI-MS/MS method for amphetamine and methamphetamine in the meconium matrix was
quite poor making identification of positive specimens difficult. Amphetamine and
methamphetamine signal intensities in positive control specimens were not dissimilar to the
signals observed in negative specimens (Figure 62). Regions between integrated signals in
Figure 62 represent baseline signal. Amphetamine and methamphetamine signal intensities in
positive control specimens were approximately equal to the baseline signal making the
identification of positive samples extremely challenging.
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Figure 62: Show the mass spectral responses for amphetamine (a) and methamphetamine (b) in
the positive quality control and four negative specimens. Signal intensities for the positive
controls were not dissimilar to those of negative specimens.

Signal intensities for cocaine and benzoylecgonine in positive specimens were significantly
greater than those observed for positive quality control specimens, allowing for easy
identification (Figure 63). The signal to noise ratio for cocaine and benzoylecgonine in both
positive quality control specimens and authentic specimens was far greater than those observed
for the amphetamines. This increase in the S/N ratio made identification of the cocaine
derivatives much easier than the amphetamines. The sensitivity of the DESI-MS/MS method for
cocaine and benzoylecgonine is encouraging and indicates that accurate and reliable screening is
possible following limited sample preparation.
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Figure 63: Shows the mass spectral responses for benzoylecgonine (a) and cocaine (b) in a
positive quality control specimen, three negative specimens (1, 2, and 3) and a true positive
specimen (4). Intense analyte signals in all true positives allowed for easy identification.

Studies indicate that mass spectrometry based screening techniques, such as the DESI-MS/MS
method, could greatly reduce the number of false positive samples and prove more cost effective
than traditional immunoassay techniques. The increased selectivity of the DESI-MS/MS screen
is hardly surprising considering mass spectrometry has long been employed for confirmatory
testing following a positive immunoassay screen. Confirmation analysis requires enhanced
selectivity for the purpose of accurately identifying and quantifying individual analytes
following a presumptive positive. The potential advantages of mass spectrometry based
screening techniques have long been recognized, however, due to extensive sample preparation
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requirements, and cost of analysis, mass spectrometry is generally not well suited to high
throughput screening. DESI-MS/MS appears to be more suited to high throughput screening as
samples can be analyzed under ambient conditions following minimal sample preparation. While
further studies are required to evaluate the sensitivity of DESI-MS/MS relative to immunoassay
techniques, the methodology appears to offer superior selectivity without the need for extensive
sample preparation. Such techniques would prove useful for the analysis of alternate biological
matrices that have traditionally required significant sample preparation prior to instrumental
analysis.
8.5

Conclusions
While further studies are required to evaluate the suitability of the DESI-MS/MS

technique for the detection of analytes other than cocaine and amphetamine derivatives,
preliminary studies indicate that the method may be well suited to the high throughput screening
of meconium samples. Implementation of mass spectrometry based screening techniques such as
DESI-MS/MS will greatly enhance screening selectivity and reduce the number of false positive
results commonly observed with immunoassay based techniques.
Immunoassay screening techniques are well suited to the analysis of traditional
biological specimens such as serum and urine, however, these techniques are limited in their
capability to accurately identify target analytes in more complex matrices such as meconium.
Furthermore, the turbid nature of meconium specimens often means that significant sample
preparation is required before the matrix can be analyzed using immunoassay screening
techniques. Development of a DESI-MS/MS method for screening meconium specimens aimed
to alleviate existing problems surrounding immunoassay analysis by increasing screening
selectivity and allowing for ambient sampling of meconium specimens following limited sample
259

preparation. When applied to the analysis of 21 authentic meconium specimens, the DESIMS/MS method significantly reduced the rate of false positives compared to immunoassay
analysis and allowed for the accurate identification authentic meconium specimens containing
cocaine, benzoylecgonine, and amphetamines.
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